text stringlengths 10 159k | url stringlengths 19 865 | crawl_date timestamp[s]date 2022-02-01 01:02:23 2024-12-02 05:16:38 | lang stringclasses 1 value | lang_conf float64 0.65 1 |
|---|---|---|---|---|
I think it is very significant that sanctions are applied on Russia: UK Foreign Secretary Liz Truss.
- Country:
- India
I think it is very significant that sanctions are applied on Russia: UK Foreign Secretary Liz Truss.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
Advertisement | https://www.devdiscourse.com/article/Newsalert/1985375-i-think-it-is-very-significant-that-sanctions-are-applied-on-russia-uk-foreign-secretary-liz-truss | 2022-03-31T16:06:24 | en | 0.972677 |
You need to enable JavaScript to run this app. | https://sportspyder.com/nhl/san-jose-sharks/articles/39005290 | 2022-03-31T16:06:26 | en | 0.738227 |
MILAN, March 31, 2022 /PRNewswire/ -- Everli, Europe's leading online grocery marketplace, announces today that it has secured an additional €22m in funding led by new investor United Ventures, the Italian venture capital firm specialising in investments in digital technologies, as part of its Series C round of investment. Everli is the third company to enter the portfolio of United Ventures' fund UV T-Growth, which focuses on highly innovative growth-stage companies.
The additional investment comes part-way through the round and will enable Everli to accelerate its existing international expansion plans and continue to drive forward its mission to build Europe's most-loved grocery marketplace.
Fedrico Sargenti, CEO Everli commented, "Everli has successfully expanded internationally in recent months, making great progress securing international retailer partnerships which are going to help us grow even faster. We are very excited to have United Ventures on board to further accelerate these opportunities in the short term, but also from a longer term perspective the experience and history they have are going to be invaluable as we continue to scale."
Everli has so far fulfilled grocery orders for more than 4 million deliveries in 135 cities in Italy, France, Poland and Czech Republic, partnering with retailers such as Lidl, Carrefour, Conad, Coop and Kaufland. Its model, which relies on a network of more than 3000 Shoppers, enables customers in small and medium density areas to do their same-day delivery large basket grocery shopping conveniently via the Everli app or website. Supermarket partners benefit from an affordable, fast solution to quickly offer an easy to use online and home delivery service that reaches high-value customers and builds loyalty.
Fabio Pirovano, Partner of United Ventures' fund UV T-Growth, commented: "Few sectors have evolved as rapidly as grocery retail in recent years. We've been following Everli's progress with interest for a while, and today we are thrilled to support the company in the next phase of its international expansion through our growth fund. We are looking forward to working together with Federico and the Everli team as they pursue their mission of creating the largest online-grocery European platform."
Everli initially announced its Series C funding last year, and since then expanded into France and the Czech Republic; won additional retail partnerships with retailers such as Kaufland, Carrefour and Casino; hired new key leadership; and grew and developed its team and capability in areas such as tech, product, operations, marketing and finance.
About Everli
Everli is on a mission to help people achieve peace of mind, by simplifying their life when shopping for groceries. No more queuing, no more parking, no more carrying heavy weights: Everli's dream is to bring just the best parts of grocery shopping, directly to your home. Founded in 2014, Everli is now the main European e-grocery marketplace. Headquartered in Milan, with offices also in Paris, Verona and Warsaw, Everli's team has grown to more than 300 people, and has created more than 100 partnerships with retailers and CPG companies, providing flexible employment for over 3,000 shoppers. Everli serves 135 cities around Europe, and has delivered groceries 4 million times. Visit us at https://about.everli.com/.
About United Ventures
United Ventures is an independent Italian Venture Capital firm investing in digital technologies. Since 2013, it has partnered with over thirty technology startups and scaleups, supporting their growth and international expansion process. United Ventures currently has €300M in assets under management on two early-stage (UV1 and UV2) and one growth (UV T-Growth) venture capital funds. The firm's portfolio includes to date twenty companies across Italy, UK, Switzerland, Israel, and USA. For more information take a look at https://unitedventures.com/
SOURCE Everli | https://www.prnewswire.com/news-releases/everli-welcomes-united-ventures-to-its-series-c-round-301514737.html | 2022-03-31T16:06:26 | en | 0.957247 |
You need to enable JavaScript to run this app. | https://sportspyder.com/nhl/san-jose-sharks/articles/39005589 | 2022-03-31T16:06:32 | en | 0.738227 |
Ukraine crisis highlights need for like-minded nations to work together: UK Foreign Secretary Liz Truss.
- Country:
- India
Ukraine crisis highlights need for like-minded nations to work together: UK Foreign Secretary Liz Truss.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
Advertisement | https://www.devdiscourse.com/article/Newsalert/1985380-ukraine-crisis-highlights-need-for-like-minded-nations-to-work-together-uk-foreign-secretary-liz-truss | 2022-03-31T16:06:32 | en | 0.908055 |
Full Reversal Of Crypto Market, The AEX Platform token GAT Rise Leads The Trend
DUBAI, UAE, March 31, 2022 /PRNewswire/ -- Crypto market obtained its reverse in March after two months of dropping. When Bitcoin reached its peak at $48,000, the whole capital market focused on cryptocurrency again. The International Ecosystem Plan launched by AEX Global attracted the attention of users worldwide and with the promotion of AEX Vietnam Support Fund of $100 million, AEX Platform Token GAT gained 50% arise in price, getting a near to its ATH.
As a platform token for cryptocurrency exchange that has sprung up in the rebound led by GameFi and SocialFi, GAT is far ahead with a price increase of more than 50%. Leading the rapid rebound of global mainstream exchanges platform token. OKB (19.86%), BNB (16.83%) and KSC (10.19%).
GAT is mainly used to support constructing the ecosystem for AEX Global aex.com, assisting it to build a global crypto financial management platform.This article will bring you the basic cognition of GAT from the angles of the development of platform token, circulation, application scenarios and so on, so that you can have reference in decision-making.
Factors of GAT rally
In the recent market, the prices of mainstream cryptocurrencies represented by BTC, have all lead to a recent rally. GAT has risen 50% in one month, leading the sector of exchange platform tokens. So how did GAT become a hot coin?
In March, AEX accelerated the global ecosystem layout through a series of special plans. On the one hand, AEX has given out more rewards to global ambassadors and started the recruitment of global partners to bring a wider range of people into AEX strategic alliance; On the other hand, AEX Research Institute was built up and AEX upgraded BitTalk, created a user space for professional content output and in-depth communication; AEX team also went to Africa to participate in blockchain meetings and launched 1,000 USDT Novice Benefits and some other events, allowing it to effectively get closer to users.
AEX also launched the Vietnam National Plan in south-east Asia, allowing Vietnamese users to enjoy considerable benefits. Not only has the operation center been established, but also a US $100 million Vietnam special fund has been allocated to construct Vietnam's crypto ecosystem. Besides, AEX opened a green light for Vietnam project listing and sent 200,000 USDT airdrops in the AEX Finance& AEX Trade sectors.
The first free IEO on AEX Listing Desk detonated users' fomo emotion, dual investment and other brand-new financial products provide users around the world with multiple financial management methods.
AEX's rapid expansion and promotion strategy have been trending among users in the AEX Global community, and hundreds of media around the world have reported massively on AEX's recent actions. With the pace of global expansion and the enrichment of financial business models, AEX will become ahead of cryptocurrency exchanges with financial management that breaks through the barrier between fin-tech and blockchain.
AEX, the first platform token creator, powers the GAT token
Global AEX Token is a token issued by AEX and traded worldwide with the GAT symbol, which has a total circulation of 23 billion. At present, nearly 59.95% of the shares (137,893,651) are circulating in the fields of trading, financial management, mining and derivatives, and the total market value reaches to $987 million.
The continually rising of GAT price reflects the fast development of the entire fin-tech industry. The promotion of brand effect has further discovered the value of GAT, and the rapid appreciation of GAT has attracted more investors to join the AEX financial ecosystem. Currently, GAT not only has the functional attribute of participating in financial interaction and platform interest representing, but also truly allows community members to share the dividends of ecosystem development through the repurchase mechanism. As of March 30, GAT had repurchased and destroyed 192 issues, accounting for 11.87% of the total issuance. Phase 192 destruction of GAT
AEX diversified financial model has mobilized the enthusiasm of GAT holders. Multiple value guarantee mechanism enables users to gain more steady returns. Creative diversified asset management services provided by AEX Exchange attracted more and more users to participate in the building of AEX Global Ecosystem. AEX will explore more application scenarios in the future development of global ecosystem layout, adding more values to GAT.
AEX: https://www.aex.com/page/h5/m_regist.html#/newByInvite?from=q0c909
SOURCE AEX exchange | https://www.prnewswire.com/news-releases/full-reversal-of-crypto-market-the-aex-platform-token-gat-rise-leads-the-trend-301514692.html | 2022-03-31T16:06:32 | en | 0.923979 |
You need to enable JavaScript to run this app. | https://sportspyder.com/nhl/san-jose-sharks/articles/39005749 | 2022-03-31T16:06:38 | en | 0.738227 |
CINCINNATI, March 31, 2022 /PRNewswire/ -- Belcan, LLC ("Belcan"), a global supplier of digital engineering, design, software, supply chain, and IT solutions to customers in the aerospace, defense, space, automotive, industrial, and government sectors, announced today that it has been recognized by General Motors as a 2021 Supplier of the Year. GM celebrated honorees at its 30th annual Supplier of the Year awards ceremony in Phoenix, Arizona.
GM's Supplier of the Year award recognizes global suppliers that distinguish themselves by exceeding GM's requirements, in turn providing GM customers with innovative technologies and among the highest quality in the automotive industry. This year, GM recognized 134 suppliers from 16 countries with the Supplier of the Year distinction.
This is the fifth time Belcan has received the award.
Belcan's CEO Lance Kwasniewski accepted the award on behalf of the Belcan team. "We are honored to have been selected by GM as a result of our vast expertise in supply chain acceleration, performance improvement, and many other areas," Kwasniewski said. "I am very proud of our team and look forward to continuing to provide high quality, cost-effective solutions to GM for many years to come."
"This year's Supplier of the Year event was special not only because it's the 30th anniversary of the program, but because it provided us with the opportunity to recognize our suppliers for persevering through one of the most challenging years the industry has ever faced," said Shilpan Amin, GM vice president, Global Purchasing and Supply Chain. "These top suppliers showed resilience and reinforced their commitment to pursuing sustainability and innovation. Through our strong relationships and collaboration, GM and our suppliers are poised to build a brighter future for generations to come."
A global cross functional team selected the 2021 Supplier of the Year winners based on performance criteria in Product Purchasing, Global Purchasing and Manufacturing Services, Customer Care and Aftersales and Logistics.
Belcan is a global supplier of digital engineering, design, software, supply chain, and IT solutions to customers in the aerospace, defense, space, automotive, industrial, and government sectors. Belcan engineers better outcomes for customers – from jet engines, airframe, and avionics to heavy vehicles, automobiles, and cybersecurity. Belcan takes a partnering approach to provide solutions that are adaptable, integrated, and value-added, and has been earning the trust of its customers for over 60 years. For more information, please visit www.belcan.com.
General Motors is a global company focused on advancing an all-electric future that is inclusive and accessible to all. At the heart of this strategy is the Ultium battery platform, which will power everything from mass-market to high-performance vehicles. General Motors, its subsidiaries and its joint venture entities sell vehicles under the Chevrolet, Buick, GMC, Cadillac, Baojun and Wuling brands. More information on the company and its subsidiaries, including OnStar, a global leader in vehicle safety and security services, can be found at https://www.gm.com.
CONTACTS:
Lambert
Jennifer Hurson
845-507-0571
[email protected]
or
Caroline Luz
203-656-2829
[email protected]
SOURCE Belcan, LLC | https://www.prnewswire.com/news-releases/general-motors-names-belcan-a-2021-supplier-of-the-year-301514576.html | 2022-03-31T16:06:38 | en | 0.947364 |
Ahead of no-trust vote, Pakistan Prime Minister Imran Khan says the country has reached a ''defining moment'' in its history.
Ahead of no-trust vote, Pakistan Prime Minister Imran Khan says the country has reached a ''defining moment'' in its history.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
- READ MORE ON:
- Imran Khan
- Pakistan
Advertisement | https://www.devdiscourse.com/article/Newsalert/1985392-ahead-of-no-trust-vote-pakistan-prime-minister-imran-khan-says-the-country-has-reached-a-defining-moment-in-its-history | 2022-03-31T16:06:39 | en | 0.957869 |
You need to enable JavaScript to run this app. | https://sportspyder.com/nhl/san-jose-sharks/articles/39006266 | 2022-03-31T16:06:44 | en | 0.738227 |
DALLAS, March 31, 2022 /PRNewswire/ -- GI Alliance, the nation's largest independent gastroenterology services organization, is pleased to announce that Dr. Casey Chapman has been named Chief Medical Officer (CMO), effective April 1. A nationally recognized leader in GI clinical research, inflammatory bowel disease (IBD), and physician quality improvement efforts, Chapman has served as Regional Medical Director of Clinical Research and Education since July of 2016.
As Chief Medical Officer, Chapman will lead organization-wide physician and clinical quality initiatives. Chapman will also serve as a liaison and advisor for the over 1200 medical staff physicians and advanced care providers. In addition to his role as CMO, he will continue to serve part-time as a practicing physician at GI Alliance in Baton Rouge.
"Casey is an outstanding physician and is an excellent choice for our new chief medical officer," said Jim Weber, M.D., CEO of GI Alliance. "He has demonstrated a strong track record of proven results, and we are looking forward to continued growth and advancement of physician quality initiatives."
I am excited to join the leadership team and I am proud to be part of the transformation of integrated GI care," said Dr. Chapman. "I look forward to working hard to continue the mission of patient-centric care, while maintaining, but growing our level of quality and value. We have a unique opportunity at GI Alliance to make a meaningful impact with clinical quality and overall physician alignment."
Dr. Chapman practiced at Gastroenterology Associates and Louisiana Endoscopy Center before joining GI Alliance. He has served as medical director at the Crohn's and Colitis Clinic at Baton Rouge General Health System. Chapman earned a Bachelor of Science in Zoology degree and his Doctor of Medicine degree from Louisiana State University. He completed his residency and fellowship in Gastroenterology at Louisiana State University Health Science Center in Baton Rouge.
About GI Alliance
GI Alliance is a physician-led and majority physician-owned GI services organization supporting the needs of more than 660 independent gastroenterologists operating in Texas, Arkansas, Arizona, Colorado, Florida, Illinois, Indiana, Louisiana, Mississippi, Oklahoma, Utah, and Washington. Practices that are part of GI Alliance are focused on providing the highest-quality care to their patients. In addition to providing operational support for practices, GI Alliance is working to unite gastroenterologists nationwide by aligning interests and improving patient care.
Contact: Dee Dee Brooks
GI Alliance
214.998.3434
[email protected]
SOURCE GI Alliance | https://www.prnewswire.com/news-releases/gi-alliance-appoints-casey-chapman-md-to-chief-medical-officer-301514288.html | 2022-03-31T16:06:44 | en | 0.962143 |
When I joined politics, I had three aims - to ensure justice, humanity and self-reliance, says Pakistan Prime Minister Imran Khan.
When I joined politics, I had three aims - to ensure justice, humanity and self-reliance, says Pakistan Prime Minister Imran Khan.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
- READ MORE ON:
- Imran Khan
- Pakistan
Advertisement | https://www.devdiscourse.com/article/Newsalert/1985397-when-i-joined-politics-i-had-three-aims---to-ensure-justice-humanity-and-self-reliance-says-pakistan-prime-minister-imran-khan | 2022-03-31T16:06:47 | en | 0.97587 |
You need to enable JavaScript to run this app. | https://sportspyder.com/mlb/toronto-blue-jays/articles/39005641 | 2022-03-31T16:06:50 | en | 0.738227 |
DUBLIN, March 31, 2022 /PRNewswire/ -- The "Global Battery Energy Storage Systems Market with COVID-19 Impact Analysis by Storage System, Element, Battery Type (Lithium-Ion, Flow Batteries), Connection Type (On-Grid, Off-Grid), Ownership, Energy Capacity, Application, and Geography - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
The global battery energy storage systems market is expected to grow from USD 4.4 billion in 2022 to USD 15.1 billion by 2027, at a CAGR of 27.9%.
The growth of this market is mainly driven by the increasing demand for grid energy storage systems owing to ongoing grid modernization, growing penetration of lithium-ion batteries in renewable energy sector, and rising trend of adopting low-carbon and less fossil fuel-based economy and ongoing renewable energy revolution. However, high capital expenditure required for installing battery energy storage systems is restraining the market growth.
Lithium-ion batteries to dominate the battery energy storage system market in 2021
The market for the lithium-ion batteries held the largest share in 2021 and is estimated to remain the same during the forecast period.
The growth of this segment is attributed to the advantages of the battery such as high energy and power density, which leads to low standby losses and a high life expectancy of about 5-15 years with 98% efficiency. Also, lithium-ion-sulfur battery energy storage systems support frequency regulation, demand charge reduction, grid-buffering, and renewable integration, which are suitable for on-grid connections.
On-grid connection type to hold the largest share of battery energy storage system market in 2021
The on-grid segment holds the largest share of the battery energy storage system market in 2021 and is expected to hold significant CAGR during the forecast period.
The on-grid connections exhibit lower upfront costs than the off-grid system, as the surplus energy is sent to the grid, which can be used later on a metered basis. The reduction in the energy bills for the customers relying on the utility grid for electricity is expected to drive the growth of the segment. The demand for grid modernization from renewable energy suppliers and new regulatory policies for the energy sector are also driving the growth of the on-grid battery energy storage system market for utilities.
Utility application dominated the battery energy storage system market in 2021
The market for utilities application is dominant in 2021. The need to fulfill the requirement of peak electricity demands is the major factor contributing to the growth of the market for utility.
The utility BESS provides power quality, frequency, and voltage control services in case of sudden fluctuation in the energy supply. The battery energy storage systems enable grid operators to save electricity when there is a surplus of renewable energy. The increasing demand for a reliable and efficient supply of electricity in most regions and the growing need for renewable energy are responsible for the high demand for battery energy storage systems in the utility sector.
Market in APAC to grow at highest CAGR during the forecast period
The market in APAC is expected to grow at the highest CAGR from 2022 to 2027. The region hold the largest share of battery energy storage system market in 2021.
APAC is a hub for the battery energy storage system industry. APAC is expected to witness plans for electrification in remote areas, which are mostly off-grid in several countries. The use of residential energy storage technology will enable to increase access to electricity for these remote and island communities in the region.
Energy storage investments are expected to increase substantially within the APAC region as the governments in growing economies are making new policies to improve the reliability and quality of the power distribution facilities to the residential customers. The governments of various countries in this region are focusing on minimizing the adverse effects of the energy sector on the environment. These factors lead to the growth in the deployment of battery energy storage systems in residential and public utility applications.
Competitive Landscape
Major players profiled in this report are as follows: BYD Company Limited (China), SAMSUNG SDI Co. Ltd. (South Korea), LG Energy Solutions Co. Ltd. (South Korea), and Panasonic Corporation (Japan), and others.
Premium Insights
- Increasing Number of Projects, Which Require Battery Energy Storage Systems is Likely to Create Lucrative Opportunities for Battery Energy Storage System Market in APAC
- Battery Energy Storage System Market for Lithium-Ion Batteries to Hold Largest Size in 2027
- Above 500 MWh Energy Capacity Segment to Dominate Battery Energy Storage System Market During Forecast Period
- Utility Application of Battery Energy Storage System Market to Witness Highest Rate During Forecast Period
- APAC to Hold Largest Size of Battery Energy Storage System Market in 2027
Market Dynamics
Drivers
- Increasing Demand for Grid Energy Storage Systems Owing to Ongoing Grid Modernization
- Growing Penetration of Lithium-Ion Batteries in Renewable Energy Sector
- Rising Trend of Adopting Low-Carbon and Less Fossil Fuel-based Economy and Ongoing Renewable Energy Revolution
Restraints
- High Capital Expenditure Required for Installing Battery Energy Storage Systems
Opportunities
- Surge in Number of Rural Electrification Projects Worldwide
- Increase in Need for Continuous Power Supply Attributed to Rising Number of Datacenters
- Decline in Prices of Lithium-Ion Batteries
Challenges
- Complexities in Installing Battery Energy Storage Systems at Islands or in Remote Areas
- Overheating of Lithium-Ion Batteries
- Aging of Lithium-Ion Batteries
Value Chain Analysis
- Ecosystem
- Trends/Disruptions Impacting Customer's Business
Porter's Five Forces Analysis
Case Study Analysis
- General Electric to Deliver Battery Energy Storage Systems to Convergent in California
- Adoption of Battery Energy Storage Systems by Utility Provider Company
- Deployment of Microgrid Battery Energy Storage Systems for Rural Electrification in Nigeria
- Deployment of Off-Grid Battery Energy Storage Systems for Renewable Energy Project
- ABB to Install Battery Energy Storage Systems in Philippines
Technology Analysis
- Sodium-Sulfur Battery
- Cobalt-Free Battery
- Metal-Air Battery
- Liquid Metal Battery
- Potassium Metal Battery
- Zinc Manganese Battery
- Lithium-Sulfur Battery
- Lithium Metal Battery
Company Profiles
- ABB
- AEG Power Solutions
- BYD Company Limited
- Delta Electronics Inc.
- East Penn Manufacturing Company
- Enerdel, Inc.
- Exergonix
- General Electric
- Hitachi, Ltd.
- Honeywell International, Inc.
- Johnson Controls
- Kokam
- LG Energy Solutions Co. Ltd.
- NEC Corporation
- Nextera Energy, Inc.
- NGK Insulators, Ltd.
- Panasonic Corporation
- Parker Hannifin Corp.
- Primus Power
- Samsung SDI Co. Ltd.
- Siemens AG
- Tesla, Inc.
- The AES Corporation
- Toshiba Corporation
- Trinabess
For more information about this report visit https://www.researchandmarkets.com/r/l8oz3h
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets | https://www.prnewswire.com/news-releases/global-15-billion-battery-energy-storage-systems-markets-to-2027-opportunities-in-the-surge-in-number-of-rural-electrification-projects-worldwide-301514685.html | 2022-03-31T16:06:51 | en | 0.888873 |
Ukraine's nuclear operator: Russian troops are leaving Chernobyl nuclear power plant, heading towards Belarus border, reports AP.
Ukraine's nuclear operator: Russian troops are leaving Chernobyl nuclear power plant, heading towards Belarus border, reports AP.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
Advertisement
ALSO READ
Rosatom rejects reports that Russia operating Zaporozhskaya and Chernobyl nuclear plants
Ukraine state nuclear company unable to monitor radiation levels around Chernobyl
Live updates: Wildfires near Chernobyl plant extinguished
Chernobyl staff rotated out for first time since capture -IAEA
All Chernobyl staff who wanted to leave are out, U.N. nuclear watchdog says | https://www.devdiscourse.com/article/Newsalert/1985399-ukraines-nuclear-operator-russian-troops-are-leaving-chernobyl-nuclear-power-plant-heading-towards-belarus-border-reports-ap | 2022-03-31T16:06:55 | en | 0.894739 |
You need to enable JavaScript to run this app. | https://sportspyder.com/mlb/toronto-blue-jays/articles/39005963 | 2022-03-31T16:06:56 | en | 0.738227 |
DUBLIN, March 31, 2022 /PRNewswire/ -- The "Ethical Fashion Global Market Opportunities And Strategies To 2030, By Type, Product, End-user" report has been added to ResearchAndMarkets.com's offering.
The global ethical fashion market reached a value of nearly $6,349.9 million in 2020, having increased at a compound annual growth rate (CAGR) of 6.1% since 2015. The market is expected to grow from $6,349.9 million in 2020 to $10,109.9 million in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth is mainly due to the growing awareness about using ethical fashion for sustainability. The market is expected to grow from $10,109.9 million in 2025 to $15,584.2 million in 2030 at a CAGR of 9.0%.
The ethical fashion market consists of sales of apparels by entities (organizations, sole traders or partnerships) that that are primarily engaged in designing, production, retail, and purchasing of ethical fashion apparels. Ethical fashion is the designing and manufacturing of clothes while caring for the people and communities involved in the process, and while also minimizing the impact on the environment. It focuses on both the social and environmental impact of fashion, seeking to improve the working conditions of laborers and the environment.
Growth in the historic period resulted from emerging markets growth, rise in foreign direct investments, and increasing customer focus towards sustainable fashion. This growth was restricted by high costs of ethical fashion and reduction in free trade.
Going forward, rising awareness, social media, government initiatives, environmental impact of fast fashion, and growth of e-commerce are expected to drive the market. Lack of standardization and impact of COVID-19 are major factors that could hinder the growth of the ethical fashion market in the future.
The ethical fashion market is segmented by product into organic, man-made/regenerated, recycled and natural. The man-made/regenerated was the largest segment of the ethical fashion market by product type, accounting for 53.6% of the total market in 2020. Going forward, organic segment is expected to be the fastest growing segment in the ethical fashion market, at a CAGR of 18.4% during 2020-2025.
The ethical fashion market is also segmented by type into fair trade, animal cruelty free, eco-friendly and charitable brands. The animal cruelty free was the largest segment of the ethical fashion market by type, accounting for 44.4% of the total market in 2020. Going forward, the eco-friendly segment is expected to be the fastest growing segment in the ethical fashion market, at a CAGR of 12.2% during 2020-2025.
The ethical fashion market is also segmented by end-user into men, women and kids. The men segment was the largest segment of the ethical fashion market by end-user, accounting for 51.9% of the total market in 2020. Going forward, the women segment is expected to be the fastest growing segment in the ethical fashion market, at a CAGR of 10.9% during 2020-2025.
Asia Pacific was the largest region in the global ethical fashion market, accounting for 31.6% of the total in 2020. It was followed by the Western Europe, North America and then the other regions. Going forward, the fastest-growing regions in the ethical fashion market will be Eastern Europe and South America, where growth will be at CAGRs of 13.6% and 12.1% respectively during 2020-2025. These will be followed by Asia Pacific and Africa, where the markets are expected to register CAGRs of 11.9% and 11.9% respectively during 2020-2025.
The ethical fashion market is highly fragmented and competitive. The top ten competitors in the market made up to 13.49% of the total market in 2020. Major players in the market include Eileen Fisher, Reformation, H&M Conscious (H&M Group), Levi Strauss & Co, Everlane, Alternative Apparel, Inc., Tentree, United By Blue, Wear Pact LLC, Amour Vert.
The top opportunities in the ethical fashion market segmented by product will arise in the man-made/regenerated segment, which will gain $1,233.5 million of global annual sales by 2025. The top opportunities in the ethical fashion market segmented by type will arise in the eco-friendly segment, which will gain $1,574.2 million of global annual sales by 2025. The top opportunities in the ethical fashion market segmented by end-user will arise in the women segment, which will gain $1,913.4 million of global annual sales by 2025. The ethical fashion market size will gain the most in the China at $806.5 million.
Market-trend-based strategies for the ethical fashion market includes focus on providing customers with compelling, tangible stories, recycling and upcycling in order to reduce wastage and minimize the impact on the environment in the manufacturing process, focus of celebrities towards ethical fashion and have tie-ups with them in order to increase the reach of their brands, include the use of animal-free leather in order to curb animal cruelty and consider using natural materials.
Key Topics Covered:
1. Ethical Fashion Market Executive Summary
2. Table of Contents
3. List of Figures
4. List of Tables
5. Report Structure
6. Introduction
6.1. Segmentation By Geography
6.2. Segmentation By Product
6.3. Segmentation By Type
6.4. Segmentation By End-User
7. Ethical Fashion Market Characteristics
7.1. Market Definition
7.2. Segmentation By Product
7.2.1. Organic
7.2.2. Man-Made/Regenerated
7.2.3. Recycled
7.2.4. Natural
7.3. Segmentation By Type
7.3.1. Fair Trade
7.3.2. Animal Cruelty Free
7.3.3. Eco-Friendly
7.3.4. Charitable Brands
7.4. Segmentation By End-user
7.4.1. Men
7.4.2. Women
7.4.3. Kids
8. Ethical Fashion Market Trends And Strategies
8.1. Recycling And Upcycling
8.2. Increased Transparency Through Storytelling
8.3. Animal-Free Leather
8.4. Vegan Fashion
8.5. Advanced Technologies
9. Impact Of COVID-19 On The Ethical Fashion Market
9.1. Introduction
9.2. Impact On Supply Chain And Workers
9.3. Impact On Companies
9.4. Increase In Demand
9.5. Consumers' Point Of View
9.6. Future Outlook
10. Global Ethical Fashion Market Size And Growth
10.1. Market Size
10.2. Historic Market Growth, 2015 - 2020, Value ($ Million)
10.2.1. Drivers Of The Market 2015 - 2020
10.2.2. Restraints On The Market 2015 - 2020
10.3. Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
10.3.1. Drivers Of The Market 2020 - 2025
10.3.2. Restraints On The Market 2020 - 2025
11. Global Ethical Fashion Market Segmentation
11.1. Global Ethical Fashion Market, Segmentation By Product, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
11.2. Global Ethical Fashion Market, Segmentation By Type, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
11.3. Global Ethical Fashion Market, Segmentation By End-User, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
12. Ethical Fashion Market, Regional And Country Analysis
12.1. Global Ethical Fashion Market, By Region, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
12.2. Global Ethical Fashion Market, By Country, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
Companies Mentioned
- Eileen Fisher
- Reformation
- H&M Concious (H&M Group)
- Levi Strauss & Co.
- Everlane
- Alternative Apparel, Inc.
- Tentree
- United By Blue
- Wear Pact LLC
- Amour Vert
For more information about this report visit https://www.researchandmarkets.com/r/lsvedy
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets | https://www.prnewswire.com/news-releases/global-ethical-fashion-markets-analysis--forecasts-2015-2020-2025f-2030f-301514707.html | 2022-03-31T16:06:57 | en | 0.896888 |
You need to enable JavaScript to run this app. | https://sportspyder.com/mlb/toronto-blue-jays/articles/39006439 | 2022-03-31T16:07:02 | en | 0.738227 |
DUBLIN, March 31, 2022 /PRNewswire/ -- The "Global Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014 to 2021" report has been added to ResearchAndMarkets.com's offering.
The Global Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides comprehensive access to available records for over 2,400 distribution deals, including contract documents where available.
Fully revised and updated, the report provides details of distribution agreements from 2014 to 2021.
The report provides a detailed understanding and analysis of how and why companies enter distribution deals. The majority of deals are multicomponent whereby the licensor retains either a right or option to distribute the resultant product of the research collaboration. There are also numerous pure distribution deals whereby the products originator takes on a distribution partner in order to maximize a products presence in the marketplace.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of over 2,400 distribution deals announced since 2014 as recorded in the deals and alliances database, including financial terms where available, plus links to online copies of actual distribution contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.
In conclusion, this report provides everything a prospective dealmaker needs to know about distribution alliances.
Report scope
Global Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 includes:
- In-depth understanding of distribution deal trends since 2014
- Analysis of the structure of distribution with numerous real life case studies
- Comprehensive access to over 2,400 distribution deals entered into by the world's biopharma companies, together with contract documents if available
- Identify leading distribution deals by value since 2014
- Identify the most active distribution dealmakers since 2014
- Full listing of distribution deals by company A-Z, deal value, phase of development, deal type, therapy and technology focus
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
In Distribution Partnering Terms and Agreements, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Therapeutic area
- Technology type
Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in distribution dealmaking
2.1. Introduction
2.2. Definition of distribution deals
2.3. Trends in distribution deals since 2014
2.3.1. Distribution dealmaking by year, 2014 to 2021
2.3.2. Distribution dealmaking by phase of development since 2014
2.3.3. Distribution dealmaking by industry sector since 2014
2.3.4. Distribution dealmaking by therapy area since 2014
2.3.5. Distribution dealmaking by technology type since 2014
2.3.6. Distribution dealmaking by most active company since 2014
2.3.7. Attributes of pure distribution deals
2.3.8. Attributes of distribution in multi-component deals
2.4. Aligning partners to make the distribution agreement work
Chapter 3 - Overview of distribution deal structure
3.1. Introduction
3.2. Distribution agreement structure
3.3. Example distribution agreements
3.3.1. Case study 1: Zeltiq Aesthetics - Advance Medical
3.3.2. Case study 2: QLT - ASD Speciality Healthcare
3.4 Distribution rights as part of a wider alliance agreement
3.4.1. Case study 1: Caleco Pharma - Natac Biotech
3.4.2. Case study 2: Purdue Pharma - Transcept Pharmaceuticals
Chapter 4 - Leading distribution deals
4.1. Introduction
4.2. Top distribution deals by value
Chapter 5 - Top 25 most active distribution dealmakers
5.1. Introduction
5.2. Top 25 most active distribution dealmakers
Chapter 6 - Distribution deals including contracts directory
6.1. Introduction
6.2. Distribution deals with contracts since 2014
Appendices
Appendix 1 - Distribution dealmaking by companies A-Z
Appendix 2 - Distribution dealmaking by industry sector
Appendix 3 - Distribution dealmaking by stage of development
Appendix 4 - Distribution dealmaking by therapy area
Appendix 5 - Distribution dealmaking by technology type
For more information about this report visit https://www.researchandmarkets.com/r/fcayty
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets | https://www.prnewswire.com/news-releases/global-pharma-biotech-and-diagnostics-distribution-partnering-terms-and-agreements-report-2021-analysis-by-company-a-z-headline-value-stage-of-development-at-signing-therapeutic-area-technology-301514697.html | 2022-03-31T16:07:03 | en | 0.885168 |
In live address, Pakistan PM Imran Khan names US as the country in question over 'threatening memo'.
In live address, Pakistan PM Imran Khan names US as the country in question over 'threatening memo'.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
- READ MORE ON:
- Imran Khan
- Pakistan
Advertisement | https://www.devdiscourse.com/article/Newsalert/1985432-in-live-address-pakistan-pm-imran-khan-names-us-as-the-country-in-question-over-threatening-memo | 2022-03-31T16:07:02 | en | 0.921434 |
You need to enable JavaScript to run this app. | https://sportspyder.com/mlb/toronto-blue-jays/articles/39006621 | 2022-03-31T16:07:08 | en | 0.738227 |
DUBLIN, March 31, 2022 /PRNewswire/ -- The "Global Psychiatry Partnering 2015-2022: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
The Global Psychiatry Partnering 2015-2022 report provides comprehensive access to available deals and contract documents for over 800 psychiatry deals.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Psychiatry disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Psychiatry deals.
The report presents financial deal terms values for Psychiatry deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
Scope of the Report
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Psychiatry dealmaking since 2015 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Psychiatry deals since 2015. Deals are listed by headline value. The chapter includes the top 25 most active Psychiatry dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Psychiatry deals since 2015 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Psychiatry partnering deals by specific Psychiatry target announced since 2015. The chapter is organized by specific Psychiatry therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Psychiatry partnering deals signed and announced since 2015.
The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Psychiatry technologies and products.
The report includes deals for the following indications: Akathisia, Anxiety disorder, Generalised anxiety disorder, Panic disorder, Post traumatic stress disorder, Attention deficit hyperactivity disorder, Bipolar disorder, Chronic fatigue syndrome, Cognitive impairment, Delirium, Dementia, Alzheimers, Dementia with lewy bodies, Vascular dementia, Depression, Dystonia, Eating disorder, Anorexia, Bulimia, Learning disability, Aspergers, Autism, Mania, Obsessive compulsive disorder, Personality disorder, Schizophrenia, Sleep disorders, Insomnia, Narcolepsy, Sleep apnoea, Tardive dyskinesia, Tourettes, plus other psychiatric indications.
Report Highlights
Global Psychiatry Partnering 2015 to 2022 includes:
- Trends in Psychiatry dealmaking in the biopharma industry since 2015
- Analysis of Psychiatry deal structure
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Psychiatry deal contract documents
- Comprehensive access to over 800 Psychiatry deal records
- The leading Psychiatry deals by value since 2015
- Most active Psychiatry dealmakers since 2015
In Global Psychiatry Partnering 2015 to 2022, available deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are the sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
For more information about this report visit https://www.researchandmarkets.com/r/ygflka
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets | https://www.prnewswire.com/news-releases/global-psychiatry-partnering-deal-trends-players-and-financials-analysis-report-2022-deal-structure-headline-upfront-milestone-and-royalty-data-most-active-psychiatry-fealmakers-301514699.html | 2022-03-31T16:07:09 | en | 0.899258 |
Vote on no-confidence motion would take place on Sunday, says Pakistan PM Imran Khan.
Vote on no-confidence motion would take place on Sunday, says Pakistan PM Imran Khan.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
- READ MORE ON:
- Imran Khan
- Pakistan
Advertisement | https://www.devdiscourse.com/article/Newsalert/1985443-vote-on-no-confidence-motion-would-take-place-on-sunday-says-pakistan-pm-imran-khan | 2022-03-31T16:07:10 | en | 0.942729 |
You need to enable JavaScript to run this app. | https://sportspyder.com/mlb/toronto-blue-jays/articles/39006696 | 2022-03-31T16:07:14 | en | 0.738227 |
GNCC CAPITAL, INC. UPDATES AND CLARIFIES ON CERTAIN ISSUES
LAS VEGAS, March 31, 2022 /PRNewswire/ -- GNCC Capital, Inc. (GNCP.PK) ("The Company", "GNCC" or "GNCP") confirms that the design on the new website is well underway and is expected to go "live" very shortly. We elected to create an exhaustive and informative website addressing as many issues as possible complete with the ability for our shareholders to register for information updates.
We are attempting to achieve providing as much information as is possible on this website in order to avoid having our shareholders being misled by false and misleading information posted on the Internet.
Shareholders are advised to please ignore any "live" website until we announce that it is completed. The website design firm occasionally takes the work in progress website "live" for short periods of time which is creating confusion amongst shareholders.
We elected to give our website design firm "creative license" given their experience in creating and managing Corporate Investor Relations websites.
Shareholders appear to be concerned about our outstanding shares as verified and displayed under your Company's Profile on the OTC Markets website. We are Transfer Agent verified with the OTC Markets and our Transfer Agent advised us that they submit these correct numbers on the last day of the month; that being today. Those numbers being submitted by the Transfer Agent are the same as are reflected on the OTC Markets website. To clarify, no shares of Common Stock have been deposited into the DTCC since November of 2021 and the DTCC deposit numbers have remain unchanged since then.
In respect of all of voluminous data pertaining to our "Silverpeak" Lithium / Uranium transaction, coupled with detailed research reports and our initial exploration planning; this will be available for download on the new GNCC Corporate website. Your Directors are delighted to be returning to the business of actual physical exploration work which we hope will result in significant increases in the value of your Company's interests.
We restructured the Company's Gold & Silver Exploration Interests into a different subsidiary Company of GNCC and dissolved the previous two GNCC subsidiary companies which had held these interests. This was effected due to potential expansion of those interests and we wished to have them unencumbered; prior to that, these interests were encumbered to certain Preferred Shareholders.
Forward Looking Statements:-
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties and assumptions.
The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file with the OTC Markets Group.
Contact Information:
GNCC CAPITAL, INC.
Telephone: (702) 990-0156
Investor Relations Contact:
Email: [email protected]
Twitter: https://twitter.com/gncccapital
SOURCE GNCC Capital, Inc. | https://www.prnewswire.com/news-releases/gncc-capital-inc-updates-and-clarifies-on-certain-issues-301514684.html | 2022-03-31T16:07:15 | en | 0.951855 |
Pakistan PM Imran Khan indicates he will not resign; says he plays till the last ball.
Pakistan PM Imran Khan indicates he will not resign; says he plays till the last ball.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
- READ MORE ON:
- Imran Khan
- Pakistan
Advertisement | https://www.devdiscourse.com/article/Newsalert/1985455-pakistan-pm-imran-khan-indicates-he-will-not-resign-says-he-plays-till-the-last-ball | 2022-03-31T16:07:18 | en | 0.912887 |
You need to enable JavaScript to run this app. | https://sportspyder.com/mlb/toronto-blue-jays/articles/39007012 | 2022-03-31T16:07:20 | en | 0.738227 |
Greenbrier declares quarterly dividend of $0.27 per share
LAKE OSWEGO, Ore., March 31, 2022 /PRNewswire/ -- The Greenbrier Companies [NYSE: GBX] announced today a quarterly cash dividend of $0.27 per share, payable on May 10, 2022 to stockholders of record as of April 19, 2022.
About Greenbrier
Greenbrier, headquartered in Lake Oswego, Oregon, is a leading international supplier of equipment and services to global freight transportation markets. Through its wholly-owned subsidiaries and joint ventures, Greenbrier designs, builds and markets freight railcars and marine barges in North America, Europe and Brazil. We are a leading provider of freight railcar wheel services, parts, maintenance and retrofitting services in North America through our rail services business unit. Greenbrier manages 443,000 railcars and offers railcar management, regulatory compliance services and leasing services to railroads and other railcars owners in North America. GBX Leasing (GBXL) is a special purpose subsidiary that owns and manages a portfolio of leased railcars that originate primarily from Greenbrier's manufacturing operations. GBXL and Greenbrier own a lease fleet of 12,900 railcars. Learn more about Greenbrier at www.gbrx.com.
"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to a variety of matters, including, without limitation, statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks and uncertainties that could cause actual results to differ materially from the results contemplated by the forward-looking statements. Information on potential factors that could cause our results to differ from our forward-looking statements is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic report on Form 10-K and subsequent report(s) on 10-Q. Except as otherwise required by law, the Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's opinions only as of the date hereof.
SOURCE Greenbrier Companies, Inc. | https://www.prnewswire.com/news-releases/greenbrier-declares-quarterly-dividend-of-0-27-per-share-301514563.html | 2022-03-31T16:07:21 | en | 0.939278 |
J&K admin sacks five employees in Kashmir
- Country:
- India
Jammu and Kashmir administration on Thursday ordered the compulsory retirement of five employees hailing from the valley for not performing their duties efficiently.
The administration invoked powers vested in it under Article 226 (2) of Jammu and Kashmir Civil Service Regulations 1956 to order the retirement of the employees.
Article 226(2) provides for constituting of a review committee to decide the functioning of employees who have completed 22 years of service or attained age of 48 years.
It also empowers the government to retire any such employee at any time if he or she is found not to be working efficiently, honestly and with integrity.
The decision was taken after the records of the employees of the housing and urban development department were scrutinised by the administration, an official said.
Those retired include executive officer Mohammad Asharaf , senior town planner Hamid Wani, divisional town planner Farzana Naqshbandi (all under suspension), executive officers Ghulam Mohammad Lone and Imtiyaz Ahmad Dar.
''In its resolve to make administration efficient and transparent, the government is taking firm action against the employees found guilty of misconduct and inefficiency,'' a senior official said.
The administration ensures timely promotions and suitable training for the employees of Jammu and Kashmir, but is also firm on weeding out inefficient and corrupt employees, according to the official.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.) | https://www.devdiscourse.com/article/business/1985311-jk-admin-sacks-five-employees-in-kashmir | 2022-03-31T16:07:25 | en | 0.956902 |
You need to enable JavaScript to run this app. | https://sportspyder.com/nhl/toronto-maple-leafs/articles/39005044 | 2022-03-31T16:07:26 | en | 0.738227 |
PORT LUIS, Mauritius, March 31, 2022 /PRNewswire/ -- During the holy month of Ramadan, global multi-asset broker HotForex offers its clients the opportunity to carry on with their trading while helping those in need with a special charity activity.
From 28th March to 2nd May 2022, for every lot traded (1 standard lot) on forex, silver and gold from trading accounts participating in the activity, HotForex will be donating 1 USD to an established charitable organization for the well-being of people in Islamic countries. Participants in the Ramadan activity will have the chance to enter three exclusive lucky draws for a chance to win generous prizes.
A HotForex spokesperson commented: "At HotForex, we largely focus on social responsibility and always look for ways to support and give back to our surrounding community. With respect to our clients' traditions, we've launched this initiative and we welcome all traders to celebrate Ramadan by joining a good cause with the chance of winning special prizes."
Visit the HotForex Ramadan page to find out more about the company's charity activity.
About HotForex
HotForex is an internationally acclaimed multi-asset broker of choice to over 2.5 million live accounts worldwide that has earned over 55 coveted industry awards since it was founded in 2010. The company offers a wide variety of account types, innovative products, platforms, tools and educational resources besides outstanding customer service and unparalleled trading conditions to facilitate individuals and institutional customers to trade Forex and CFDs online.
HF Markets Ltd, [email protected], +44-2030978571
Photo - https://mma.prnewswire.com/media/1777799/HotForex_Ramadan_Kareem_2022.jpg
Logo - https://mma.prnewswire.com/media/830182/HotForex_Logo.jpg
SOURCE HotForex | https://www.prnewswire.com/news-releases/hotforex-celebrates-ramadan-2022-with-a-special-charity-activity-301514730.html | 2022-03-31T16:07:27 | en | 0.922065 |
You need to enable JavaScript to run this app. | https://sportspyder.com/nhl/toronto-maple-leafs/articles/39005361 | 2022-03-31T16:07:28 | en | 0.738227 |
Solidifying its Position as Total Solution Provider to Engineering and Manufacturing Organizations
WESTON, Fla., March 31, 2022 /PRNewswire/ -- Inceptra LLC, a global Product Lifecycle Management (PLM) and Manufacturing System solutions provider, announced today it has acquired the assets of Noble Technologies Corp. (NobleTek), an engineering services provider focused on NC programming, composite manufacturing, and 3D design services and formed NobleTek LLC. Terms of the transaction were not disclosed.
Inceptra supports engineering and manufacturing organizations across a variety of industries with solutions and services to digitally design, simulate, produce, and manage their products and processes. Dedicated exclusively to the Dassault Systèmes portfolio of products and complementary solutions, the company combines its best-in-class product offerings with expert services to help customers achieve enhanced productivity and product innovation.
The acquisition of NobleTek fits into Inceptra's strategy to maximize its customer value as a total solution provider. The purchase of NobleTek's assets expands Inceptra's solution offerings to include product design and production manufacturing services, rounding out a comprehensive product development portfolio of software and services comprised of implementation, training, support, integration, automation, and customization services.
"We've been helping our customers solve mission-critical business challenges since 1986 and have experienced customers' needs for product design or NC programming resources to meet tight deadlines," said Tim Peterson, CEO, Inceptra. He continued, "By adding NobleTek's demonstrated expertise in delivering such services to companies in aerospace and other industries, Inceptra customers will now have access to qualified design and manufacturing professionals to support any urgent project needs they might have."
NobleTek will operate as an independent subsidiary of Inceptra under the name of NobleTek, An Inceptra Company. Longtime NobleTek key executive Nick Westover will continue to lead the company and serve as Executive Vice President of NobleTek, reporting to Tim Peterson, Inceptra's CEO, ensuring operational and customer continuity.
"Bringing together our two companies is a natural fit, with Inceptra and NobleTek having a large number of customers in common and both fostering a culture of excellence," commented Nick Westover, NobleTek Executive Vice President. He continued, "Our combined customers can benefit from an all-in-one solution provider, including those customers supporting US Department of Defense contracts thanks to NobleTek's ITAR Compliance and Classified Data Clearance Certifications."
About Inceptra
Headquartered in Weston, FL, with resources throughout North America, Inceptra provides engineering and manufacturing software and services to companies across a variety of industries. The company is dedicated to Dassault Systèmes' 3DEXPERIENCE and PLM software portfolio, plus complementary solutions and internally developed PLM accelerators, and related training, support, and consulting services including implementation, integration, and automation services. Inceptra also offers product design and production manufacturing services through its subsidiary, NobleTek.
SOURCE Inceptra | https://www.prnewswire.com/news-releases/inceptra-acquires-nobletek-301514228.html | 2022-03-31T16:07:33 | en | 0.94367 |
Ruchi Soya fixes FPO issue price at Rs 650 per share; to raise Rs 4,300cr
Patanjali Ayurved-owned Ruchi Soya on Thursday fixed the issue price of its follow-on public offer at the upper limit of its price band at Rs 650 per equity share to raise Rs 4,300 crore.Ruchi Soya hit the capital market with its FPO on March 24 to raise Rs 4,300 crore as it aims to become a debt-free company.The issue closed on March 28.
- Country:
- India
Patanjali Ayurved-owned Ruchi Soya on Thursday fixed the issue price of its follow-on public offer at the upper limit of its price band at Rs 650 per equity share to raise Rs 4,300 crore.
Ruchi Soya hit the capital market with its FPO on March 24 to raise Rs 4,300 crore as it aims to become a debt-free company.
The issue closed on March 28. The price band had been fixed at Rs 615-650 per share. In a regulatory filing, Ruchi Soya informed that the board of directors has approved the issue price at Rs 650 per equity share and also anchor investor issue price at Rs 650 per share.
The company had already raised Rs 1,290 crore from anchor investors last week by issuing around 1.98 crore shares. Ruchi Soya shares closed at Rs 955.60 apiece on the BSE, down 2.23 per cent.
Meanwhile, nearly 97 lakh bids were withdrawn by FPO investors after markets watchdog Sebi directed Ruchi Soya to give investors the option to withdraw their bids, according to sources.
In a rare move, Sebi, on March 28, had asked bankers of Baba Ramdev-led Patanjali group's Ruchi Soya to give an option to investors in its FPO to withdraw their bids while also cautioning them about the ''circulation of unsolicited SMS'' about the share sale.
The FPO closed on March 28 and the withdrawal window was open for two days till March 30 as per the Sebi directive.
The sources said the subscription of the offer came down to 3.39 times on March 30 from 3.6 times, which was the level when the offer closed on March 28. This reflects that around 97 lakh bids were withdrawn, primarily by foreign investors.
On March 28, more than 17.60 crore bids had come in for the FPO whereas the number of shares on offer was a little over 4.89 crore. To raise Rs 4,300 crore, the company will now issue and make an allotment of 6.61 crore shares only.
On Sebi's directions, bankers issued an advertisement in newspapers on Tuesday and Wednesday (March 29, 30) cautioning investors about the circulation of SMSes and also asked to give an option to investors to withdraw their already placed bids till March 30.
Ruchi Soya came out with the FPO in order to meet the minimum public shareholding norm of 25 per cent as required for a listed entity. Currently, Patanjali Group owns about 98.9 per cent stake in Ruchi Soya whle public shareholders own about 1.1 per cent stake.
Post the FPO, Patanjali Group's holding in Ruchi Soya will come down to about 81 per cent, and the public will hold about 19 per cent. The company would utilise the entire issue proceeds for furthering its business by repayment of certain outstanding loans, meeting its incremental working capital requirements and other general corporate purposes, according to the Draft Red Herring Prospectus.
In 2019, Patanjali acquired Ruchi Soya through an insolvency process for Rs 4,350 crore.
Ruchi Soya primarily operates in the business of processing oilseeds, refining crude edible oil for use as cooking oil, manufacturing soya products and value-added products. The company has an integrated value chain in palm and soya segments, having a farm-to-fork business model.
It has brands like Mahakosh, Sunrich, Ruchi Gold and Nutrela.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
ALSO READ
Ruchi Soya raises Rs 1,290 cr from anchor investors
Patanjali says Rs 4,300-cr Ruchi Soya FPO to open on Mar 24; sets price band at Rs 615-650
Sunteck Inspires Beach Lovers at the pristine 'Suruchi Beach'
Sunteck inspires beach lovers at the pristine 'Suruchi Beach'
Ruchi Soya hits capital market to raise Rs 4,300 cr; to become debt-free | https://www.devdiscourse.com/article/business/1985315-ruchi-soya-fixes-fpo-issue-price-at-rs-650-per-share-to-raise-rs-4300cr | 2022-03-31T16:07:33 | en | 0.966574 |
You need to enable JavaScript to run this app. | https://sportspyder.com/nhl/toronto-maple-leafs/articles/39005718 | 2022-03-31T16:07:34 | en | 0.738227 |
INSPIRING SOCIAL MEDIA SENSATION AND INDIE MUSIC ARTIST AUTI SIGNS WITH PIVOTAL RECORDS DIVISION OF PIVOTAL MOMENTS MEDIA
NEW MUSIC SET TO BE RELEASED THIS SPRING
NASHVILLE, Tenn., March 31, 2022 /PRNewswire/ -- Viral music sensation AUTI, with 400 million + views of her "Shallow" duet with her father, announces studio sessions and upcoming EP in signing with Pivotal Moments Media (PMM), Pivotal Records division. The deal signals Auti's commitment to using her platform as an advocate for suicide prevention and mental health. The partnership includes new recordings, co-writing projects, and advocacy for brands and non-profits focused on ending mental health stigma helping more young feel safe and supported in asking for help.
"My journey, including facing the pain that comes from losing a friend to suicide, as well as dealing with my own mental health challenges, is a big part of my music and drive. I love hearing from people around the world that my music is something they can relate to and derive comfort from. I'm thrilled to work with Pivotal Records at this early stage in my career to reach more people," said AUTI.
AUTI is currently in the studio recording her first EP. Her style is alternative pop with an engaging sound influenced by her fandom for artists like Billie Eilish, Ariana Grande, and Avril Lavigne. Look for her first single release in early May.
Her signing with Pivotal Moments follows the organization's recently announced deal with Multi-platinum country music recording artist Ty Herndon. Herndon announced that he will host a new, ten-episode podcast SOUNDBOARD on the PMM platform channel Resilience, featuring conversations with high-profile artists discussing their wins and struggles in their mental fitness journeys.
"I've been in music for a long time now. I've experienced the ups and downs associated with mental wellness and standing up for something bigger than music. To see AUTI at such a young age align her music with passion for mental health is a model of courage that I am proud to support as ambassador for Pivotal Moments," said Herndon.
Pivotal Moments Media is a newly formed global entertainment and education brand, whose mission is to strengthen mental fitness worldwide by creating, distributing, and promoting entertainment and education programs that inspire and motivate people to become mentally fit, overcome adversity, and lead fulfilling lives.
About AUTI
Growing up in the Charleston, West Virginia area, Auti has looked at life through a different lens after being bullied in school and experiencing the loss of a close friend to suicide that led to her own mental health challenges. At 14, Auti went viral in a video singing "Shallow" (originally performed by Lady GaGa and Bradley Cooper) with her dad, amassing over 400 million views across various outlets, and hosted social media live performances to her following of more than 350,000 amazing fans. Auti taught herself multiple instruments in order to deliver the compassionate, imaginative, and reflective lyrics she has been writing for years. She has since worked with Dolly Parton's producer Kent Wells and recorded a duet with artist, MattyB, that has accumulated another 3 million views. She has opened for multi-platinum, Grammy nominated artists, Ty Herndon, Brady Seals, Jamie Floyd and others. In 2021, Auti won "Artist of the Year '' at The Josie Awards, which is the largest independent artist award show globally. Look for new music to be released in 2022.
About Pivotal Moments Media:
Pivotal Moments Media recognizes that many people do not get the information and education to identify and cope with mental health issues early enough. Recent health reports indicate that we live in an unprecedented mental health crisis, and our youth are especially affected (HHS). The PMM platform will curate and produce education and entertainment through its website, film, music, and other avenues with resources to encourage mental fitness. Instagram / Twitter / LinkedIn / Website
SOURCE Pivotal Moments Media | https://www.prnewswire.com/news-releases/inspiring-social-media-sensation-and-indie-music-artist-auti-signs-with-pivotal-records-division-of-pivotal-moments-media-301514636.html | 2022-03-31T16:07:39 | en | 0.959095 |
You need to enable JavaScript to run this app. | https://sportspyder.com/nhl/toronto-maple-leafs/articles/39005760 | 2022-03-31T16:07:40 | en | 0.738227 |
Domestic natural gas prices doubled; CNG, cooking gas to get costlier
Domestic natural gas prices will be more than doubled to USD 6.10 per million British thermal unit (mmBtu) effective from April 1, 2022, from the current USD 2.90 per mmBtu, Petroleum Planning and Analysis Cell (PPAC) of the Ministry of Petroleum and Natural Gas announced on Thursday.
- Country:
- India
Domestic natural gas prices will be more than doubled to USD 6.10 per million British thermal unit (mmBtu) effective from April 1, 2022, from the current USD 2.90 per mmBtu, Petroleum Planning and Analysis Cell (PPAC) of the Ministry of Petroleum and Natural Gas announced on Thursday. The new price will be effective for the first six months of the financial year 2022-23.
"In accordance with Para 8 of the 'New Domestic Natural Gas Pricing Guidelines, 2014' issued vide Ministry of Petroleum and Natural Gas, Govt of India, F.No. O-22-13/27/2012-ONG-D-V dated 25-10-1014 the price of domestic natural gas for the period 1st April 2022 to 30th September 2022 is $6.10/MMBtu on the Gross Caloric Value (GCV) basis," Petroleum Planning and Analysis Cell said in a release. This will result in an increase in the prices of piped cooking gas, CNG and other energy product. Apart from CNG and piped cooking gas, natural gas is also used to produce electricity and fertilisers.
The prices of the natural gas from deep fields will be increased to USD 9.92 per MMBtu for the April-September 2022 period from the existing price of USD 6.13 per mmBtu. (ANI)
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.) | https://www.devdiscourse.com/article/business/1985317-domestic-natural-gas-prices-doubled-cng-cooking-gas-to-get-costlier | 2022-03-31T16:07:41 | en | 0.883032 |
Joy Spreader Group Announces Strategic Investment in Mixed-Ownership Reform with Poly Culture Group
BEIJING, March 31, 2022 /PRNewswire/ -- Joy Spreader Group Inc. ("Joy Spreader" or the "Company", Stock Code: 06988.HK), a leader in new media performance-based marketing, is pleased to announce that on March 29, 2022, the Company entered into the Investment Agreement with Poly Boyi Culture Media Corporation ("Poly Boyi"), a wholly owned subsidiary of Poly Culture Group (03636.HK).
Poly Boyi is a wholly-owned subsidiary of Poly Film, under the control of central state-owned enterprise Poly Culture Group Corporation Limited.
After the mixed-ownership reform, Poly Boyi remains a central state-owned enterprise, and will explore new digital business opportunities combining film, television, culture and entertainment with internet technology, including but not limited to (1) businesses focusing on incubation and development of film, television, variety, internet entertainment and other products based on premium intellectual property (IP); (2) businesses focusing on digital transformation of central state-owned enterprises; (3) businesses focusing on the incubation, development and transaction of digital assets in culture and other fields; and (4) consultancy and advisory businesses based on the above-mentioned business fields.
With China's national policy support and the ongoing trend across all sectors to "go digital", the integration of technology into the making of movies and television programs has become the inevitable direction of the industry. State-owned players will play an increasingly important role in guidance and demonstration in the film and entertainment sectors. The joint investment by Joy Spreader and its controlling shareholder in the mixed-ownership reform of Poly Film's subsidiary is a move in line with this trend.
With the signing of the agreement and the establishment of the hybrid platform, as well as the deepening cooperation between the two parties, Joy Spreader will be able to leverage the complementary advantages of working with a central state-owned culture enterprise, as well as capitalize on the growth opportunities presented by the film, television, culture and entertainment industries going digital. The tie-up and the opportunities being made available will go a long way in facilitating the next stage of development of China's film, television, culture and entertainment sectors as well as setting a new bar for high-quality growth of the industry.
For more information about Joy Spreader Group Inc., please visit here.
Related Links www.joyspreader.com.cn
SOURCE Joy Spreader Group Inc. | https://www.prnewswire.com/news-releases/joy-spreader-group-announces-strategic-investment-in-mixed-ownership-reform-with-poly-culture-group-301514672.html | 2022-03-31T16:07:45 | en | 0.936821 |
You need to enable JavaScript to run this app. | https://sportspyder.com/nhl/toronto-maple-leafs/articles/39005763 | 2022-03-31T16:07:46 | en | 0.738227 |
You need to enable JavaScript to run this app. | https://sportspyder.com/nhl/toronto-maple-leafs/articles/39005792 | 2022-03-31T16:07:48 | en | 0.738227 |
Russia to give 100 bln roubles to support domestic air sector
- Country:
- Russian Federation
President Vladimir Putin said on Thursday that Russia would provide the domestic air sector with 100 billion roubles ($1.25 billion) in support to help it deal with the consequences of international sanctions.
In televised remarks at the end of a meeting with representatives of Russian airlines and aircraft manufacturers, he said domestic flights would also receive government subsidies in 2022. ($1 = 80.1250 roubles)
(Writing by Kevin Liffey; Editing by Mark Trevelyan)
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
- READ MORE ON:
- Russia
- Russian
- Kevin Liffey
- Vladimir Putin
Advertisement
ALSO READ
NATO to begin planning for more troops on eastern flank after Russia's Ukraine invasion
Ukraine president says positions of Ukraine, Russia at talks sound more realistic
Japan to revoke Russia's most-favoured nation trade status -sources
Russia's war in Ukraine may 'fundamentally alter' global economic, political order - IMF
Canada imposes sanctions on 15 more Russian officials | https://www.devdiscourse.com/article/business/1985337-russia-to-give-100-bln-roubles-to-support-domestic-air-sector | 2022-03-31T16:07:49 | en | 0.912749 |
You need to enable JavaScript to run this app. | https://sportspyder.com/nhl/toronto-maple-leafs/articles/39006535 | 2022-03-31T16:07:54 | en | 0.738227 |
30% tax on crypto income to come into effect from Friday
Several income tax proposals, including 30 per cent tax on income from trade in cryptocurrencies will come into effect from Friday.
Also, the revised norms for levy of 1 per cent TDS (tax deducted at source) on sale of immovable property exceeding Rs 50 lakh will come into effect from April 1, the beginning of the new financial year.
As per the revised norms, TDS of 1 per cent shall be deducted on consideration or stamp duty value, which ever is higher, as against the earlier provision of consideration.
Beginning next fiscal year, assessees will have the option to update their income tax returns in case there is any omission in original ITR. It would also provide opportunity to voluntarily disclose such income by filing an updated tax return with additional tax calculated based on the delay.
Taxpayers will be allowed to file such an updated return only once per financial year.
From April 1, 2022, income from transfer of virtual digital assets or cryptocurrencies is taxable at 30 per cent. Such income will be taxable even if taxpayers' total income is below the threshold limit of Rs 2.50 lakh. Further, no deduction other than cost of acquisition is allowed while computing the taxable amount.
Nangia Andersen LLP Partner Neeraj Agarwala said that disallowance of expenses under Section 14A would come into effect from April 1, 2022.
From Friday, expenses incurred for earning exempt income will not be allowed as a deduction.
The tax treatment of first time homebuyers as per Finance Act 2022 will come into effect from Friday.
According to Anita Basrur - Partner, Direct Tax - Sudit K Parekh & Co. LLP, in order to enable homebuyers have affordable and low cost funds at their disposal, a deduction of up to Rs 1,50,000 in respect of interest on loan, taken for residential house, was allowed subject to meeting certain conditions i.e. loan should be sanctioned during 2019-20, stamp value of the house should not exceed Rs 45,00,000 and the taxpayer should not own any other residential house on the date of sanction of the loan.
The period of sanction of the loan was extended from March 31, 2020 to March 31, 2021 and finally March 31, 2022 in the subsequent Finance Bills. There is no extension granted now.
''With the sunset of this section, homebuyers can still avail deduction for interest on loans taken for purchase of house property but the rate of interest will not be concessional but as per market. This would surely not make it feasible for people to afford houses due to the higher interest rates,'' Basrur said.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
ALSO READ
Ukraine sees room for compromise, as 20,000 escape Mariupol
China registers over 1,000 new daily COVID cases for fourth day
Jet fuel (ATF) price hiked by steepest ever 18 pc to record Rs 1,10,666.26 per kilolitre: Oil company price notification.
Microsoft releases Windows 11 Build 22000.588 to Insiders
At least 500 Kharkiv city residents killed so far in war with Russia - emergency service | https://www.devdiscourse.com/article/business/1985341-30-tax-on-crypto-income-to-come-into-effect-from-friday | 2022-03-31T16:07:56 | en | 0.9587 |
Main Street Announces New Portfolio Investment
Invests $36.4 Million in Jorgensen Laboratories, LLC
HOUSTON, March 31, 2022 /PRNewswire/ -- Main Street Capital Corporation (NYSE: MAIN) ("Main Street") is pleased to announce that it recently completed a new portfolio investment to facilitate the recapitalization of Jorgensen Laboratories, LLC ("JorVet" or the "Company"), a leading supplier of equipment and supplies to the veterinary profession. Main Street, along with its co-investor, partnered with the Company's existing owners and management team to facilitate the transaction, with Main Street funding $36.4 million in a combination of first lien term debt and a direct minority equity investment.
Founded in 1965 and headquartered in Loveland, Colorado, JorVet (www.jorvet.com) provides an extensive selection of veterinary medical equipment and supplies to veterinary practices, veterinary hospitals and universities across North America through a network of veterinary-specific distributors. Building on over 55 years of experience in the veterinary space, the Company, which markets both third-party products and a wide variety of products under the Company's JorVet brand, offers an unmatched product catalog of over 7,000 SKUs to meet the varying needs of its veterinarian end customer base.
Main Street (www.mainstcapital.com) is a principal investment firm that primarily provides long-term debt and equity capital to lower middle market companies and debt capital to middle market companies. Main Street's portfolio investments are typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. Main Street seeks to partner with entrepreneurs, business owners and management teams and generally provides "one stop" financing alternatives within its lower middle market investment strategy. Main Street's lower middle market companies generally have annual revenues between $10 million and $150 million. Main Street's middle market debt investments are made in businesses that are generally larger in size than its lower middle market portfolio companies.
Main Street, through its wholly owned portfolio company MSC Adviser I, LLC ("MSC Adviser"), also maintains an asset management business through which it manages investments for external parties. MSC Adviser is registered as an investment adviser under the Investment Advisers Act of 1940.
Contacts:
Main Street Capital Corporation
Dwayne L. Hyzak, CEO, [email protected]
Jesse E. Morris, CFO & COO, [email protected]
713-350-6000
Dennard Lascar Investor Relations
Ken Dennard | [email protected]
Zach Vaughan | [email protected]
713-529-6600
SOURCE Main Street Capital Corporation | https://www.prnewswire.com/news-releases/main-street-announces-new-portfolio-investment-301514066.html | 2022-03-31T16:07:57 | en | 0.932652 |
You need to enable JavaScript to run this app. | https://sportspyder.com/nhl/toronto-maple-leafs/articles/39006599 | 2022-03-31T16:08:00 | en | 0.738227 |
Mathew S. Rosengart Receives Prestigious California Lawyer 'Attorney of the Year' Award
LOS ANGELES, March 31, 2022 /PRNewswire/ -- Mathew S. Rosengart, a shareholder in global law firm Greenberg Traurig, LLP's Los Angeles office, was named a 2022 California Lawyer "Attorney of the Year" by the Los Angeles and San Francisco Daily Journal, which honors the state's top attorneys for their significant legal accomplishments and impact on public policy, law, and the profession over the past year.
Rosengart was also recently honored by the Los Angeles Business Journal as one of the leading litigators in Los Angeles who are "masters of their craft," "superb litigation specialists," and "the lawyers you want in your corner," while also being named one of the Top 100 attorneys in the state of California by the Daily Journal.
In addition to representing Britney Spears and helping free her from her 13-year conservatorship, Rosengart has served as lead counsel in numerous cases of national and international significance with a client list including A-list Hollywood talent such as Julia Louis-Dreyfus, Sean Penn, and Steven Spielberg, prominent film and television production companies, and corporations ranging from Verizon to Facebook. He has recently been recognized twice in The American Lawyer's Litigator of the Week column; been named Lawyer of the Year by Above the Law, Sports & Entertainment Trailblazer by The National Law Journal; and one of the top attorneys in the industry by Billboard. Rosengart has also been perennially recognized as one of the nation's leading litigators in media and entertainment by Variety and The Hollywood Reporter in their annual "Legal Impact" and Top 100 "Power Lawyer" Reports.
About Greenberg Traurig: Greenberg Traurig, LLP has more than 2400 attorneys in 42 locations in the United States, Europe, Latin America, Asia, and the Middle East. The firm, often recognized for its focus on philanthropic giving, innovation, diversity, and pro bono, reported gross revenue of over $2 Billion for FY 2021. The firm is consistently among the top firms on the Am Law 100, Am Law Global 100, NLJ 250, and Law360 (US) 400. On the debut 2022 Law360 Pulse Leaderboard, it is a Top 15 firm. Greenberg Traurig is Mansfield Rule 4.0 Certified Plus by The Diversity Lab and net carbon neutral with respect to its office energy usage. Web: www.gtlaw.com.
Media Contact:
L Brezo Scholl
212-801-2131
[email protected]
SOURCE Greenberg Traurig | https://www.prnewswire.com/news-releases/mathew-s-rosengart-receives-prestigious-california-lawyer-attorney-of-the-year-award-301514516.html | 2022-03-31T16:08:03 | en | 0.953131 |
Interest rates on small savings schemes unchanged for first quarter of FY23
The government on Thursday kept interest rates unchanged for small savings schemes, including PPF and NSC, for the first quarter of 2022-23 amid rising inflation.
The interest rate has not been revised since the first quarter of 2020-21.
Public Provident Fund (PPF) and National Savings Certificate (NSC) will continue to carry an annual interest rate of 7.1 per cent and 6.8 per cent, respectively, in the first quarter of the next financial year.
''The rate of interest on various small savings schemes for the first quarter of the financial year 2022-23, starting from April 1, 2022, and ending on June 30, 2022, shall remain unchanged from the current rates applicable for the fourth quarter (January 1, 2022, to March 31, 2022) for FY 2021-22,'' the finance ministry said in a notification.
Interest rates for small savings schemes are notified on a quarterly basis.
The one-year term deposit scheme will continue to earn an interest rate of 5.5 per cent in the first quarter of the next fiscal while the girl child savings scheme Sukanya Samriddhi Yojana will fetch 7.6 per cent.
It is to be noted that the country's biggest lender State Bank of India (SBI) offers 5 per cent interest rate on one-year fixed deposit.
The interest rate on the five-year senior citizens' savings scheme will be retained at 7.4 per cent. The interest on the senior citizens' scheme is paid on a quarterly basis.
The interest rate on savings deposits will continue to be at 4 per cent per annum.
Term deposits of one to five years will fetch an interest rate in the range of 5.5-6.7 per cent, to be paid quarterly while the interest rate on five-year recurring deposits will earn a higher interest of 5.8 per cent.
Recently, the Provident Fund (PF) rate was reduced to a four-decade low of 8.1 per cent for 2021-22 from 8.5 per cent.
Defending the proposal to cut interest rate paid on employees' provident fund deposits, Finance Minister Nirmala Sitharaman, earlier this month, said the rate is dictated by today's realities where interest rate on other small saving instruments was even lower.
Sitharaman had also cited the comparative prevailing interest rates of other schemes saying Sukanya Samriddhi Yojana offers 7.6 per cent, Senior Citizen saving scheme (7.4 per cent) and PPF (7.1 per cent) while SBI's 5-10 year fixed deposits gives 5.50 per cent.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
ALSO READ
Sri Lankan finance minister to meet Nirmala Sitharaman this week
Govt has borne higher cost of urea, not passed it on to farmers: FM Nirmala Sitharaman in Rajya Sabha on excess spending approval sought.
BJP's central observer for Manipur, finance minister Nirmala Sitharaman announces N Biren Singh will remain the state's chief minister.
100 pc COVID vaccination of eligible pollution achieved in J&K: FM Nirmala Sitharaman replying to debate on J&K budget in Rajya Sabha.
New industrial policy, investment proposal will create employment in Jammu and Kashmir: FM Nirmala Sitharaman on J&K Budget. | https://www.devdiscourse.com/article/business/1985342-interest-rates-on-small-savings-schemes-unchanged-for-first-quarter-of-fy23 | 2022-03-31T16:08:04 | en | 0.929661 |
You need to enable JavaScript to run this app. | https://sportspyder.com/nhl/toronto-maple-leafs/articles/39006645 | 2022-03-31T16:08:06 | en | 0.738227 |
SAN FRANCISCO, March 31, 2022 /PRNewswire/ -- Memberful, the leading membership software for independent entrepreneurs and creators, today announced Molly Baz and her exclusive members-only space, 'The Club,' will join Memberful.
'The Club' is an exclusive members-only space where Baz, a New York Times bestselling cookbook author, offers a community for food-loving people by food-loving people. Inside The Club, Molly shares her newest recipes, hosts giveaways, and offers special discounts to her favorite brands.
Memberful aligns Baz's mission with its full-service capabilities, keeping her brand and style front and center while serving as a central place for all of her ventures. With Memberful's integrated tools and decentralized software, Baz will be able to power an immersive and fully branded experience for her members.
"We are so excited to have Molly Baz join the Memberful family and use our best-in-class software to grow her business and connect more deeply with the community she has built." said Jen Matichuk, Strategic Partnerships Lead at Memberful.
Memberful's software is designed for independent creators and entrepreneurs like Baz, who want to own their content and audience while monetizing their passions.
Using a simplified interface, Memberful provides fully customizable software services, including WordPress, podcasts, newsletters, and community-based memberships, with no coding required. For more information on Memberful, visit www.memberful.com.
About Memberful
Founded in 2013, Memberful provides best-in-class membership software for entrepreneurs and independent content creators, including publishers, educators, podcasters, and more. Through Memberful, customers can quickly sell memberships to their audience and build sustainable businesses. For more information, visit www.memberful.com.
Press Inquiries:
Tribe Builder Media
Kristen Shea
929-367-8993
[email protected]
SOURCE Memberful | https://www.prnewswire.com/news-releases/memberful-announces-the-addition-of-the-club-by-molly-baz-301510934.html | 2022-03-31T16:08:09 | en | 0.940527 |
Wipro Consumer Care - Ventures invests in Singapore-based fund
- Country:
- India
Wipro Consumer Care & Lighting's venture funding arm, Wipro Consumer Care - Ventures, has invested in a Singapore-based VC Fund DSG Consumer Partners IV, a statement said.
The company did not disclose the amount of funding.
DSG, since its inception in 2012, is focused on the Asian consumer segment with marquee investments in Southeast Asia as well as India, a statement from Wipro Consumer Care - Ventures said.
Last week, Wipro Consumer Care - Ventures had invested in a D2C Ayurveda brand - T.A.C.-The Ayurveda Co.
Wipro Consumer Care & Lighting CEO Vineet Agrawal said: ''This is our first overseas investment from Wipro Consumer Care - Ventures. This is also the first time we are investing in a fund as Limited Partners (LP). Wipro Consumer Care & Lighting has a strong presence in South-east Asia, and we would be able to support startups in the region.” PTI KRH KRH MR MR
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
ALSO READ
Indians fight in court for right to be forgotten online
U.S., EU, India, S.Africa reach compromise on COVID vaccine IP waiver text
Inconsistent India bowled out for 134 against England in ICC Women's WC
India to host 44th World Chess Olympiad 2022 at Chennai
Alniche Lifesciences Bullish on Health Awareness Marketing Campaigns in India | https://www.devdiscourse.com/article/business/1985346-wipro-consumer-care---ventures-invests-in-singapore-based-fund | 2022-03-31T16:08:12 | en | 0.931956 |
You need to enable JavaScript to run this app. | https://sportspyder.com/nhl/toronto-maple-leafs/articles/39006757 | 2022-03-31T16:08:12 | en | 0.738227 |
Meta to Open Hyperscale Data Center in Temple, Texas
Company to invest $800 million, support 100 jobs in Central Texas
TEMPLE, Texas, March 31, 2022 /PRNewswire/ -- Meta, formerly the Facebook company, announced today that it will invest $800 million in the creation of a Hyperscale Data Center in Temple, Texas. The new facility, which will total approximately 900,000 square feet when completed, will be located on 393 acres off NW H K Dodgen Loop and Industrial Blvd., and will support approximately 100 operational jobs in the community. The project is expected to employ 1,250 construction workers onsite during peak construction, which will begin in Spring 2022.
"We are thrilled to announce Meta's decision to open a facility in Temple," said Adrian Cannady, President and CEO of Temple Economic Development Corporation. "Texas was recently named the top state in the nation for tech worker migration. When you combine that with Temple's low cost of doing business and central location between major markets, it creates an incredible competitive advantage for our region. The Hyperscale Data Center will have a positive impact on our community not only by creating jobs, but because of Meta's commitment to invest in local schools, nonprofits and community projects."
Meta builds and operates some of the world's most sustainable data centers, which are supported by 100% renewable energy. Meta's data centers use 32% less energy, have achieved net zero carbon emissions, are LEED Gold level certified and are 80% more water-efficient on average than industry standard, with a goal to restore more water than they consume by 2030.
In Texas, Meta has invested in more than 700 MW of new wind and solar energy. The company adds new renewable energy to each data center's local grid.
"Temple is the home of our newest data center, and we are excited to join the community," said Darcy Nothnagle, director of community and economic development at Meta. "We've been welcomed by a strong set of local partners who are committed to the long-term success of the region. This is just the beginning of a strong partnership, and we look forward to working with you to invest in this great community."
In Temple, businesses have access to a prime location between Dallas and Austin and 28 million people within two-and-a-half hours. From logistics and life sciences to the technology and services that support these sectors, Temple is home to a thriving industry base.
"Meta's continued expansion in Texas is a testament to the exceptional business climate and skilled, diverse workforce we have here in the Lone Star State," said Texas Governor Greg Abbott. "It is because of hardworking Texans and our commitment to helping businesses grow that companies continue to move and expand all across Texas. We are excited to welcome Meta to Temple and look forward to the new job opportunities they will bring to the local community, as well as the advancements in technology we will see in the future."
Temple is also a regional employment hub on the rise with 450,000 residents. Expanding career opportunities, diversified industries and a low cost of living are attracting the next generation of skilled workers. Savvy college grads, highly trained military veterans and technical expertise are powering business in Temple.
"The City of Temple is known in the region for its business-friendly environment. Meta's decision to establish a presence here in Temple is a significant win for our community and proof that our process works." said Mayor of Temple, Tim Davis, "We are excited for the opportunities this project will create for our residents and look forward to being a part of Meta's continued growth."
For more information on the data center, please follow facebook.com/TempleDataCenter.
About Temple Economic Development Corporation
The Temple Economic Development Corporation (Temple EDC) is a nonprofit organization that serves as the designated economic development entity for the City of Temple, Texas. Temple EDC strengthens relationships, builds partnerships, and provides solutions that cause entities to choose Temple. To learn more about doing business in Temple, visit TempleEDC.com.
About the City of Temple
Temple, located 45 minutes north of Austin, offers the perfect compromise between welcoming small-town living and the hustle of a big city. Striking a balance between vibrancy and livability, Temple continues to grow its amenities for residents, while maintaining a safe, family-friendly, caring culture. Whether it is the scenic parks and trails, the family friendly atmosphere, or the unique neighborhoods with Texas charm, we think you will find something here that you love! Our vision is for Temple to be a place that you love to call home. Visit templetx.gov for more information.
About Meta
Meta builds technologies that help people connect, find communities, and grow businesses. When Facebook launched in 2004, it changed the way people connect. Apps like Messenger, Instagram and WhatsApp further empowered billions around the world. Now, Meta is moving beyond 2D screens toward immersive experiences like augmented and virtual reality to help build the next evolution in social technology. Visit about.facebook.com/meta/ for more information.
SOURCE Temple Economic Development Corporation | https://www.prnewswire.com/news-releases/meta-to-open-hyperscale-data-center-in-temple-texas-301514530.html | 2022-03-31T16:08:15 | en | 0.950864 |
You need to enable JavaScript to run this app. | https://sportspyder.com/nhl/toronto-maple-leafs/articles/39006758 | 2022-03-31T16:08:18 | en | 0.738227 |
IMF says 'clear-eyed' about risks to Argentine economy, IMF program
- Country:
- United States
The International Monetary Fund and Argentine government have been 'clear-eyed' about the exceptionally high risks facing the Argentine economy and a new $44 billion IMF program approved Friday, IMF spokesperson Gerry Rice said on Thursday.
Rice told reporters Argentina's economy was recovering more strongly than expected after three years of recession and persistent high inflation, but it was also subject to the global shock caused by the war in Ukraine.
"So, it's no surprise that the risks to the Argentine economy, and therefore, to the program are high," he said, adding that the IMF would work closely with Argentine authorities to ensure successful implementation of the program.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
- READ MORE ON:
- Rice
- The International Monetary Fund
- Ukraine
- Argentina
- Gerry Rice
- Argentine
ALSO READ
NATO to begin planning for more troops on eastern flank after Russia's Ukraine invasion
Ukraine president says positions of Ukraine, Russia at talks sound more realistic
Biden expected to announce $800 mln in security aid for Ukraine -official
Ukraine war creating a child refugee almost every second: UNICEF
Russia's war in Ukraine may 'fundamentally alter' global economic, political order - IMF | https://www.devdiscourse.com/article/business/1985348-imf-says-clear-eyed-about-risks-to-argentine-economy-imf-program | 2022-03-31T16:08:19 | en | 0.94739 |
NATIVE AMERICAN-OWNED INSURANCE FIRM BRIDGING TOGETHER INNOVATIVE SOLUTIONS FOR INDIAN COUNTRY
Now Open – Ribbon Cutting April 2022
JACKSON, Miss., March 31, 2022 /PRNewswire/ -- Tribal Edge Insurance, a Native America-owned brokerage firm, is excited to announce it has opened its doors for business. Tribal Edge was formed to address the unique challenges and opportunities every Tribe faces. Our approach is simple: we build a customized solution based on each Tribe's individual needs.
Tribal Edge has a game-changing approach; We don't just want to be your broker we want to be your community partner and promote health and wellness throughout Indian Country. We focus on controlling costs, allowing Tribes and Native-owned businesses to reinvest this savings into alternative benefits that are relevant to their Tribal Member and employee population and community. Additionally, we have an Innovative Workforce Development Approach that with your guidance and when feasible, we hire and train benefit representatives from your Tribe for your Tribe! We look forward to helping your Tribe, and/or business, with innovative broker services, underwriting, employee benefits, health insurance, pharmacy, clinical and human resource solutions.
Our Tribal Edge team is brought to you by Tribal Solutions Group a National Native American-owned company with a long history of Tribal government and Tribal enterprise experience with a national presence across the United States. Premier Workforce Solutions, a strategic partner to Tribal Edge, brings HR, Benefit, and Health Plan experience.
Save the Date! Mark your calendars for Thursday, April 21, 2022 at 11:00 a.m. – 1:00 p.m. to join us for a Ribbon Cutting Ceremony and Open House at the Tribal Edge office located at 4780 I-55 Suite #450, Jackson, MS 39211.
Call us today at 215.896.6162 or visit us online at tribaledgeinsurance.com to learn more and set up a consultation to discuss how we can help your business start saving today.
Contact Information:
Tribal Edge, LLC
Ted McKenzie, Administrator
(215) 896-6162
[email protected]
Wendy Feldbauer
[email protected]
SOURCE Tribal Edge Insurance | https://www.prnewswire.com/news-releases/native-american-owned-insurance-firm-bridging-together-innovative-solutions-for-indian-country-301514485.html | 2022-03-31T16:08:21 | en | 0.927523 |
You need to enable JavaScript to run this app. | https://sportspyder.com/nhl/toronto-maple-leafs/articles/39006800 | 2022-03-31T16:08:24 | en | 0.738227 |
VIENNA, Va., March 31, 2022 /PRNewswire/ -- Euclid Fiduciary released a new whitepaper authored by the underwriting company's Managing Principal Daniel Aronowitz reviewing the common misleading tactics used by plaintiff law firms to allege excessive plan administration fees. While recordkeeping fees represent less than twenty percent of total fees for defined contribution plans, the majority of purported excessive fee cases still allege a claim of excess recordkeeping fees. The goal in all of these cases is to survive a motion to dismiss and then leverage settlement pressure based on high discovery costs and inflated damage models. Unfortunately, most courts have allowed claims of excess recordkeeping fees to proceed to discovery, which allows many illegitimate cases to create settlement pressure based on litigation uncertainty and a high damages model.
According to Euclid's whitepaper, "most large defined contribution retirement plans in this country have low recordkeeping fees – fees that are often five to ten times lower than the recordkeeping fees in most under $100 million small-asset plans." But given the rampant misrepresentations of actual fee levels in the excess fee lawsuit claims, federal courts have not been given the proper perspective or context to make informed decisions on threshold pleading motions.
The whitepaper reviews that the Supreme Court held in Hughes v. Northwestern, 142 S. Ct. 737 (2022), held that all excess fee claims based on circumstantial evidence must be subjected to context-based scrutiny in order to survive as a plausible lawsuit. According to Daniel Aronowitz, "the only credible way to meet this context-based plausibility standard is if the fees are egregious based on a reliable, third-party benchmark." Aronowitz further indicates that, "Fees within a reasonable range of established benchmarks – not plaintiff-manufactured benchmarks – are not plausible under the Supreme Court pleadings standard. In a claim of excessive fees, the only context that makes sense is if the fees are actually excessive at the threshold stage of the case. "
The common theme in all of the tactics debunked in the Euclid whitepaper is that the excessive fee plaintiffs bar is estimating or speculating on the plan's recordkeeping fees. In most cases, inaccurate and inflated data is taken from the Form 5500 filings. Plaintiff firms know these Form 5500 fee numbers include transaction fees beyond plan recordkeeping, but assume that courts will defer to their allegations as true, even when the purported excess fee claims are often overstated and factually incorrect. But Euclid demonstrates that there is no need to estimate or speculate as to the plan fees, because every participant suing in these cases has access to Department of Labor mandated fee disclosures every three months. The participant fee disclosure contains the actual recordkeeping fees. Euclid urges the courts to demand accountability by requiring all excess fee lawsuits to disclose the true plan fees and investments from regulated fee disclosures. In addition, Euclid urges that the actual fees must be judged against valid, third-party fee benchmarks, and not plaintiff-contrived comparators. Only then can courts provide the careful, context scrutiny of excess fee claims based on circumstantial evidence. And with a true portrait of the low plan administration fees enjoyed by most large defined contribution plans, courts will have more complete perspective and context to dismiss implausible cases of excess plan fees.
To learn more, download the Whitepaper "Debunking Recordkeeping Fee Theories in "Excessive" Fee Cases" or visit our website at www.euclidfiduciary.com.
About Euclid Fiduciary
Euclid Specialty Managers, LLC, dba Euclid Fiduciary, is an insurance program administration company specializing in fiduciary liability insurance coverage for America's employee benefit plans. Euclid offers best-in-class fiduciary, crime/ERISA fidelity, cyber liability, employment practices, and other professional liability insurance coverages to protect the fiduciaries of U.S. employee benefit plans. Our underwriters and claim professionals are experts in complex fiduciary liability and crime exposures, with decades of fiduciary liability experience and expertise.
SOURCE Euclid Fiduciary | https://www.prnewswire.com/news-releases/new-euclid-fiduciary-whitepaper--debunking-recordkeeping-fee-theories-in-excessive-fee-cases-301514423.html | 2022-03-31T16:08:27 | en | 0.925258 |
Odisha hikes bus fares as diesel price spirals
The Odisha government on Thursday increased the fares of buses across all categories as the diesel price continued to skyrocket in the country.
In an order, the State Transport Authority (STA) justified the hike as the diesel price shot up to Rs 98.40 currently in the state as against Rs 91.61 on November 6 last year.
The fares for ordinary and express categories of buses have been revised by 3 paise per kilometre to 90 paise/km and 94 paise/km respectively.
It has risen by six paise/km for Deluxe and AC Deluxe, which will charge Rs 1.31 and Rs 1.59 per kilometre respectively.
The super premium buses will be costlier by 9 paise/km as the rate has increased to Rs 2.47 per km.
The fare for stage carriages, other than town buses plying within the state, will be fixed at the increased rate, which will be effective from the date of the order, the STA said.
A ride in an ordinary bus from the Baramunda stand in Bhubaneswar to Malkangiri will cost Rs 619, the highest for a journey to any district headquarter from the capital.
Petrol and diesel prices were on Thursday hiked by 80 paise a litre each, taking the total increase in rates in the last 10 days to Rs 6.40 per litre, according to a price notification of state fuel retailers.
This is the ninth increase in prices since March 22 after a four-and-a-half-month-long hiatus in rate revision.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
- READ MORE ON:
- Odisha
- Malkangiri
- Deluxe
- AC Deluxe
- Baramunda
- Bhubaneswar
- State Transport Authority | https://www.devdiscourse.com/article/business/1985352-odisha-hikes-bus-fares-as-diesel-price-spirals | 2022-03-31T16:08:27 | en | 0.951379 |
You need to enable JavaScript to run this app. | https://sportspyder.com/nhl/toronto-maple-leafs/articles/39006893 | 2022-03-31T16:08:31 | en | 0.738227 |
Novavax Submits Request to Expand Conditional Marketing Authorization of COVID-19 Vaccine in the European Union to Adolescents (Ages 12-17)
- If granted, Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) would be the first protein-based option for adolescents aged 12-17 years in Europe
GAITHERSBURG, Md., March 31, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced submission of its request to expand the conditional marketing authorization (CMA) of Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) in the European Union (EU) to adolescents aged 12 through 17 years.
"We are continuing to see spikes in COVID-19 across Europe and recognize the need to improve vaccination rates, particularly in the pediatric population," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "We look forward to a decision from the European Medicines Agency and firmly believe in the benefit of diversified vaccine options."
The submission includes clinical data from the ongoing pediatric expansion of PREVENT-19, a pivotal Phase 3 trial of 2,247 adolescents aged 12 through 17 years across 73 sites in the U.S., to evaluate the safety, effectiveness (immunogenicity), and efficacy of Novavax' COVID-19 vaccine. The vaccine, also known as NVX-CoV2373, achieved its primary effectiveness endpoint in the trial and demonstrated 80% efficacy overall at a time when the Delta variant was the predominant circulating strain in the U.S.
Additionally, preliminary safety data from the pediatric expansion of PREVENT-19 showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups, and not considered related to the vaccine. Local and systemic reactogenicity was generally lower than or similar to adults, after the first and second dose. The most common adverse reactions observed were injection site tenderness/pain, headache, myalgia, fatigue, and malaise.
The submission builds on Novavax' efforts to expand authorizations of its COVID-19 vaccine to younger populations. The Drugs Controller General of India recently approved NVX-CoV2373 for restricted use in emergency situation for adolescents aged 12 through 17 years in India. SK bioscience, Novavax' licensee in South Korea, also recently submitted a regulatory filing for adolescent authorization of the vaccine to the Korean Ministry of Food and Drug Safety. Novavax expects to initiate rolling submissions of regulatory filings in this age group to additional regulatory authorities worldwide and to initiate additional studies globally evaluating younger age groups during the second quarter of 2022.
The European Commission granted CMA for Nuvaxovid to prevent COVID-19 in people 18 years of age and older in December 2021. Doses of Nuvaxovid began shipping to EU member states shortly thereafter. For additional information on Nuvaxovid, please visit the following websites:
European Commission has granted conditional marketing authorization for Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.
NVX-CoV2373 has not yet been authorized for use in the U.S. and the trade name Nuvaxovid has not yet been approved by the U.S. FDA.
- Nuvaxovid is contraindicated in persons who have a hypersensitivity to the active substance, or to any of the excipients.
- Events of anaphylaxis have been reported with administration of COVID-19 vaccines. Appropriate medical treatment and supervision should be available in case of an anaphylactic reaction following the administration of the vaccine. Close observation for at least 15 minutes is recommended and a second dose of the vaccine should not be given to those who have experienced anaphylaxis to the first dose of Nuvaxovid.
- Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation, or stress‐related reactions may occur in association with vaccination as a psychogenic response to the needle injection. It is important that precautions are in place to avoid injury from fainting.
- Vaccination should be postponed in individuals suffering from an acute severe febrile illness or acute infection. The presence of a minor infection and/or low-grade fever should not delay vaccination.
- Nuvaxovid should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
- The efficacy of Nuvaxovid may be lower in immunosuppressed individuals.
- Administration of Nuvaxovid in pregnancy should only be considered when the potential benefits outweigh any potential risks for the mother and foetus.
- The effects with Nuvaxovid may temporarily affect the ability to drive or use machines.
- Individuals may not be fully protected until 7 days after their second dose. As with all vaccines, vaccination with Nuvaxovid may not protect all vaccine recipients.
- The most common adverse reactions observed during clinical studies were headache, nausea or vomiting, myalgia, arthralgia, injection site tenderness/pain, fatigue, and malaise.
For additional safety information, including the full Summary of Product Characteristics with Package Leaflet, please visit www.NovavaxCovidVaccine.com.
Information on this medicine is also available on the European Medicines Agency website.
NVX-CoV2373 is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Novavax' patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.
Novavax' COVID-19 vaccine is packaged as a ready-to-use liquid formulation in a vial containing ten doses. The vaccination regimen calls for two 0.5 ml doses (5 mcg antigen and 50 mcg Matrix-M adjuvant) given intramuscularly 21 days apart. The vaccine is stored at 2°- 8° Celsius, enabling the use of existing vaccine supply and cold chain channels. Use of the vaccine should be in accordance with official recommendations.
Novavax has established partnerships for the manufacture, commercialization and distribution of NVX-CoV2373 worldwide. Existing authorizations leverage Novavax' manufacturing partnership with Serum Institute of India (SII), the world's largest vaccine manufacturer by volume. They will later be supplemented with data from additional manufacturing sites throughout Novavax' global supply chain.
NVX-CoV2373 is being evaluated in two pivotal Phase 3 trials.
PREVENT-19, a trial in the U.S. and Mexico that enrolled almost 30,000 participants aged 18 years and older, achieved 90.4% efficacy overall. It was designed as a 2:1 randomized, placebo-controlled, observer-blinded study to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373. The primary endpoint for PREVENT-19 was the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19 with onset at least 7 days after the second dose in serologically negative (to SARS-CoV-2) adult participants at baseline. The statistical success criterion included a lower bound of 95% CI >30%. A secondary endpoint was the prevention of PCR-confirmed, symptomatic moderate or severe COVID-19. Both endpoints were assessed at least seven days after the second study vaccination in volunteers who had not been previously infected with SARS-CoV-2. It was generally well-tolerated and elicited a robust antibody response after the second dose in both studies. Full results of the trial were published in the New England Journal of Medicine (NEJM).
A trial conducted in the U.K. with 14,039 participants aged 18 years and older was designed as a randomized, placebo-controlled, observer-blinded study and achieved overall efficacy of 89.7%. The primary endpoint was based on the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19 with onset at least 7 days after the second study vaccination in serologically negative (to SARS-CoV-2) adult participants at baseline. Full results of the trial were published in NEJM.
Novavax' patented saponin-based Matrix-M™ adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company's COVID-19 vaccine, has received conditional authorization from multiple regulatory authorities globally, including the European Commission and the World Health Organization. The vaccine is also under review by multiple regulatory agencies worldwide. In addition to its COVID-19 vaccine, Novavax is also currently evaluating a COVID-seasonal influenza combination vaccine in a Phase 1/2 clinical trial, which combines NVX-CoV2373 and NanoFlu, its quadrivalent influenza investigational vaccine candidate. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on Twitter, LinkedIn, Instagram and Facebook.
Statements herein relating to the future of Novavax, its operating plans and prospects, its partnerships, the timing of clinical trial results, the ongoing development of NVX-CoV2373, including Novavax' plans to initiate pediatric studies in Q2 2022, its COVID-seasonal influenza investigational vaccine candidate, the scope, timing and outcome of future regulatory filings and actions, including Novavax' plans to supplement existing authorizations with data from the additional manufacturing sites in Novavax' global supply chain, additional worldwide authorizations of NVX-CoV2373 for adolescents, the potential impact and reach of Novavax and NVX-CoV2373 in addressing vaccine access, controlling the pandemic and protecting populations, and the efficacy, safety and intended utilization of NVX-CoV2373 are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax' Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Contacts:
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
[email protected]
Solebury Trout
Alexandra Roy | 617-221-9197
[email protected]
Media
Ali Chartan | 240-720-7804
Laura Keenan Lindsey | 202-709-7521
[email protected]
SOURCE Novavax, Inc. | https://www.prnewswire.com/news-releases/novavax-submits-request-to-expand-conditional-marketing-authorization-of-covid-19-vaccine-in-the-european-union-to-adolescents-ages-12-17-301514498.html | 2022-03-31T16:08:34 | en | 0.922754 |
OneCode raises Rs 100 cr led by General Catalyst
Fintech firm OneCode on Thursday said it has raised Rs 100 crore in a funding round led by General Catalyst. The series A funding round also saw participation from existing investors including Sequoia Capital Indias Surge, Nexus Venture Partners, and Waterbridge Ventures.
- Country:
- India
Fintech firm OneCode on Thursday said it has raised Rs 100 crore in a funding round led by General Catalyst. The series A funding round also saw participation from existing investors including Sequoia Capital India's Surge, Nexus Venture Partners, and Waterbridge Ventures. Angel investors like Vidit and Sanjeev from Meesho, Madhusudhan from M2P, Vikas Choudhary (President at Reliance Jio), DSP Family Office, and Reddy Futures Fund also participated in the funding round, the startup said. ''OneCode will use this capital to invest in hiring across functions and accelerate the product and tech development. The company will be expanding its presence to 100 additional cities and will increase the size of its agent network by 500 per cent by 2025,'' OneCode said.
''Its distribution network of trusted agents offers the much-needed assurance to customers as people rely heavily on their networks for recommendations, especially when it comes to critical financial services,” OneCode Co-founder and CEO Manish Shara said.
The company was founded in 2019 by Manish Shara and Yash Desai. PTI PRS RUJ RUJ
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.) | https://www.devdiscourse.com/article/business/1985354-onecode-raises-rs-100-cr-led-by-general-catalyst | 2022-03-31T16:08:35 | en | 0.945187 |
You need to enable JavaScript to run this app. | https://sportspyder.com/nhl/toronto-maple-leafs/articles/39006906 | 2022-03-31T16:08:37 | en | 0.738227 |
Company recognized for its leadership in community service and corporate social responsibility as well as environmental responsibility
PROVO, Utah, March 31, 2022 /PRNewswire/ -- Nu Skin Enterprises, Inc. (NYSE: NUS), a global leader in beauty and wellness, today received two Communitas Awards for Leadership in Community Service and Corporate Social Responsibility, as well as Leadership in Ethical and Environmental Responsibility.
The Communitas Awards is an international effort to recognize the spirit of communitas—people helping people. The awards recognize exceptional businesses, organizations and individuals for excellence in community service and corporate social responsibility.
"Our force for good efforts are at the heart of who we are at Nu Skin. As a beauty and wellness company, we hope that in addition to our incredible product offering, we will always keep our sights on the health and well-being of people and our planet," said Ruth Todd, chief reputation officer at Nu Skin. "We are honored to receive recognition in community service, corporate responsibility and environmental efforts, and we are committed to continued enhancement and expansion in each of these areas in the months and years ahead."
Communitas Awards evaluated Nu Skin's sustainability and corporate social responsibility efforts based on the extent and effectiveness of its efforts to fight malnutrition, provide health and wellness opportunities for children and reduce its carbon footprint. They also evaluated Nu Skin's global charity efforts, including more than 30 community-based outreach projects and sustainability commitments stretching to 2030.
For more information about Nu Skin's sustainability and community outreach efforts, visit nuskin.com/forceforgood.
Communitas Awards was started in 2010 as an outgrowth of the pro bono recognition program of the Association of Marketing and Communication Professionals (www.amcpros.com), a several-thousand-member group that honors creative achievement and fosters partnerships with charities and community organizations. As part of its mission, AMCP gives grants to community organizations and underwrites a large portion of Communitas expenses.
Communitas Awards seeks to honor those special companies, organizations and individuals who go beyond rhetoric and whose commitment sets them apart from their competition. Communitas winners are dedicated to helping the less fortunate in their communities and are changing the way they do business to benefit their employees, communities and environment.
Nu Skin Enterprises, Inc. (NYSE: NUS) is a leading beauty and wellness company, powered by a dynamic affiliate opportunity platform. The company helps people, look, feel and live their best with products that combine the best of science, technology and nature. Backed by more than 35 years of scientific research, Nu Skin develops innovative products including Nu Skin® personal care, Pharmanex® nutrition and the ageLOC® anti-aging brand which includes an award-winning line of beauty device systems. Nu Skin operates in approximately 50 markets worldwide in the Americas, Asia, Europe, Africa and the Pacific. Rhyz Inc. is the company's strategic investment arm that includes a collection of technology and manufacturing companies to support growth in the core Nu Skin business. Nu Skin is committed to sustainability, including global initiatives such as transitioning to reduced and sustainable packaging for all products by 2030. The Nu Skin Force for Good Foundation also strives to improve children's health, education and economic circumstances throughout the world. For more information, visit nuskin.com.
Nu Skin Social Media Channels
fb.com/nuskin twitter.com/nuskin instagram.com/nuskin fb.com/ForceForGood
SOURCE Nu Skin Enterprises | https://www.prnewswire.com/news-releases/nu-skin-receives-two-communitas-awards-for-csr-leadership-301514106.html | 2022-03-31T16:08:40 | en | 0.958219 |
Net claims of non-residents on India up by USD 21.1 bn in Sep-Dec quarter
Net claims of non-residents on India increased by USD 21.1 billion during the December quarter due to an increase in foreign-owned assets combined with a decline in Indian residents' overseas financial assets, according to the RBI data.
Higher inward direct investment, trade credit and loans contributed to the increase in non-residents’ claims on India even as foreign portfolio investment in India reduced during the quarter, said India’s International Investment Position (IIP), December 2021.
''Net claims of non-residents on India increased by USD 21.1 billion during October-December 2021 due to an increase of USD 16.2 billion in foreign-owned assets in India combined with a decline of USD 4.9 billion in Indian residents’ overseas financial assets,'' it said.
Indian residents’ overseas financial assets declined during the quarter, mainly due to reduction in currency and deposits.
As per the IIP, reserve assets accounted for 68.4 per cent of Indian residents’ foreign assets.
Also, the share of debt liabilities in total liabilities increased marginally during the quarter and stood at 48.5 per cent in December 2021.
The ratio of India’s international financial assets to international financial liabilities stood lower at 72.1 per cent in December 2021 (73.4 per cent in September 2021), the RBI said.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
- READ MORE ON:
- Indian
- International Investment Position
- India | https://www.devdiscourse.com/article/business/1985355-net-claims-of-non-residents-on-india-up-by-usd-211-bn-in-sep-dec-quarter | 2022-03-31T16:08:43 | en | 0.95484 |
Veteran Biotech Executive with Broad Oncology Perspective to Lead Nuvalent Board as Company Advances its Pipeline of Precisely Targeted Therapies
CAMBRIDGE, Mass., March 31, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical stage biopharmaceutical company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics, as Chair of its Board of Directors.
"I am excited to join the Nuvalent Board of Directors and have been impressed by both the team's capital efficient advancement of its two lead programs towards potential clinical proof of concept and the strong potential to deliver meaningful value to patients," said Ms. Protopapas. "The Nuvalent team has demonstrated that it can combine drug discovery expertise with a deep understanding of medical needs to advance molecules that are differentiated in meaningful ways for the potential benefit of patients. I anticipate the portfolio will continue to grow and mature, and look forward to working with the team towards the goal of building a sustainable organization that can repeatedly discover, develop, and deliver meaningful new therapies for patients with cancer."
Ms. Protopapas joined Mersana in March 2015 and has a substantial track record of executive leadership and business growth in the field of oncology. Her broad industry experience ranges from global development to commercial expertise with a focus on building companies from start-ups to leaders in their categories. She will assume the role of Board Chair from Cameron Wheeler, Ph.D., Partner at Deerfield Management, who will remain on Nuvalent's Board of Directors.
"I am proud to have worked closely with this talented team to accelerate the formation and early growth of Nuvalent, and to help drive its successful evolution into a public company," said Dr. Wheeler. "With continued confidence in Nuvalent's approach and long-term vision, we welcome Anna as incoming Board Chair to further strengthen the team as we navigate the next phase of Nuvalent's growth."
Nuvalent is currently enrolling patients in the Phase 1 portion of its ARROS-1 study, a Phase 1/2 clinical trial evaluating its lead candidate NVL-520, a ROS1-selective inhibitor, in patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) and other solid tumors. In addition, Nuvalent recently announced clearance of its Investigational New Drug application for its parallel lead candidate NVL-655, an ALK-selective inhibitor. The company expects to initiate the Phase 1 portion of the Phase 1/2 ALKOVE-1 study for advanced ALK-positive NSCLC and other solid tumors in the second quarter of 2022. NVL-520 and NVL-655 are designed with the aim to address the clinical challenges of emergent treatment resistance, CNS adverse events, and brain metastases that may limit the use of currently available kinase inhibitors.
"On behalf of the Nuvalent team, I thank Cam and the Deerfield team for their continued support and strategic guidance. We are fortunate to build on the strong foundation they have helped to establish as we transition Anna into the role of Board Chair," said James Porter, Ph.D., Chief Executive Officer at Nuvalent. "Anna has made a tremendous impact on the field of oncology therapeutics and brings with her a stellar reputation of guiding and growing companies. I welcome her experience and guidance to Nuvalent as we continue advancing our mission of delivering precisely targeted therapies for patients with cancer."
Prior to Mersana, Ms. Protopapas was President of Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Limited, where she led Takeda's oncology business. Ms. Protopapas also served as Executive Vice President of Global Business Development at Takeda, was a member of the company's executive committee, and served as a corporate officer. Earlier, Ms. Protopapas was an executive officer at Millennium and served in various senior leadership positions, playing an integral role in the company's transformation from a genomics start-up to a fully integrated oncology leader.
Ms. Protopapas has proven leadership in building and growing biotechnology companies, previously serving on the Board of Directors for ARIAD Pharmaceuticals, Bioverativ and Dicerna Pharmaceuticals. She earned her B.S. in Science and Engineering from Princeton University, M.S. in Chemical Engineering Practice from the Massachusetts Institute of Technology, and M.B.A. from Stanford Graduate School of Business.
About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC), along with multiple discovery-stage research programs. We routinely post information that may be important to investors on our website at www.nuvalent.com. Follow us on Twitter (@nuvalent) and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Nuvalent's strategy, business plans, and focus; the clinical development programs for NVL-520, NVL-655 and the timing thereof; the potential clinical effect of NVL-520 and NVL-655; the design and enrollment of the ARROS-1 study and the timing thereof; the design and initiation of the ALKOVE-1 Phase 1/2 study and the timing thereof; the potential of Nuvalent's pipeline programs, including NVL-520 and NVL-655; Nuvalent's research and development programs for the treatment of cancer; risks and uncertainties associated with drug development; capital allocation; Nuvalent's future financial and operating results and its expectations related thereto; and the expected benefits from the appointment to the Nuvalent Board of Directors of Ms. Protopapas. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "aim," "goal," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" or the negative of these terms and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. You should not place undue reliance on these statements or the scientific data presented.
Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: risks that Nuvalent may not fully enroll the ARROS-1 study or it will take longer than expected; unexpected concerns that may arise from additional data, analysis, or results obtained during clinical trials; the occurrence of adverse safety events; risks of unexpected costs, delays, or other unexpected hurdles; the impact of COVID-19 on countries or regions in which Nuvalent has operations or does business, as well as on the timing and anticipated timing and results of its clinical trials, strategy, and future operations, including the global ARROS-1 study and the planned initiation of the ALKOVE-1 Phase 1/2 study; the timing and outcome of Nuvalent's planned interactions with regulatory authorities; and obtaining, maintaining, and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Nuvalent's views only as of today and should not be relied upon as representing its views as of any subsequent date. Nuvalent explicitly disclaims any obligation to update any forward-looking statements
SOURCE Nuvalent, Inc. | https://www.prnewswire.com/news-releases/nuvalent-appoints-anna-protopapas-as-chair-of-board-of-directors-301514364.html | 2022-03-31T16:08:46 | en | 0.959438 |
Independent review identified, no safety concerns in trial's final safety run-in
Cohort supported by prior clinical data showing a pelareorep-based combination driving a 90% clinical benefit rate in KRAS-mutated colorectal cancer patients
Multi-indication trial being conducted in collaboration with Roche and AIO also includes pancreatic and advanced anal cancer cohorts
SAN DIEGO, Calif. and CALGARY, AB, March 31, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the successful completion of the three-patient safety run-in for the third-line metastatic colorectal cancer (mCRC) cohort of the phase 1/2 GOBLET study, following an independent review by the study's Data Safety Monitoring Board (DSMB). The DSMB noted no safety concerns in these patients and has recommended that the study proceed to full enrollment pending clearance by the Paul Ehrlich Institute (PEI; Germany's medical regulatory body). The PEI recently cleared the study's pancreatic cancer cohort for full enrollment following a similar recommendation by the DSMB. The trial's anal cancer and first-line mCRC cohorts do not include safety run-ins and are proceeding as planned.
The GOBLET study is designed to evaluate the safety and efficacy of pelareorep in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab in patients with metastatic pancreatic, metastatic colorectal, and advanced anal cancers. The study includes 14 clinical trial sites across Germany and is being managed by AIO, a leading academic cooperative medical oncology group.
"The successful completion of GOBLET's final safety run-in underscores the trial's strong momentum and supports the ability of pelareorep to be safely combined with checkpoint inhibitors," said Thomas Heineman, M.D., Ph.D., Chief Medical Officer of Oncolytics. "This achievement positions us to continue building on prior clinical data that demonstrate the potential of pelareorep to provide a clinical benefit in colorectal and other gastrointestinal (GI) cancers. Existing data suggest this clinical benefit likely results from the stimulation of protective immune responses that may be enhanced by the addition of checkpoint inhibition. Given the high prevalence of GI malignancies, including colorectal and pancreatic cancer, and the fact that most cases do not respond to checkpoint inhibition, we view GOBLET as an important opportunity to evaluate a novel therapeutic approach that may address a pressing unmet medical need."
The GOBLET study's metastatic colorectal cancer cohorts are supported by prior clinical data demonstrating adaptive anti-tumor immune responses and a 90% clinical benefit rate in KRAS-mutated mCRC patients treated with a pelareorep-based combination (link to PR, link to study). In addition to primary endpoints evaluating safety and efficacy, GOBLET also includes exploratory endpoints designed to explore the potential of CEACAM6 and T cell clonality to serve as predictive biomarkers. This may increase the likelihood of success of future registrational studies by allowing for the selection of the most appropriate patients.
About GOBLET
The GOBLET (Gastrointestinal tumors exploring the treatment combinations with the oncolytic reovirus pelareorep and anti-PD-L1) study is a phase 1/2 multiple indication study in advanced or metastatic gastrointestinal tumors. The study is being conducted at 14 centers in Germany. The co-primary endpoints of the study are objective response rate (ORR) assessed at week 16 and safety. Key secondary and exploratory endpoints include additional efficacy assessments and evaluation of potential biomarkers (T cell clonality and CEACAM6). The study employs a Simon two-stage design with Stage 1 comprising four treatment groups expected to enroll a total of approximately 55 patients:
- Pelareorep in combination with atezolizumab, gemcitabine, and nab-paclitaxel in 1st line metastatic pancreatic cancer patients (n=12);
- Pelareorep in combination with atezolizumab in 1st line MSI (microsatellite instability)-high metastatic colorectal cancer patients (n=19);
- Pelareorep in combination with atezolizumab and TAS-102 in 3rd line metastatic colorectal cancer patients (n=14); and
- Pelareorep in combination with atezolizumab in 2nd line advanced and unresectable anal cancer patients (n=10).
Any cohort showing an ORR above a pre-specified threshold in Stage 1 may be advanced to Stage 2 and enroll additional patients.
About AIO
AIO-Studien-gGmbH (AIO) emerged from the study center of the internal oncology working group within the German Cancer Society (DKG). AIO operates with a non-profit purpose of promoting science and research with a focus on internal oncology. Since its foundation, AIO has become a successful sponsor and study management company and has established itself both nationally and internationally.
About Gastrointestinal Cancer
Excluding skin cancers, colorectal cancer is the third most common cancer, with estimates indicating that 106,180 new cases of colon cancer and 44,850 new cases of rectal cancer will be diagnosed in the U.S. in 20221. Also, for the 2022 year, the American Cancer Society estimates there will be 62,210 new cases of pancreatic cancer2 and 9,440 new cases of anal cancer3 in the U.S.
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards a registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.
References
- "Key Statistics for Colorectal Cancer." The American Cancer Society, American Cancer Society, Inc., https://www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html
- "Key Statistics for Pancreatic Cancer." The American Cancer Society, American Cancer Society, Inc., https://www.cancer.org/cancer/pancreatic-cancer/about/key-statistics.html
- "Key Statistics for Anal Cancer." The American Cancer Society, American Cancer Society, Inc., https://www.cancer.org/cancer/anal-cancer/about/what-is-key-statistics.html
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential and benefits of pelareorep as a cancer therapeutic; Oncolytics' expectations as to the purpose, design, outcomes and benefits of its current or pending clinical trials involving pelareorep; management's expectations as to enrollment in the company's GOBLET study, our beliefs regarding the potential of CEACAM6 and T cell clonality to predict patient responses to therapy and improvements to our ability to select patients most likely to respond to pelareorep-based therapies in future trials across multiple indications; our plans to advance towards a registration study in metastatic breast cancer; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. In particular, we may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption, and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.
SOURCE Oncolytics Biotech® Inc.
Related Links
https://mma.prnewswire.com/media/1554674/Oncolytics_Biotech__Inc_Logo.jpg
https://mma.prnewswire.com/media/1554674/Oncolytics_Biotech__Inc_Logo.jpg | https://www.prnewswire.com/news-releases/oncolytics-biotech-provides-positive-safety-update-on-the-third-line-metastatic-colorectal-cancer-cohort-of-its-multi-indication-phase-12-gastrointestinal-cancer-trial-301514611.html | 2022-03-31T16:08:52 | en | 0.915562 |
USFDA issues 13 observations to Lupin's Novel Laboratories
Pharma major Lupin Ltd on Thursday said the USFDA has issued 13 observations to its US-based wholly-owned subsidiary Novel Laboratories, Inc after an inspection.The USFDA US Food and Drug Administration has concluded an inspection at the companys wholly-owned subsidiary Novel Laboratories, Inc., based in Somerset, New Jersey.
- Country:
- India
Pharma major Lupin Ltd on Thursday said the USFDA has issued 13 observations to its US-based wholly-owned subsidiary Novel Laboratories, Inc after an inspection.
The USFDA (US Food and Drug Administration) has concluded an inspection at the company's wholly-owned subsidiary Novel Laboratories, Inc., based in Somerset, New Jersey. The inspection commenced on March 7, 2020 and concluded on March 30, 2022, Lupin Ltd said in a regulatory filing.
''The inspection closed with thirteen observations. We are confident of addressing these observations and will work closely with the Agency to address their concerns. We uphold quality and compliance with utmost importance and are committed to be compliant with Good Manufacturing Practice standards across all our facilities,'' it said.
The company does not believe that this will have an impact on disruption of supplies or the existing revenues from operations of this facility. The facility contributes less than 5 per cent of the company's global revenues.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
ALSO READ
COVID-19 retreating in the Americas, says regional health agency
UK's Johnson lands in Saudi Arabia - state news agency
UK's Johnson lands in Saudi Arabia - state news agency
Magnitude 5.1 quake hits China's northwestern Zhangye city, says agency
UK-registered P&O Ferries to sack staff and hire agency workers - Times | https://www.devdiscourse.com/article/business/1985358-usfda-issues-13-observations-to-lupins-novel-laboratories | 2022-03-31T16:08:51 | en | 0.951343 |
Orea Completes First Phase of Exploration at Antino Gold Project, Suriname
VANCOUVER, BC, March 31, 2022 /PRNewswire/ - Orea Mining Corp. ("Orea") (TSX: OREA) (OTCQX: OREAF) (FSE: 3CG) is pleased to provide an update on exploration at the Antino Gold Project ("Antino"), located in Suriname, South America. As announced on March 17, 2022, Orea has entered into an option agreement to acquire up to a 75% interest in Antino.
Orea has completed the initial data acquisition and compilation that includes:
- GIS compilation of historical exploration and drilling data;
- Airborne Light Detection and Ranging (LiDAR) high-resolution topographic and orthophoto survey covering 110 square kilometers;
- Re-processing of maiden 1994 airborne geophysical survey data; and
- Geological/structural mapping of the gold mineralized zones exposed in open pits and core relogging.
This first phase of exploration by Orea has provided a comprehensive dataset for the planning of a drilling program on select resource definition targets.
Antino Geological Setting, Gold Mineralization and Targeting
Antino lies within the underexplored Southern Greenstone Belt of the Guiana Shield and at the intersection of major deformation corridors known as the CGSZ and NSSZ. Gold mineralization is spatially associated with large-scale shear (ductile fault) corridors. In Precambrian Greenstone Belts, such as in the Guiana Shield, the large-scale shears and associated gold mineralization are known to be vertically extensive (>1 km depth).
Antino project location map is available at the following link:
Small-scale open pit gold mining has been active at Antino since 1999 and mainly in two areas known as Upper Antino and Buese. The open pits are mined to a maximum depth of 50 meters, limited to soft rock at the surface within the weathered saprolite layer. No tonnage/grade data of the mined pits are available.
Geophysical and structural analysis suggest that the Upper Antino and Buese areas are linked by a regional fault named the Antino Main Shear. The Antino Main Shear and associated splays and second order structures are interpreted as the principal conduits/controls for gold mineralization. Very limited exploration has been conducted along the 5-kilometer trend between Upper Antino and Buese.
Upper Antino and Buese location maps are available at the following links:
- www.oreamining.com/i/nr/2022-03-31-map-antino-locations.pdf
- www.oreamining.com/i/nr/2022-03-31-map-antino-geophysics.pdf
Two styles of shear associated gold ores are exploited by open pit at Upper Antino and Buese:
- North- to northwest-striking, sub-vertically dipping, shear-tension quartz-sulfide vein systems of up to 10 meters in width cutting volcanic and sedimentary units and adjoining porphyritic intrusions; high-grade ore shoots (>10 g/t gold) are recognized; and
- Quartz-sulfide vein stockworks of several tens of meters in diameter developed in porphyritic intrusive stocks in proximity to shears.
Both styles of gold mineralization are considered to have economic potential for industrial scale mining. The intrusive-hosted stockworks have potential for bulk tonnage gold mineralization.
Structural fabrics within the mineralized shears are consistent at both the Upper Antino and Buese areas and indicate a dominant dip-slip (oblique-vertical) movement along the structures. This implies that the ore shoots within the shear plane would preferentially be elongated in the vertical direction. The first phase of drilling will need to confirm this interpretation, specifically below high-grade historical drill holes intersections.
Although the Antino land holdings remain largely unexplored, Orea's objective is to define economic gold mineralization along the depth and lateral extent of the exploited open pits at Upper Antino, Buese and the immediate surroundings. Both the underground and open pit potential will be considered.
Upper Antino Target
The Upper Antino area offers several targets for resource development in 2022. The geology of the area and extent of gold mineralization remains poorly defined despite past drilling campaigns and mining. Numerous shallow open pits have been exploited over an area of 1,000m by 1,200m along a set north- to northwest-striking splays and second order structures to the Main Antino Shear. Initial drilling targets identified include:
- Froyo I and Froyo II pits - The Upper Antino Shear (UAS) was exploited by 4 pits over a strike extent of 1 kilometer, namely the Froyo I, Froyo II, Ginger and E-Clair pits (see link to figure below). Notable historical drill hole intersections along the southern Froyo I and Froyo II pits include: 30.47 g/t gold over 10.5 meters, 8.28 g/t gold over 8.0 meters, 17.37 g/t gold over 2.6 meters, 10.54 g/t gold over 4.0 meters, 4.16 g/t gold over 8.2 meters and 5.47 g/t gold over 4.6 meters. Orea's channel sampling of the quartz-sulfide vein zone exposed on the south wall of the Froyo I pit returned 4.53 g/t gold over 6.2 meters. Orea's drilling will target vertically below historical higher-grade intersections beneath the pits and the south strike extent of the UAS, where historical intersections include 4.16 g/t gold over 8.2 meters.
- Cup Cake pit - Located to the east of the UAS, the Cup Cake pit exploited a gold mineralized shear that remains untested by drilling within the pit area and along its northern and southern projections.
- Donut pit - Located at the eastern end of the mined area, the Donut pit exploited a vein stockwork hosted in a porphyritic intrusive stock, bordered to the west by a gold mineralized shear revealed by a single fence of 4 historical drill holes, which returned an intersection of 6.19 g/t gold over 5.2 meters. At surface, a nearby trench returned 18.0 meters averaging 6.92 g/t gold. The exploited intrusive-hosted stockwork remains untested by drilling.
Upper Antino Area map is available at the following link:
Buese Target
Similar to Upper Antino, the geology of the area and extent of gold mineralization remains poorly defined despite past drilling campaigns and mining. Shallow open pits at Buese are developed to the north and south of the interpreted trace of the Antino Main Shear over an area of 1500m by 750m. The mined gold ores are similar to Upper Antino consisting of:
- Shear-vein systems (Para North and Para South pits), potentially along second order shears to the Antino Main Shear; and
- Vein stockworks in porphyritic intrusive stocks (Terzah Bergi, Filuca and Para East pits).
The Terzah Bergi and Para East pits are starter pits currently in exploitation. The Terzah Bergi intrusive-hosted vein stockwork and its potential extensions towards the Para and Filuca pits are a priority target of interest.
Buese Area map is available at the following link:
About Antino
Antino is a resource definition stage gold exploration project located in the Sipaliwini mining district, southeastern Suriname, 275 km of the capital city of Paramaribo. Orea has entered into an option agreement to acquire up to a 75% interest in Antino. The project can be accessed by air from Paramaribo or by barge 250 kilometers up the Maroni/Lawa river bordering French Guiana.
The project consists of Rights to Exploitation of Gold (Suriname mining titles) covering 200 square kilometers. Under Suriname mining regulations, the mining titles allow for exploration, drilling and small-scale mining without any additional permits.
The project is located in a significant area of alluvial and small-scale saprolite open pit gold mining. Alluvial gold was first discovered in the Antino area in 1891. Recorded alluvial gold production from 1895 to 1969 is estimated at 425,430 ounces. Small-scale open pit gold mining at Antino commenced in 1999 and is currently active. The mining is mainly in two areas known as Upper Antino and Buese. The open pits are limited to the surface weathered saprolite layer. Recovered and recorded gold production from 1999 to 2021 is estimated at 105,970 ounces from alluvial and saprolite. Gold recoveries are estimated at approximately 30%, therefore, the total content of gold in the material mined is much higher. Past exploration was conducted by Canadian junior exploration companies during 1993-97 and 2006-07, including over 32,000 meters of drilling. The exploration programs largely predate the open pit mining. The land holdings remain largely unexplored.
Accommodations, communications, equipment, machinery, security and personnel have been established at Antino by the optionor, facilitating logistics for exploration.
Qualified Person
Rock Lefrançois, President & Chief Executive Officer of Orea and Qualified Person under National Instrument 43-101, has reviewed this news release and is responsible for the technical information reported herein, including verification of the data disclosed.
About Orea Mining Corp.
Orea is a leading gold exploration and development company operating in a prospective and underexplored segment of the Guiana Shield, South America. Its mission is to develop gold deposits with a reduced environmental footprint using innovative technologies, upholding the highest international standards for responsible mining. In French Guiana, Orea holds a major interest in the world-class Montagne d'Or mine development project and is also advancing the Maripa gold exploration project. In Suriname, Orea is advancing the Antino gold exploration project through its option agreement to acquire up to a 75% interest.
For more about Orea visit the company's website at www.oreamining.com.
ON BEHALF OF THE BOARD:
Rock Lefrançois
President & CEO
Forward-looking statements
Certain statements made herein, including statements relating to matters that are not historical facts and statements of the Company's beliefs, intentions and expectations about developments, results and events which will or may occur in the future, constitute "forward looking information" within the meaning of applicable Canadian securities legislation ("forward-looking statements"). Forward-looking statements relate to future events or future performance, reflect current expectations or beliefs regarding future events and are typically identified by words such as "anticipate", "could", "should", "expect", "seek", "may", "intend", "likely", "budget", "plan", "estimate", continue", "forecast", "believe", "predict", "potential", "target", "would", "might", "will", and similar words, expressions or phrases (including negative variations) suggesting future outcomes or statements regarding an outlook. These include, but are not limited to, statements and information regarding: the Company's plans to earn into the Antino gold project; the Company's objective to become an emerging gold producer; the acquisition of exploration projects including terms of acquisition, exploration or development plans, intentions to acquire additional exploration or development interests and the implications thereof; the production capacity and potential of future plant and equipment; future exploration and mine plans, objectives and expectations and corporate planning of the Company, future studies and environmental impact statements and the timetable for completion and content thereof and statements as to management's expectations with respect to, among other things, the matters and activities contemplated in this news release.
Forward-looking statements are made based upon certain assumptions and other important factors that, if untrue, could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such statements. Such assumptions and analyses are made by the Company's management in light of their experience and perception of historical trends, current conditions and expected future developments, as well as other factors management believes are reasonable and appropriate in the circumstances. All assumptions and analyses are those of the Company's. There can be no assurance that such statements will prove to be accurate. Forward-looking statements are based on numerous assumptions regarding present and future business strategies, local and global economic conditions, and the environment in which the Company will operate in the future, including compliance by the Company with regulatory and permitting requirements applicable in Suriname, the sufficiency of Company's working capital; the Company's ability to secure additional funding for the continued exploration and development of its properties; the price of gold and other metals; and the Company's ability to retain key personnel. You are hence cautioned not to place undue reliance on forward-looking statements.
Certain important factors that could cause actual results, performance or achievements to differ materially from those in the forward-looking statements include, among others, political and economic risks in Suriname, regulatory risk including but not limited to unforeseen changes in regulatory requirements, the Company's ability to enforce its contractual and other legal rights to explore and exploit its properties, risks related to exploration and development, permitting and licensing risk, future profitability of the Company, the ability to obtain additional financing on a timely basis, the price of gold and marketability thereof, government regulations including with respect to taxes, royalties, land tenure and land use, title to the Company's properties, currency exchange rates and fluctuations, environmental risks, dilution resulting from the issuance of additional securities of the Company, joint venture risks, the availability of equipment, conflicts of interest, competition in the mining industry, uninsured risks, market fluctuations, global financial conditions, credit risk and risks arising from pandemics and epidemics such as the COVID-19 pandemic. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. These statements, however, are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements.
Readers are cautioned not to place undue reliance on forward-looking statements. By their nature, forward-looking statements involve numerous assumptions, inherent risks and uncertainties, both general and specific, which contribute to the possibility that the predicted outcomes will not occur. Events or circumstances could cause the Company's actual results to differ materially from those estimated or projected and expressed in, or implied by, these forward-looking statements. Important factors that could cause actual results to differ from these forward-looking statements are included in the "Risk Factors" section in Company's annual information form dated December 15, 2021 for the year ended September 30, 2021 ("AIF").
Readers are further cautioned that the list of factors enumerated in the "Risk Factors" section of the AIF that may affect future results is not exhaustive. When relying on the Company's forward-looking statements and information to make decisions with respect to the Company, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Furthermore, the forward-looking statements and information contained herein are made as of the date of this document and the Company does not undertake any obligation to update or to revise any of the included forward-looking statements or information, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements and information contained herein are expressly qualified by this cautionary statement.
SOURCE Orea Mining Corp. | https://www.prnewswire.com/news-releases/orea-completes-first-phase-of-exploration-at-antino-gold-project-suriname-301514459.html | 2022-03-31T16:08:58 | en | 0.932762 |
Highlight: Notable intercept of 0.82 g/t Au over 61.2 meters
TORONTO, March 31, 2022 /PRNewswire/ - Orvana Minerals Corp. (TSX: ORV) (the "Company" or "Orvana") is pleased to announce infill and expansion drilling results for the Company's 100%-owned Taguas Project in San Juan, Argentina.
As of March 27th 2022, 24 DDH holes totaling 3,845 meters have been drilled, of which 1946.5 meters (12 DDH) have analytical readings already. Work to date represents the first set of infill and expansion drilling of the ongoing fiscal 2022 program. The drilling program continues progressing well and the Company expects to achieve a total of 7,400 meters by May 2022. The company expects to disclose further drilling results in the near future, as they become available.
Juan Gavidia, CEO of Orvana, commented, "Based on the reported intercepts, we are very optimistic that the Taguas Project could improve its initial economics, as we enter the Pre-Feasibility stage. In addition, efforts are being made to understand the high-grade oxides in Cerro Campamento, which could potentially be a cash flow catalyst for the first years of the operation. Our team on the ground is working 24/7 to complete drilling targets before snow season settles in."
COVID, and a large exploration drilling demand in San Juan prevented the Company from starting 45 days before the preliminary plan. Infill program has been divided in two phases, the first one between late December 2021 and May 2022, and the second one starting in November 2022. Below is a summary of the Company's 2022 drill program at Taguas:
- Cerros Taguas
- Program focused on the oxides portion.
- Infill drilling phase-1 (6,000 meters) to upgrade a significant portion of the mineralization currently classified as Inferred to the Measured and Indicated categories. Phase-2 (additional 11,000 meters) is targeted to be completed in second quarter of fiscal 2023. Re-classification to be used as the basis for a prefeasibility study, which is targeted to be delivered in fiscal 2023.
- Testing for lateral extensions to the northeast.
- Drilling in areas within the pit proposed in the Preliminary Economic Assessment (December 29, 2021) that are currently outside the block model due to lack of drillholes (e.g., TADD246 and TADD249 in Figure 1).
- Cerro Campamento
- Program focused on the oxides portion.
- Infill drilling phase-1 (1,400 meters) to delineate the shallower part of high gold grade veins in this area, which can potentially be mined by open pit. Phase-2 (additional 3,000 meters) is targeted to be completed in second quarter of fiscal 2023.
- 24 core holes totaling 3,845 meters drilled to date.
- Results for 12 core holes totaling 1,946.5 meters (Table 1).
- Early lab assays showing solid results, identifying more high grades structures than previously modeled:
- 61.2 meters @ 0.82 g/t Au and 16.59 g/t Ag
- 25.7 meters @ 0.53 g/t Au and 17.49 g/t Ag
- 84.6 meters @ 0.36 g/t Au and 3.82 g/t Ag
- Proved continuity of structures and grade in Cerros Taguas Oxides deposit.
- Additional 2,000 meters planned.
- Drilling has commenced in Cerro Campamento in order to define the shallower part of high gold grade oxides, which can potentially be mined by open pit.
- 3 core holes totaling 251.2 meters.
- All assays are pending.
Samples were prepared and analyzed by Alex Stewart International Argentina SA Laboratory in Mendoza. This laboratory is ISO 9001; ISO 17025, and ISO 14001 certified. Samples were prepared following the P-5 laboratory preparation code: the samples were dried, crushed to passing 10 mesh (>80%), riffle split of 1kg sample and pulverized to 106 microns (>95%). The assays included 50 g Au by fire assay (FA), AA finish and 39 element package with aqua regia dilution and ICP OES finish. Over limits for Au and Ag were run in 50 g sample by FA and gravimetric method finish. Coarse and pulp rejects were returned and are stored in the Piuquenes storage facilities.
The reported work has been completed using industry standard procedures, including a quality assurance/quality control ("QA/QC") program consisting of the insertion of quarter core field duplicates, coarse duplicates split after laboratory crushing, pulp duplicates split after laboratory pulverization, coarse analytical blank samples and 2 different CRMs inserted in batches of roughly 50 samples.
The exploration update was prepared under the supervision of Raúl Alvarez Cifuentes, a qualified person for the purposes of NI 43-101 and an employee of the company.
Table 1 – Intercepts from Cerros Taguas
The table shows the most significant results:
ABOUT ORVANA - Orvana is a multi-mine gold-copper-silver company. Orvana's assets consist of the producing El Valle and Carlés gold-copper-silver mines in northern Spain, the Don Mario gold-silver property in Bolivia, currently in care and maintenance, and the Taguas property located in Argentina. Additional information is available at Orvana's website (www.orvana.com).
Certain statements in this presentation constitute forward-looking statements or forward-looking information within the meaning of applicable securities laws ("forward-looking statements"). Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, potentials, future events or performance (often, but not always, using words or phrases such as "believes", "expects", "plans", "estimates" or "intends" or stating that certain actions, events or results "may", "could", "would", "might", "will" or "are projected to" be taken or achieved) are not statements of historical fact, but are forward-looking statements.
The forward-looking statements herein relate to, among other things, Orvana's ability to achieve improvement in free cash flow; the ability to maintain expected mining rates and expected throughput rates at El Valle Plant; the potential to extend the mine life of El Valle and Don Mario beyond their current life-of-mine estimates including specifically, but not limited to, in the case of Don Mario, the processing of the mineral stockpiles and the reprocessing of the tailings material; Orvana's ability to optimize its assets to deliver shareholder value; the Company's ability to optimize productivity at Don Mario and El Valle; estimates of future production, operating costs and capital expenditures; mineral resource and reserve estimates; statements and information regarding future feasibility studies and their results; future transactions; future metal prices; the ability to achieve additional growth and geographic diversification; future financial performance, including the ability to increase cash flow and profits; and future financing requirements; mine development plans.
Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the date of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies, which includes, without limitation, as particularly set out in the notes accompanying the Company's most recently filed financial statements. The estimates and assumptions of the Company contained or incorporated by reference in this information, which may prove to be incorrect, include, but are not limited to the various assumptions set forth herein and in Orvana's most recently filed Management's Discussion & Analysis and Annual Information Form in respect of the Company's most recently completed fiscal year (the "Company Disclosures") or as otherwise expressly incorporated herein by reference as well as: there being no significant disruptions affecting operations, whether due to labour disruptions, supply disruptions, power disruptions, damage to equipment or otherwise; permitting, development, operations, expansion and acquisitions at El Valle and Don Mario being consistent with the Company's current expectations; political developments in any jurisdiction in which the Company operates being consistent with its current expectations; certain price assumptions for gold, copper and silver; prices for key supplies being approximately consistent with current levels; production and cost of sales forecasts meeting expectations; the accuracy of the Company's current mineral reserve and mineral resource estimates; labour and materials costs increasing on a basis consistent with Orvana's current expectations; and the availability of necessary funds to execute the Company's plan. Without limiting the generality of the foregoing, this presentation also contains certain "forward-looking statements" within the meaning of applicable securities legislation, including, without limitation, statements with respect to the results of the preliminary economic assessment, including but not limited to the mineral resource estimation, conceptual mine plan and operations, internal rate of return, sensitivities, taxes, net present value, potential recoveries, design parameters, operating costs, capital costs, production data and economic potential; the timing and costs for production decisions; permitting timelines and requirements; exploration and planned exploration programs; the potential for discovery of additional mineral resources; timing for completion of a feasibility study; timing for first gold production at Taguas; processing the stockpile at El Valle in connection with the metal production catch-up program; identifying additional resources beyond the replenishment of annual depletion rates at El Valle for the extension of mine life; issuing an expanded resource PEA for Taguas in a timely manner; completion of the infill drilling program at Taguas; making a decision on the oxides stockpile at Don Mario in a timely manner; and the Company's general objectives and strategies.
A variety of inherent risks, uncertainties and factors, many of which are beyond the Company's control, affect the operations, performance and results of the Company and its business, and could cause actual events or results to differ materially from estimated or anticipated events or results expressed or implied by forward looking statements. Some of these risks, uncertainties and factors include: the potential impact of the COVID-19 on the Company's business and operations, including: our ability to continue operations; our ability to manage challenges presented by COVID-19; the accounting treatment of COVID-19 related matters; Orvana's ability to prevent and/or mitigate the impact of COVID-19 and other infectious diseases at or near our mines; our ability to support the sustainability of our business including through the development of crisis management plans, increasing stock levels for key supplies, monitoring of guidance from the medical community, and engagement with local communities and authorities; fluctuations in the price of gold, silver and copper; the need to recalculate estimates of resources based on actual production experience; disruption of supply chains that are not within the control of the Company causing a reduction of available supplies and materials to continue anticipated operational activity levels; the failure to achieve production estimates; variations in the grade of ore mined; variations in the cost of operations; the availability of qualified personnel; the Company's ability to obtain and maintain all necessary regulatory approvals and licenses; the Company's ability to use cyanide in its mining operations; risks generally associated with mineral exploration and development, including the Company's ability to continue to operate the El Valle and/or ability to resume long-term operations at the Carlés Mine; the Company's ability to successfully implement a sulphidization circuit and ancillary facilities to process the current oxides stockpiles at Don Mario; the Company's ability to successfully carry out development plans at Taguas; sufficient funding to carry out development plans at Taguas and to process the oxides stockpiles at Don Mario; the Company's ability to acquire and develop mineral properties and to successfully integrate such acquisitions; the Company's ability to execute on its strategy; the Company's ability to obtain financing when required on terms that are acceptable to the Company; challenges to the Company's interests in its property and mineral rights; current, pending and proposed legislative or regulatory developments or changes in political, social or economic conditions in the countries in which the Company operates; general economic conditions worldwide; the challenges presented by COVID-19; fluctuating operational costs such as, but not limited to, power supply costs; current and future environmental matters; and the risks identified in the Company's disclosures. This list is not exhaustive of the factors that may affect any of the Company's forward-looking statements and reference should also be made to the Company's Disclosures for a description of additional risk factors.
Any forward-looking statements made herein with respect to the anticipated development and exploration of the Company's mineral projects are intended to provide an overview of management's expectations with respect to certain future activities of the Company and may not be appropriate for other purposes. Forward-looking statements are based on management's current plans, estimates, projections, beliefs and opinions and, except as required by law, the Company does not undertake any obligation to update forward-looking statements should assumptions related to these plans, estimates, projections, beliefs and opinions change. Readers are cautioned not to put undue reliance on forward-looking statements. The forward-looking statements made in this information are intended to provide an overview of management's expectations with respect to certain future operating activities of the Company and may not be appropriate for other purposes.
SOURCE Orvana Minerals Corp. | https://www.prnewswire.com/news-releases/orvana-reports-latest-taguas-project-drilling-results-301514682.html | 2022-03-31T16:08:58 | en | 0.931848 |
Hindustan Zinc to invest Rs 350 crore to develop 200 MW renewable capacity
Mining firm Hindustan Zinc Limited HZL on Thursday said it will invest Rs 350 crore to develop up to 200 megawatt MW renewable energy capacity through a special purpose vehicle.The project will be built under group captive norms on Build-Own-Operate BOO basis through a special purpose vehicle SPV, HZL said in a statement.
- Country:
- India
Mining firm Hindustan Zinc Limited (HZL) on Thursday said it will invest Rs 350 crore to develop up to 200 megawatt (MW) renewable energy capacity through a special purpose vehicle.
The project will be built under group captive norms on Build-Own-Operate (BOO) basis through a special purpose vehicle (SPV), HZL said in a statement. HZL will own 26 per cent equity in the SPV with contributions of up to Rs 350 crore, it said.
''We have set an ambitious target for a 40 per cent reduction in carbon footprint by 2030 and achieving carbon neutrality by 2050 by transitioning towards renewable energy. Towards this goal, we are happy to announce that the company has approved the proposal for entering a long-term group captive renewable power development plan up to a capacity of 200 MW,'' the statement said.
The company however did not divulge any details on the formation of SPV and the location for setting up the green energy capacity.
HZL CEO Arun Misra said: ''I am elated that we are marching ahead in our ESG (Environmental, Social, and Governance) road map for the development of renewable power supply up to 200 MW. We stand committed to decarbonising its operations and transition to the production of green products of zinc and lead.'' According to its website, Hindustan Zinc is a subsidiary of Vedanta Limited which owns 64.9 per cent stake in the company while the government of India holds 29.5 per cent equity.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
ALSO READ
Indians fight in court for right to be forgotten online
U.S., EU, India, S.Africa reach compromise on COVID vaccine IP waiver text
Inconsistent India bowled out for 134 against England in ICC Women's WC
India to host 44th World Chess Olympiad 2022 at Chennai
Alniche Lifesciences Bullish on Health Awareness Marketing Campaigns in India | https://www.devdiscourse.com/article/business/1985361-hindustan-zinc-to-invest-rs-350-crore-to-develop-200-mw-renewable-capacity | 2022-03-31T16:08:59 | en | 0.918848 |
Otis Releases Inaugural Environmental, Social and Governance Report
- Report's ''Sustaining Connections" theme highlights how Otis builds connections that help people, societies and environments thrive -
FARMINGTON, Conn., March 31, 2022 /PRNewswire/ -- Otis Worldwide Corp. (NYSE: OTIS) today launched its first Environmental, Social and Governance (ESG) Report as an independent company. The report provides updates on its 13 ESG targets – each aligned with select United Nations Sustainable Development Goals – and makes disclosures to the Global Reporting Initiative (GRI) standard and against the Sustainability Accounting Standards Board (SASB) and Task Force on Climate-Related Financial Disclosures (TCFD) frameworks. Otis is the world's leading elevator and escalator manufacturing, installation and service company.
"At Otis, we give people freedom to connect and thrive in a taller, faster, smarter world. Our first ESG report demonstrates how we're setting this vision in motion and bringing our purpose to life through actions such as focusing on reducing our greenhouse gas emissions, expanding our STEM-focused Made to Move Communities™ signature social impact program and advancing Diversity, Equity & Inclusion programs globally," said Otis Chair & CEO Judy Marks. "ESG is embedded in our strategy, culture and programs, and we are committed to continue moving these initiatives forward as we drive value for all our stakeholders."
Following a robust materiality assessment last year to identify the ESG topics most important to Otis and its stakeholders, the company set measurable goals and strategic actions around its four ESG focus areas of Health & Safety, Environment & Impact, People & Communities and Governance & Accountability. Through the end of 2021, Otis' progress on ESG targets includes:
- All global factories completed ISO 14001 certification, four years ahead of the target.
- A 7% reduction in Scope 1 and Scope 2 emissions vs. its 2019 baseline. Otis' target is to reduce its Scope 1 and Scope 2 emissions 50% by 2030.
- Achieving its annual goal of educating 100% of Otis field professionals and subcontractor companies in Otis' life-saving Cardinal Rules.
- 78% of Otis colleagues worldwide have access to an Employee Assistance Program. Otis is now targeting 100% coverage of its global colleagues in 2022, one year ahead of its original target.
- 36% of executives globally are women. Otis was the first in its industry to sign the Paradigm for Parity® gender parity commitment and aims for gender parity in its executive ranks by 2030.
- Achieving its annual >20% target of U.S supplier spend to diverse suppliers*
In addition to these 2021 ESG milestones, Otis became a signatory of the U.N. Global Compact, completed its first CDP disclosure, and launched the second year of Made to Move Communities. Winners of this challenge will be announced in April 2022.
The full ESG Report can be found on www.otis.com and www.otisinvestors.com
* Diverse supplier is defined as a minority owned, small businesses and/or operating in an economically-challenged zone.
About Otis
Otis is the world's leading elevator and escalator manufacturing, installation and service company. We move 2 billion people a day and maintain more than 2.1 million customer units worldwide, the industry's largest Service portfolio. Headquartered in Connecticut, USA, Otis is 70,000 people strong, including 41,000 field professionals, all committed to meeting the diverse needs of our customers and passengers in more than 200 countries and territories worldwide. For more information, visit www.otis.com and follow us on LinkedIn, Instagram, Facebook and Twitter @OtisElevatorCo.
Cautionary Statement
This release contains forward-looking statements (including statements that constitute forward-looking statements under the securities laws), including but not limited to, statements that relate to our intent to achieve certain environmental, social and governance plans, targets, goals and future risks associated with climate change. These forward-looking statements are intended to provide management's current expectations or plans for our future operating performance, based on assumptions currently believed to be valid. All such forward-looking statements are subject to risks and uncertainties, and our future results of operations could differ materially from our historical results or current expectations reflected by such forward-looking statements. The forward-looking statements are subject to future events, risks, uncertainties and other factors, many of which are beyond the control of the company, that could cause actual results to differ materially from our historical results or current expectations, including, but not limited to, changes in regulations and law; severe weather events, including from the effects of climate change; challenges in the development, production, delivery, support, performance and realization of the anticipated benefits of advanced technologies and new products and services; changes in the economic and political conditions in the industry and markets in which we operate; and other risks and uncertainties described in detail in the company's most recent Form 10-K, Form 10-Q and in similar sections of other filings made by the company with the Securities and Exchange Commission from time to time. The forward-looking statements speak only as of this date. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Media Contact:
Ray Hernandez
+1-860-674-3029
[email protected]
Investor Relations Contact:
Michael Rednor
+1-860-676-6011
[email protected]
SOURCE Otis Worldwide Corporation | https://www.prnewswire.com/news-releases/otis-releases-inaugural-environmental-social-and-governance-report-301514633.html | 2022-03-31T16:09:04 | en | 0.931451 |
Maha transport minister warns of action against striking MSRTC employees as deadline ends
Maharashtra Transport Minister Anil Parab warned on Thursday that action would be taken as per the rules against the employees of the Maharashtra State Road Transport Corporation MSRTC who did not join duty despite the deadline of March 31.
- Country:
- India
Maharashtra Transport Minister Anil Parab warned on Thursday that action would be taken ''as per the rules'' against the employees of the Maharashtra State Road Transport Corporation (MSRTC) who did not join duty despite the deadline of March 31. Parab, who is also the chairman of the loss-making corporation, told reporters here that the government had set the deadline of Thursday for ending the strike.
Since October 28, 2021, the majority of over 90,000 MSRTC employees are on strike, which has paralyzed the state-run bus service for over five months, causing hardship to lakhs of commuters, especially in rural parts. Besides pay hike, the employees are demanding merger of the MSRTC with the state government. ''As per the rules, all the action that needs to be taken will be taken now. It could be suspension, dismissal or termination of service,'' Parab said after a meeting of the state cabinet.
He had appealed to striking employees to join duty seven times, he noted.
No action will be taken against those who have already resumed duty, he clarified.
''Those who are absent from duty do not need a job...that is the perception. So they deserve punishment,'' the minister, who is a senior Shiv Sena leader, added.
The MSRTC has decided to hire 11,000 employees on contract basis, for which a tender will be issued soon, Parab said.
He denied that the Bombay High Court has barred the corporation from taking any action against the striking employees.
According to Parab, the corporation operated over 12,000 daily services before the strike. The number dwindled to 5,000 after the strike began, and now they have planned to increase it to at least 8,000 daily services with the help of contractual staff.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
- READ MORE ON:
- Parab
- Maharashtra
- Anil Parab
- Shiv Sena
- Bombay High Court
- MSRTC
ALSO READ
Body of unidentified man recovered from Maharashtra's Thane
In a bid to preserve tribal culture, school in Maharashtra's Gadchiroli teaches Gondi language to students
Maharashtra Congress expresses confidence in Sonia Gandhi's leadership
Maharashtra records 237 COVID-19 cases, two deaths
IT Dept raids cable operator, State Govt employee in Maharashtra | https://www.devdiscourse.com/article/business/1985374-maha-transport-minister-warns-of-action-against-striking-msrtc-employees-as-deadline-ends | 2022-03-31T16:09:06 | en | 0.958984 |
You need to enable JavaScript to run this app. | https://sportspyder.com/nhl/minnesota-wild/articles/39005222 | 2022-03-31T16:09:08 | en | 0.738227 |
Concepted in partnership with hospitality impresario Scott Sartiano, founder of Bond Hospitality
NEW YORK, March 31, 2022 /PRNewswire/ -- Park Lane New York is proud to announce the debut of Darling, a chic new rooftop bar and lounge offering panoramic views of the Manhattan skyline and Central Park. Located on the 47th floor of the famed hotel, Darling is the only rooftop bar on Billionaire's Row, heralding a new beginning for this historic New York icon on Central Park South. Featuring a wraparound outdoor patio oasis and bold indoor lounge designed to embrace the expansive views, Darling is an intimate and whimsical gathering space featuring an elevated gourmet cocktail menu and a selection of thoughtfully curated programming. As the final piece to the reimagined Park Lane New York after an $80 million renovation, Darling will debut to the public on April 2nd as the newest addition to Manhattan's nightlife scene, bringing the eccentric spirit of the hotel to life.
Designed by LUCID, Highgate's in-house Design & Construction Studio, Darling invites guests to enter through a staircase encased in an intricate mural of bold colors, florals, and animals paying homage to the neighboring Central Park. An ornate pink chandelier presides over the staircase, transporting guests to the hotel's rooftop garden oasis. The indoor lounge and bar area features a sprawling mural designed by artists, En Viu, continuing the visual artwork thread of storytelling found throughout the property, with pressed metal ceilings, black and white floors, and paneled walls, all juxtaposed with rich colored furniture, marble tables, and ornate lighting. On the exterior, a wraparound patio with lush greenery and eclectic furniture pieces in a variety of seating groups include canopied chairs that give a nod to the iconic horse carriages of Central Park.
The food & beverage program has been concepted by Scott Sartiano, founder of Bond Hospitality and impresario behind Zero Bond, Manhattan's most coveted private members club. The menu features an eclectic mix of gastronomic options including caviar grilled cheese, seafood towers and a A5 Wagyu Katsu Sando. Complementing this is an extensive beverage program featuring signature cocktails such as Harry's Old Fashioned; Park Lane Margarita; Darling Unlimited (Grey Goose Vodka, spiced pear, ginger, lemon, angostura) and Central Park South (Tanqueray Gin, Campari, Melon de Provence, sweet vermouth, lemon). Curated weekly programming and entertainment will feature an ongoing DJ series, exclusive events, and unique collaborations in partnership with Sartiano's Bond Hospitality.
"As the final element in the renovation of Park Lane New York, we are thrilled to unveil Darling to Billionaire's Row," said Prince A. Sanders, Managing Director of Park Lane New York. "A former luxurious, penthouse residence, now transformed to a sophisticated lounge. The views are breathtaking, but for me, it's the chic design that is so unexpected and sets the tone for the space. It's playfulness with also a little mischief. As you ascend the stairway, you enter a secret garden, greeted by whimsical creatures, hiding among the oversized flowers and vines. On the guest list are the eccentric, the creative, the conservative, and shall we say, all sorts."
"We're excited to be providing Park Lane New York guests as well as locals a truly unique experience at Darling. With all the spaces we've created at Park Lane New York, we've transformed what is to be expected of a venue in Midtown Manhattan and Darling will be no different," says Scott Sartiano, Founder of Bond Hospitality. "Upon entering the space, you are transported to a time when you can feel the energy of the city celebrating its renaissance."
Darling at Park Lane New York is located on 36 Central Park South and is open for service Tuesdays through Thursdays from 5pm to 12am and Friday and Saturday from 5pm to 1am. While walk-ins are welcome, reservations are strongly encouraged and available through Resy.
About Highgate
Highgate is a leading real estate investment and hospitality management company widely recognized as an innovator in the industry. Highgate is the dominant player in major U.S. gateway cities including New York, Boston, Miami, San Francisco and Honolulu, with a growing footprint in Europe, the Caribbean and Latin America. The hospitality forward company provides expert guidance through all stages of the property cycle, from planning and development through recapitalization or disposition. Highgate has proven record of developing its diverse portfolio of bespoke lifestyle hotel brands, legacy brands, and independent hotels and resorts with contemporary programming and digital acumen. The company utilizes industry-leading revenue management tools that efficiently identify and predict evolving market dynamics to drive out performance and maximize asset value. With an executive team consisting of some of the most experienced hotel management leaders, the company is a trusted partner for top ownership groups and major hotel brands. Highgate maintains corporate offices in New York, Dallas, London, Miami, Seattle and Waikiki.
About LUCID
LUCID, Highgate's Design & Construction Studio, led by Paul McElroy, brings together a growing team of the industry's most experienced and innovative leaders to deliver design and construction concepts for a variety of distinct product types and service platforms. These include Luxury, Lifestyle and Full Service Repositionings, featuring world-class interior and architectural designs; Highgate Select Renovation, which updates and refreshes existing properties; Highgate Select New Construction, for ground up new builds of select service hotels; and Restaurant Design which develops new and inviting F&B experiences for Highgate's hotels.
About Scott Sartiano
Scott Sartiano is the founder of Zero Bond, a private, members-only social club in the heart of NoHo. After making his move to New York City over 25 years ago, Scott Sartiano established himself as one of the foremost authorities in New York City hospitality by building a brand that both his peers and clients could respect and trust. Sartiano graduated from Columbia University in 1997 with a degree in political science. In 2000, after opening Butter Restaurant, Sartiano formed what became The Butter Group. Over the next 15 years Sartiano created, owned, and operated Butter downtown, Butter midtown, The Darby, Up and Down, and 1 Oak (NYC, Vegas, LA, Southampton, and Tokyo). In 2017, Sartiano formed Bond Hospitality a lifestyle hospitality company that would also invest in and acquire real estate. Bond Hospitality's first venture, Broken Coconut, a 3 meal a day fast casual concept opened in 2017 with great success. Bond Hospitality has most recently partnered with hospitality management company Highgate to conceptualize three new food and beverage venues at the newly renovated Park Lane Hotel New York.
SOURCE Highgate | https://www.prnewswire.com/news-releases/park-lane-new-york-debuts-darling-central-park-souths-only-rooftop-lounge-301514107.html | 2022-03-31T16:09:10 | en | 0.925038 |
You need to enable JavaScript to run this app. | https://sportspyder.com/nhl/minnesota-wild/articles/39006266 | 2022-03-31T16:09:14 | en | 0.738227 |
French police say kid playing with toy gun in Lille triggered Kalashnikov false alarm
- Country:
- France
French police said on Thursday suspicions that a man had been walking around the northern city of Lille with a Kalashnikov assault rifle turned out to be a false alarm, and that instead it had been a seven-year-old boy playing with a toy weapon.
Train traffic resumed after a police operation triggered by the initial reports momentarily paralysed the city center.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
- READ MORE ON:
- Kalashnikov
- Lille
- French
Advertisement | https://www.devdiscourse.com/article/business/1985377-french-police-say-kid-playing-with-toy-gun-in-lille-triggered-kalashnikov-false-alarm | 2022-03-31T16:09:14 | en | 0.952973 |
Growing Smart(ly) in a Way That Matters
ENGLEWOOD, N.J., March 31, 2022 /PRNewswire/ -- Pathstone, an independently operated, partner-owned advisory firm offering comprehensive customized investment advice and family office services for families, family offices, and foundations and endowments, today announced it entered into an agreement to acquire certain assets of Eaton Vance WaterOak Advisors ("WaterOak")*. WaterOak, based in Winter Park, Florida, provides institutional and private wealth clients with custom investment solutions that leverage WaterOak's thoughtful, technology-driven approach.
WaterOak advises on approximately $3 billion in assets, bringing Pathstone's total assets under advisement to more than $35 billion. The combination will significantly expand Pathstone's footprint in Florida; Pathstone will now be in 14 locations in the U.S. with 235 team members, more than 100 of whom are shareholders of the firm.
Like Pathstone, WaterOak offers highly customized solutions and individualized attention to clients, with an emphasis on long-term, multigenerational wealth management. The addition of WaterOak delivers advanced technology, systems and process to enhance Pathstone's already-robust platform. WaterOak clients will gain access to Pathstone's innovative offerings and professional services. Further, the scale of the combined firms will benefit the clients of both organizations by delivering greater access to cutting-edge investment solutions as well as cost efficiencies over time.
"We are very excited to welcome WaterOak to our family," said Matthew Fleissig, President of Pathstone. "They, like Pathstone, are driven by innovation and believe that unique technology and process will keep us a generation ahead of the industry." Matt added, "Our client service strategy at Pathstone is founded on our people. We believe that bringing together talented individuals from different backgrounds will allow us to generate even greater value for our clients."
L. Clarke Lemons, Director, Southeast for Eaton Vance WaterOak Advisors (and founder of WaterOak Advisors), said, "Pathstone represents the culture, vision, and perspective that we so highly value in our care for our people and clients. We share the same values with Pathstone, and we believe Pathstone will be a fantastic partner for our team and our clients for the foreseeable future."
Willkie Farr & Gallagher, LLP served as legal counsel for Eaton Vance WaterOak Advisors. Schulte Roth & Zabel, LLP served as legal counsel to Pathstone.
*WaterOak was acquired by Eaton Vance Investment Counsel, a wholly owned subsidiary of asset management firm Eaton Vance Corp., in November of 2020. Eaton Vance Corp. and its subsidiaries, including WaterOak were subsequently acquired by Morgan Stanley in March of 2021.
About Pathstone
Pathstone is an independently operated, partner-owned advisory firm offering comprehensive family office services and customized investment advice for families, family offices, and foundations and endowments. Pathstone is institutionally backed by Lovell Minnick Partners.
With decades of experience as trusted advisors, we employ an advocacy-focused model that empowers our clients to define and achieve their unique long-term goals and support their legacy. For more information, please visit www.pathstone.com.
SOURCE Pathstone | https://www.prnewswire.com/news-releases/pathstone-announces-the-acquisition-of-wateroaks-investment-advisory-and-wealth-management-business-301514427.html | 2022-03-31T16:09:16 | en | 0.957618 |
WASHINGTON, March 31, 2022 /PRNewswire/ -- As we approach the end of celebrating Women's History Month, the Pharmaceutical Research and Manufacturers of America is taking a closer look at the biopharmaceutical progress made and challenges to be addressed for women's health.
Innovations in women's health have prolonged and extended lives. In breast cancer, the second leading cause of cancer death in women, death rates have fallen 42% from 1989 through 2019. In cervical cancer, which is almost always caused by the human papillomavirus (HPV), widespread use of the HPV vaccine has driven down prevalence of HPV infection in teenage girls by 86% and 71% in young adult females since the vaccine has been in use in the United States. And today, we now have a treatment for endometriosis, a painful condition caused when tissue similar to the lining of the uterus grows outside of the uterus.
This progress is part of a biopharmaceutical ecosystem that continues to bring new innovative treatment solutions for women's health. In a new report, PhRMA explores the research and development pipeline of medicines in clinical trials or under review by the U.S. Food and Drug Administration (FDA) for diseases which solely or disproportionately impact women.
While considerable progress has been made, women experience unique health challenges throughout their lifetime. Women are more likely to be diagnosed with certain diseases than men – such as autoimmune diseases, depression, osteoporosis, Alzheimer's disease and more. Nearly 40% of women will be diagnosed with a chronic disease, compared to 30% of men. Furthermore, due to gender bias in health care, women can also be misdiagnosed, which can ultimately delay proper care and treatment. Minority patients can face additional challenges due to racial disparities in health care.
Additionally, while the COVID-19 pandemic has had a negative impact on the mental health of all Americans, women are reported to bear a disproportionate share. Gender roles, family caregiving responsibilities for children and elderly family members, combined with workforce participation contribute to the unique mental health challenges faced by women.
To address these challenges, America's biopharmaceutical research companies are developing 625 medicines targeting diseases that disproportionately or solely affect women. Among the medicines include:
- 200 medicines for cancers primarily affecting women including 119 for breast cancer, 66 for ovarian cancer, 4 for uterine cancer and 22 for cervical cancer. It's estimated that, all together, these cancers will kill more than 76,000 women in 2022.
- 133 for neurologic disorders including Alzheimer's, migraine and multiple sclerosis.
- 87 for autoimmune diseases, which are twice as prevalent among women including lupus, myasthenia gravis, scleroderma and Sjogren's syndrome.
- 45 for mental health disorders, which are also twice as prevalent among women, including anxiety disorders, depression, postpartum depression and eating disorders.
- 43 for respiratory diseases that disproportionately affect women, including asthma and chronic obstructive pulmonary disease.
- 37 for arthritis and musculoskeletal disorders, including fibromyalgia, osteoporosis and rheumatoid arthritis.
- 34 for eye diseases, including dry eye disease.
- 33 for obstetric/gynecologic health issues, including endometriosis, menopausal symptoms, polycystic ovarian syndrome, pregnancy complications and uterine fibroids.
- 23 for infectious diseases affecting women, including candidiasis, chlamydia, genital herpes and urinary tract infections.
- 14 for other diseases that disproportionately affect women, including chronic fatigue syndrome, interstitial cystitis, irritable bowel syndrome and urinary incontinence.
Critical to bringing new medicines to patients are clinical trials. The biopharmaceutical industry is committed to taking steps to enhance the diversity of clinical trial participants, including with regard to sex/gender. Enhancing diversity in clinical trial populations can lead to studies better reflecting the patient populations most likely to use the product once it is approved. This can include understanding how pregnant or lactating women can safely participate in the clinical trial process where appropriate.
Policymakers have taken a number of recent steps to further enhance the understanding of how medicines may affect pregnant and lactating women. For example, the Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC), established under the 21st Century Cures Act in December 2016, offered a list of recommendations and an implementation plan to the U.S. Health and Human Services Secretary to promote the inclusion and integration of pregnant women and lactating women into clinical research. Further, the FDA issued guidance for industry on the inclusion of pregnant women in clinical trials providing recommendations about how and when to include pregnant women in drug development trials. Finally, the PDUFA VII goals letter, negotiated by industry and FDA, contains commitments to further enhance understanding of medicines used with pregnant and lactating women. This includes new Sentinel demonstration projects for assessing pregnancy outcomes in women and the development of a framework addressing the use of pregnancy registries and electronic health care data sources including Sentinel, with a goal of ensuring the most efficient means of obtaining highest quality safety data available.
As we look to the future, America's biopharmaceutical research companies are making significant strides in developing new treatments and cures for diseases that disproportionately impact women.
To learn more, please read our Medicines in Development for Women report click here.
CONTACT: Andrew Powaleny, [email protected], 202-835-3460
SOURCE Pharmaceutical Research and Manufacturers of America (PhRMA) | https://www.prnewswire.com/news-releases/phrma-report-more-than-600-medicines-in-development-for-diseases-affecting-women-301514719.html | 2022-03-31T16:09:18 | en | 0.934584 |
You need to enable JavaScript to run this app. | https://sportspyder.com/nhl/minnesota-wild/articles/39006473 | 2022-03-31T16:09:21 | en | 0.738227 |
Future Retail CEO Sadashiv Nayak resigns after 7 months of his appointment
- Country:
- India
Debt-ridden Future Retail Ltd's CEO Sadashiv Nayak has resigned from the post seven months after his appointment, according to a filing.
Future Group CEO Kishore Biyani has been re-appointed as executive chairman of the company for three years, a regulatory filing said on Thursday.
''Sadashiv Nayak, who was appointed as Chief Executive Officer effective August 25, 2021, has tendered his resignation which is effective from the closure of business hours of March 31, 2022,'' Future Retail Ltd (FRL) said in the regulatory filing.
The founder and CEO of the Future Group, Kishore Biyani, has been reappointed as the Executive Chairman of FRL for another three years, the filing said.
''Based on the recommendation made by the Nomination and Remuneration Committee of the Company, we hereby inform that Kishore Biyani, who holds the position of Executive Chairman has been re-appointed for a period of three years with effect from April 1, 2022,'' it said.
This would be subject to compliance of applicable provisions and other regulatory approvals including the approval of shareholders of the company, said Future Retail.
Earlier this month, FRL's director Rahul Garg had resigned from the board.
FRL has already defaulted on a payment of Rs 3,494.56 crore to banks in January under the OTR plan and the account has been declared as NPA by the lenders.
Future Retail, which operates various formats such as Big Bazaar, Koryo, Foodhall and Easyday, is part of the 19 Future group companies, which would be transferred to Reliance Retail as part of Rs 24,713 crore deal announced in August 2020.
The deal is contested by e-commerce major Amazon and is under litigation at various forums including Supreme Court, Delhi High Court and Singapore International Arbitration Center.
In February, Reliance Retail took over the operations of at least 300 stores of FRL and has offered jobs to its employees after the Kishore Biyani-led group failed to make lease payments to landlords.
On this, FRL had said it is ''committed'' to the reversal of the takeover of its stores by Reliance Retail and take all such action as may be necessary to seek value adjustments.
As per the deal, all 19 Future companies operating in retail, wholesale and logistics arms, would be consolidated into one entity -- Future Enterprises Ltd (FEL)-- and then transferred to Reliance.
In April, Future Group companies will be conducting meetings of their respective shareholders and creditors between April 20 to April 23, 2022, to seek their approval for the Rs 24,713 crore deal.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
- READ MORE ON:
- Delhi High Court
- Koryo
- Future Group
- Executive
- Future Retail
- Rahul Garg
- Kishore Biyani
- FEL)--
- Singapore
- Future Retail Ltd
- Easyday
- Supreme Court
- Reliance Retail
- International Arbitration Center
- Sadashiv Nayak
- Future Enterprises Ltd
- Nomination and Remuneration Committee of Company
- Future Retail Ltd's
- Reliance
- Amazon | https://www.devdiscourse.com/article/business/1985385-future-retail-ceo-sadashiv-nayak-resigns-after-7-months-of-his-appointment | 2022-03-31T16:09:22 | en | 0.976201 |
TAMPA, Fla., March 31, 2022 /PRNewswire/ -- Pinnacle Embryology School opens its doors to train and build an esteemed cohort of top-notch embryologists to serve its network of high-performing clinics across the country. Supported by Pinnacle Fertility, a rapidly expanding, physician-led network of fertility practices, the Pinnacle Embryology School trains future laboratory scientists with the option to be placed in a Pinnacle-affiliated laboratory and hopes to bring up to 30 competent, energetic and professional graduates to its network of clinics each year.
"As the nation's fastest growing fertility care platform, our leadership team looked ahead and realized that for our network to grow, we needed to provide our clinics with a highly skilled workforce," says Beth Zoneraich, COO of Pinnacle, "When we struggled to find enough embryologists, it became clear that we needed to build from within."
The Pinnacle Embryology School, created by Pinnacle's visionary Physician and Laboratory Councils, and instructed by Dr. Zhang and Dr. Park offers a three-to-six-month program with a curriculum that is tailored to the experience of the students. Students spend eighty percent of their time immersed in hands-on training to cultivate advanced laboratory techniques that are commonly practiced in an in vitro fertilization (IVF) laboratory. The program also educates on theories and underlying laboratory procedures through lectures and group discussions.
"Pinnacle Fertility's vision is to ensure that we are providing the best care for our patients throughout our growing network," shares Andrew Mintz, CEO of Pinnacle Fertility, "Among the many initiatives we have, our embryology school ensures that we have sufficient qualified lab staff to provide high-quality outcomes for patients and support the remarkable group of highly-skilled lab professionals we already have on our team."
Those who have completed the required education and are interested in helping others build the family of their dreams can become an embryologist tuition-free at Pinnacle Fertility. Students need a four-year Bachelor of Science degree or an associate degree with at least 120 credit hours in chemistry and life sciences. Embryology School graduates hired can expect to be placed in an embryology lab fully prepared on day one after completing the program, earning market-rate salaries.
"The quality of an IVF laboratory and its staff are imperative to ensure outstanding pregnancy rates for patients," says Dr. Priya Maseelall, physician at Reproductive Gynecology and Infertility, "We chose to partner with Pinnacle because their strategic plan aligned with ours, to be industry leaders in our field of medicine. Endeavors such as the embryology school underscore Pinnacle's commitment to innovation and advancing the reproductive medicine industry. We're delighted to be one of the locations for the school and look forward to helping educate tomorrow's distinguished embryologists."
About Pinnacle Fertility
Pinnacle Fertility is the nation's fastest-growing physician-centric fertility care platform, supporting high-performing fertility clinics and comprehensive fertility service providers nationwide. Under a united mission of fulfilling dreams by building families, Pinnacle clinics offer innovative technology and processes, compassionate patient care, and comprehensive fertility treatment services, ensuring families receive a high-touch experience on their path to parenthood.
For more information about Pinnacle Fertility, visit pinnaclefertility.com
Contact
Walt Conrad
[email protected]
SOURCE Pinnacle Fertility | https://www.prnewswire.com/news-releases/pinnacle-fertility-launches-distinguished-embryology-school-to-grow-tomorrows-expert-laboratory-scientists-and-help-people-build-the-family-of-their-dreams-301514379.html | 2022-03-31T16:09:24 | en | 0.950928 |
JACKSONVILLE, Fla. — It's all about impact at Generation W and their empowerment conference is back in-person.
Appropriately titled Exploring the Superpower of CONNECTION. It's happening Friday, April 1 from 7 a.m. to 5 p.m. at the University of North Florida's Lazzara Theater at 1 UNF Drive.
"Lives are changed for the better,” exclaimed Donna Orender, Generation W Founder. “The experience is unique and extraordinary."
Generation W’s purpose is to educate, inspire and connect women and girls. During their signature event this year, they're taking a look at how we're connected to the world in general, as well as ourselves.
Featured speakers include:
- Marcus and Ann Ericksen, Environmental Scientists
- Patrick Geraghty, President and CEO of GuideWell
- Kate Isler, CEO, The W Marketplace
- Jan Miller, Partner, Advancit Capital
- Jennifer Rosenthal, VP of Communications, Grayscale Investments
- Deb Levy DM.Ed., PCC and Certified Life and Business Coach
- Denise Williams, Chief People Officer, FIS
Orender says if you’re in need of inspiration, Exploring the Superpower of CONNECTION is something you need to experience.
“I can tell you what they do feel and express and if that continues we're happy," Orender shared feedback from past convention participants. "They say I feel like I can take on the world. I feel like my spirit is elevated and uplifted. I feel like I've learned things I never knew I needed to learn but I am so better off now that I did. and I feel happily connected.”
You can register for Exploring the Superpower of CONNECTION at genwnow.com. | https://www.firstcoastnews.com/article/features/lives-are-changed-for-the-better-the-experience-is-unique-and-extraordinary-says-donna-orender-of-generation-w/77-0395eb8f-edec-47fb-ab6b-6f33c92f59fb | 2022-03-31T16:09:25 | en | 0.950998 |
You need to enable JavaScript to run this app. | https://sportspyder.com/nhl/minnesota-wild/articles/39006800 | 2022-03-31T16:09:27 | en | 0.738227 |
- Questa Capital and existing investor Radical Ventures provide new equity investment to support PocketHealth's rapid expansion across the United States and Canada
- PocketHealth's revolutionary platform makes it easy for patients to access their medical images and health records, share them with a doctor, and take a more active role in their care
- Investment will accelerate new product development, go-to-market expansion and new employee hiring
- PocketHealth is now used by more than 600,000 patients and 550 care provider sites, and will exceed one billion images stored by the end of 2022
TORONTO, March 31, 2022 /PRNewswire/ -- PocketHealth, the patient-centric medical image sharing platform, today announced that it has raised $16 million USD ($20 million CAD) in Series A funding led by healthcare venture capital firm Questa Capital. Initial venture capital investor Radical Ventures also participated in the round, which brings the total capital raised to date by PocketHealth to $22.5 million USD ($29 million CAD). PocketHealth will use the funding to expand its talent base, build new U.S. and Canada clinical partnerships and continue to invest in product innovation.
Founded by brothers Harsh Nayyar and Rishi Nayyar in 2016, PocketHealth is built on the belief that the most effective way to ensure a health record gets where it needs to go is to give it to the patient. Challenging long-standing medical image sharing norms, PocketHealth liberates patient images from care provider silos, putting diagnostic quality images in the hands of patients whenever and wherever they need them. Patients on PocketHealth can permanently store their historical medical imaging and access them from any device or browser, all protected with bank-level encryption. The integrated PocketHealth platform also helps patients understand their results through its Report Reader functionality, which allows patients to tap or click on anatomical or medical terms common within most medical imaging reports and view term meaning in easily understandable language.
"PocketHealth's approach shares power and self-agency among care provider and patient, giving patients a new sense of comfort and control in managing their care journeys," said Ryan Drant, founder and Managing Partner, Questa Capital. "The technical elegance and simplicity of PocketHealth makes it an appealing choice for any forward-looking health system invested in improving care experiences for their patients and their families. We look forward to supporting Rishi, Harsh and PocketHealth team as they rapidly expand their North American footprint."
"Consumers now have access to real-time information in every area of their lives except the most important area, their healthcare," said Jordan Jacobs, co-founder and managing partner, Radical Ventures. "We are doubling down on our initial investment because we believe PocketHealth has the product and the team to finally address this important problem and improve outcomes for patients and care providers."
Imaging is almost always a source or confirmation of medical diagnosis, and can often be the single spark for a long-term care journey. While the emotional nature of a care journey may range from delight (maternity) to anxiety (tumor discovery), to everything in between, many patients who have moved through an image-based journey know the pain of image access and sharing. Today, X-rays, ultrasounds, CT scans, MRIs and other visual assets are essential for understanding a treatment course or for soliciting second opinions. Yet at a time where many may be at their most vulnerable, patients typically find themselves in frustrating records release expeditions, requiring in-person visits, CD-ROM hardware and locked image-sharing networks.
"Knowledge and access are power. At PocketHealth, we believe that frictionless health record access is a patient's right," said Rishi Nayyar, Co-Founder & CEO of PocketHealth. "We're thrilled that Ryan and the team at Questa also embody this belief, and we look forward to ensuring that any patient, anywhere, can own and control the images most essential to advocating and guiding their own health outcomes."
PocketHealth is trusted by over 600,000 patients and 550 hospitals and outpatient imaging facilities across North America, and will exceed one billion images stored on the platform by the end of 2022. As PocketHealth expands, the company will look to bring its conviction in patient empowerment into more aspects of medical record sharing.
About PocketHealth
PocketHealth is the world's first patient-centric image sharing platform. With PocketHealth patients can instantly access, share and take ownership over their own medical imaging and records at any time, anywhere, and with anyone. PocketHealth also enables direct sharing between hospitals and physicians, as well as instant DICOM retrieval and automated importing capability, creating a unified image management solution for more than 550 hospitals and imaging clinics across North America. PocketHealth believes that by placing patients at the center of their care journey, records move more ethically, easily and securely throughout the healthcare system. Learn more at www.pockethealth.com.
About Questa Capital
Questa Capital is a venture growth equity firm focusing on investments in expansion-stage healthcare companies. Questa seeks out disruptive, technology-enabled business models that help improve patient lives, streamline market inefficiencies, and provide better quality care. The firm partners with superior management teams to help build innovative market leaders in the healthcare technology, services and medical devices sectors. Questa is led by industry veterans in healthcare investment and operations who have invested in and advised more than 50 growth-stage companies. More information is available at www.questacapital.com.
About Radical Ventures
Radical Ventures is an early-stage venture capital firm investing in people applying artificial intelligence to shape the future of how we live, work and play. From healthcare and financial services to infrastructure and manufacturing, Radical partners with entrepreneurs who understand the transformational power of AI. Learn more at www.radical.vc.
Media Contacts
For Canada:
Livy Jacobs | [email protected]
For U.S.:
Nate Hermes | 646-828-9172
[email protected]
SOURCE PocketHealth | https://www.prnewswire.com/news-releases/pockethealth-closes-16m-usd-20m-cad-series-a-financing-to-transform-how-patients-and-care-providers-access-and-share-medical-images-301514463.html | 2022-03-31T16:09:30 | en | 0.947246 |
DMRC will always be in my heart, says Mangu Singh as he signs off as Delhi Metro chief
- Country:
- India
Delhi Metro chief Mangu Singh on Thursday bid an emotional farewell to the DMRC after an illustrious career of 25 years, including the last decade as its managing director.
On the last day of his tenure on March 31, he said the ''Delhi Metro will always be in my heart'' and he was ''satisfied'' with his long journey.
Senior officials and many members of the Delhi Metro Rail Corporation (DMRC) board of directors visited Singh at his office at the Metro Bhawan here and extended their best wishes.
''But, this is not a traditional retirement, I would say, where one would sort of move away after completing one's service. I will be in Delhi and in the age of technology, with mobile phones and WhatsApp, will be in touch with the people,'' he told PTI in an interview on Thursday.
A Bijnor native and a graduate in civil engineering from the University of Roorkee (now IIT-Roorkee), he bid adieu to his ''DMRC family'' and accepted greetings from his colleagues and his successor Vikas Kumar, who will take charge as the new managing director on April 1.
Singh, considered as the foremost tunnelling expert, became part of the Indian Railways Services of Engineers (IRSE) in 1981.
He then joined the Indian Railways and worked in various capacities, including as deputy chief engineer of the Kolkata Metro Railway from 1989 to 1996.
Asked how would he describe his journey at the DMRC, he said, ''My journey with a metro began much earlier than the DMRC. I was associated with the Calcutta Metro from '89-'96, so it's been almost 33 years with metros''.
''And nothing can be more satisfying than this career of several decades, including 33 years in metros, including 25 years in DMRC and then 10 years and three months as its MD.'' ''God has been very kind in giving me such opportunities. I have been able to create 310 km of network while being part of different metros, and I don't think anybody had that sort of opportunity, anywhere in the world,'' he said with a sense of pride.
This span of 310 km includes the network added in the DMRC and other metros while working in various capacities, he said.
Singh's tenure as MD of DMRC had begun on January 1, 2012 after his predecessor E Sreedharan handed over the charge to him on December 31, 2011. His tenure was extended multiple times.
Delhi Metro, under Singh's leadership, endeavoured to bounce back after being severely hit by the COVID-19 pandemic and ensuing lockdowns. His journey had begun with the Delhi Metro back in 1997 when he started working in the capacity of a chief engineer/chief project manager.
Later, he rose to become executive director and then director (works) in the DMRC before taking the charge as its MD in 2012, officials said.
He has contributed greatly in the project implementation of metros in Delhi and Kolkata and has been responsible for bringing revolutionary changes in the execution of large metro engineering projects (civil) within tight deadlines and budget, the DMRC had earlier said.
Asked about DMRC's association with other metros in India under his leadership, he said, ''I am very fortunate to have been involved with almost all metro networks in the country, whether a metro is operational or under construction or in initial stage of planning, I had the opportunity to get involved everywhere.'' ''It was a big opportunity in life and I am really very satisfied with this journey,'' he said.
One project outside Delhi that he felt special about is the Line2A of Mumbai Metro, which is slated to be inaugurated on Saturday.
''That project, I personally feel, was very challenging in a city like Mumbai. Why I am particular about that project is because in Mumbai, they already have an MMRC (Mumbai Metro Rail Corporation) that they are executing. But confidence and faith was shown in us and the then CM personally called me and said, 'you (Mangu Singh) have to deliver a line in Mumbai','' he said.
''So, that is why I feel it is more fascinating and challenging and we have done that,'' he said.
The DMRC network's current span is nearly 392 km with 286 stations, including the Noida-Greater Noida Metro Corridor and Rapid Metro in Gurugram.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
ALSO READ
Indians fight in court for right to be forgotten online
U.S., EU, India, S.Africa reach compromise on COVID vaccine IP waiver text
Inconsistent India bowled out for 134 against England in ICC Women's WC
India to host 44th World Chess Olympiad 2022 at Chennai
Alniche Lifesciences Bullish on Health Awareness Marketing Campaigns in India | https://www.devdiscourse.com/article/business/1985401-dmrc-will-always-be-in-my-heart-says-mangu-singh-as-he-signs-off-as-delhi-metro-chief | 2022-03-31T16:09:30 | en | 0.980489 |
JACKSONVILLE, Fla — "The College Tour" TV series is designed to help ease the stress on high schoolers looking for a college that fits them best.
Executive Producer Alex Boylan created the concept after taking his niece on a college visit just as COVID-19 began, putting an even bigger strain on travel and on families financially.
“Each episode tells the story of a different college campus, but the best part is we tell that story through the authentic lens of real students," Boylan said. "High schoolers and their parents get a real sense of that campus culture, all the opportunities that university can give.”
More than 50 episodes and five seasons later, Boylan finds himself this week showing off his alma mater.
“Jacksonville University made me who I am today. This university was so supportive in guiding my career choices, some of my best friends to this day are from Jacksonville University and this location is so special," Boylan said.
Students like lacrosse athlete Jenny Kinsey will share their stories of what made them choose JU.
"I’m going to be showing the student-athlete experience that we have at JU and talking about the holistic approach that the athletics department takes with the student-athletes and just kind of what a day in my life looks like," Kinsey said.
Kinsey said it was her own college tour that made the decision for her.
“It was actually pouring down the day I was here, and I still just loved the campus, loved the people that I was here talking with. It was just a no-brainer for me right away that I wanted to go to school here," Kinsey said.
Filming will wrap up next week and the episode is expected to air sometime in August. | https://www.firstcoastnews.com/article/features/trending-today/jacksonville-university-students-starring-amazon-tv-series/77-f8ed18ae-f003-4e41-81f5-2257507ae3ff | 2022-03-31T16:09:32 | en | 0.987378 |
You need to enable JavaScript to run this app. | https://sportspyder.com/nhl/minnesota-wild/articles/39006941 | 2022-03-31T16:09:33 | en | 0.738227 |
JACKSONVILLE, Fla. — The Lake City Police Department is looking for a murder suspect who they say should be considered armed and dangerous.
Around 7:08 p.m., officers from the Lake City Police Department learned about the location of a man wanted out of Hillsborough County for murder.
Police say Katrell Hubbard, 25, was believed to be in Lake City driving a black 2008 Chevrolet four door vehicle. Through surveillance, officers say they were able to verify that Hubbard was the driver and sole occupant of the vehicle.
Officers attempted to conduct a traffic stop on the vehicle Hubbard was driving, but he allegedly refused to stop and fled from officers.
After a brief chase by deputies, police say Hubbard crashed his vehicle at the intersection of Main Boulevard and Duval Street. He then fled on foot in a northern direction, police say.
A perimeter was established by officers with the assistance of deputies from the Columbia County Sheriff’s Office as well as troopers from the Florida Highway Patrol.
The area was searched for several hours, however, police say Hubbard was not located.
Again, police say Hubbard is considered armed and dangerous. He was last seen wearing no shirt and red pants.
If you see, or know of the location of Hubbard, police caution to not approach and to contact local law enforcement. | https://www.firstcoastnews.com/article/news/crime/lake-city-police-looking-for-murder-suspect-who-fled-after-crashing-car/77-bf981427-6be9-45fc-93af-ff9a9c4f1ec1 | 2022-03-31T16:09:38 | en | 0.977842 |
DDMA to do away with fine for not wearing face masks at public places: Sources
However, the rule related to wearing of masks at public places, including in buses and metro trains, continued.Residents welfare associations described the development as risky and shocking, claiming that with the new relaxations, 99 per cent of the citys population will stop taking any precaution.This is shocking that despite the number of Covid cases rising worldwide, the mandate of wearing masks has been removed.
- Country:
- India
The Delhi Disaster Management Authority (DDMA) decided on Thursday that there will be no fine now for not wearing face masks at public places in view of a significant decline in the number of fresh COVID-19 cases in the national capital, official sources said.
They said at a meeting chaired by Lieutenant Governor (LG) Anil Baijal, there was consensus among all the participants about the lifting of all Covid-related restrictions, even though the DDMA is yet to issue an order in this regard.
However, most of the Covid-related restrictions have already been lifted by the authorities.
The sources said the DDMA is likely to issue an advisory for people, asking them to wear masks at crowded places.
Currently, there is a fine of Rs 500 for not wearing masks at public places in Delhi.
The Centre had earlier advised the states and Union territories to consider discontinuing the Covid containment measures in view of a sharp decline in the number of fresh cases of the infection in the country.
The decision to lift the restrictions in Delhi was taken at a meeting attended by Chief Minister Arvind Kejriwal, his deputy Manish Sisodia, Chief Secretary Vijay Dev and senior officers of the departments concerned.
With a rise in the number of coronavirus cases in December last year due to its Omicron variant, the Delhi government had imposed several restrictions.
The restrictions were lifted gradually when the situation normalised and finally, the curbs were removed from February 28. However, the rule related to wearing of masks at public places, including in buses and metro trains, continued.
Residents' welfare associations described the development as ''risky and shocking'', claiming that with the new relaxations, 99 per cent of the city's population will stop taking any precaution.
''This is shocking that despite the number of Covid cases rising worldwide, the mandate of wearing masks has been removed. They are resuming flights and markets have been opened completely. Now, the mask, which was providing basic precaution, has also been made optional,'' BS Vohra, who heads the East Delhi RWA joint front, told PTI.
President of North Delhi Resident Welfare Federation Ashok Bhasin said he supports the relaxation but complete removal of the rule is not sensible.
''It is a good thing because now, the terror in the name of civil defence will not be there. But masks should have been made compulsory at crowded places,'' he said.
After the DDMA meeting, the LG took to Twitter and said it was decided that the focus would be on hospital-based sentinel surveillance and enhancing vaccination coverage of the targeted population.
''While appreciating the efforts made by all stakeholders in management of COVID-19, emphasised upon the need to follow the 5 fold strategy of Test, Track, Treat, Vaccinate and adherence to COVID Appropriate Behaviour as advised by the Ministry of Health and Family Welfare, GOI.
''To effectively meet any scenario in future that may arise, advised all agencies to remain vigilant without lowering the guard,'' he said in a series of tweets.
Delhi reported 113 fresh Covid cases and no death due to the viral disease on Thursday, while the positivity rate stood at 0.49 per cent, according to data shared by the city health department.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
ALSO READ
Northeast Delhi Violence: Court denies bail to Gulfisha saying allegations are prima facie true
Brother of northeast Delhi riots victim Ankit Sharma gets govt job
13-year-old boy killed, 4 hurt after car hits autorickshaw in southeast Delhi: Police
Northeast Delhi violence: Court defers order on bail plea of Sharjeel Imam
Owner's son, worker asphyxiate in shop's basement in east Delhi | https://www.devdiscourse.com/article/business/1985403-ddma-to-do-away-with-fine-for-not-wearing-face-masks-at-public-places-sources | 2022-03-31T16:09:38 | en | 0.970442 |
JACKSONVILLE, Fla. — The trial for a Jacksonville Beach man accused of murder in the 1994 death of a Nassau County teen continues Thursday.
Ronnie Hyde, 65, is charged with first degree murder in the cold case, in which an unidentified torso was discovered behind a gas station Dumpster. It was later identified as 16-year-old Fred Laster.
Thursday, prosecutors have three more witnesses to call before the defense begins. Wednesday, witnesses included the Chief Medical Examiner and two of Fred's siblings.
The defense is expected to request that an item already submitted into evidence, an anatomy textbook found in Hyde's Jax Beach home, be excluded from the case.
The case is expected to conclude Friday.
Wednesday's recap:
Siblings testified Wednesday about the disappearance of 16-year-old Fred Laster at the trial of a former youth pastor accused of murdering and dismembering him.
Ronnie Hyde, 65, is charged with first degree murder in the 1994 cold case, in which an unidentified torso was discovered behind a gas station Dumpster in Lake City.
The case went unsolved until Hyde’s arrest in 2017. He is also charged with 25 counts of possessing child pornography but those will be pursued at a separate trial He has pleaded not guilty to all charges.
Laster’s twin sister Daisy Williams testified about a childhood with lax supervision following the death of their mother, to the extent that they didn’t notice “Freddie” was missing for a few weeks. The siblings say they believed their brother was with Hyde, a close friend of the family and youth pastor at their mother’s church. The last time they heard from Fred Laster was in a phone call with their older sister, which she recounted in her testimony.
“She said ‘Fred?’ And he said, ‘Yeah.’
“And she’s like ‘Are you with Ron?’ And he said ‘Yeah,’ in like a really different tone, had a funny tone to him.
“And she’s like, ‘You OK?’ and he said ‘Yeah,’ and then he goes, ‘I just wanted call to tell you all that I love you and I love Pumpkin,’ which is what he called my sister’s daughter.
“And that was it.”
Prosecutor Alan Mizrahi asked, “Was that the last time you ever spoke to Fred Laster?” She responded, “Yessir.”
But Daisy Williams was also grilled by Hyde’s attorney Ann Finnell, who challenged her memory and suggested her recollection of seeing knives and nonstick bathtub stickers in Hyde’s Jacksonville Beach house was a “convenient” piece of testimony.
“[That] just happened to end up being something that was also kind of like what was found in a Dumpster in 1994, and you just -- in 2002 -- thought those things might be important?” Finnell asked.
“Never know what could be important,” Williams replied.
Fred Laster’s brother Travis Laster told jurors that as a youth pastor, Ronnie Hyde became a big part of their financially vulnerable family. Travis Laster said he spent virtually every weekend with Ronnie Hyde, alone, and sometimes travelled with him. As he grew older and spent less time with Hyde, he said, his brother Fred took on that role. He alluded to “some of the stuff that happened that I’m not allowed to talk about” prompting a strong objection from Finnell, a lengthy sidebar and a stern admonishment from Circuit Judge Tatiana Salvador.
Travis Laster testified in earlier suppression hearings about alleged abuse at the hands of Hyde. Those topics that have been disallowed at trial, but Prosecutor Alan Mizrahi asked around their edges.
“I’m going to ask this very directly, Mr. Lassiter: Do you regret not being there for your brother?”
“It’s probably the biggest regret I ever have in my life,” he said soberly. “Very much so.”
He also testified that while Hyde told his siblings he dropped off Fred Laster in June 1994 when the teenager all but jumped out of his car at night, Travis Laster said Hyde never told him that version of events for a decade, despite the two remaining in contact.
Chief Medical Examiner Dr B. Robert Pietak also testified Wednesday, saying it was impossible to determine how the teen was murdered based only on the condition of the torso. Laster’s head, hands and legs were never found.
In court, the usually stoic Hyde reacted ever so slightly as the medical examiner showed jurors pictures of the dismembered torso, shaking his head and looking down.
Court resumes Thursday at 9:15 am. The case is schedule to conclude Friday. | https://www.firstcoastnews.com/article/news/crime/trial-continues-accused-killer-ronnie-hyde-1994-death-fred-laster/77-405f1b2b-3f56-4159-a685-16989e4e777e | 2022-03-31T16:09:44 | en | 0.98362 |
Govt to borrow Rs 8.45 lakh crore from market during April-September period
The government raises money from the market to fund its fiscal deficit through dated securities and treasury bills.
- Country:
- India
The Union government is looking to raise Rs 8.45 lakh crore through borrowings in the first half of 2022-23 to fund the revenue gap for reviving the economy, the finance ministry said on Thursday.
Out of the gross market borrowing of Rs 14.31 lakh crore estimated for the next financial year, Rs 8.45 lakh crore is planned to be borrowed in the first half or April-September period.
The government has front loaded its borrowing programme as the 60 per cent of the record borrowing planned for the financial year beginning April 1 would be complete in the first six months itself.
Front loading of borrowing will be done with the objective of pushing capital expenditure which will have a multiplier effect on the economy.
As per the Union Budget document, the gross market borrowing through dated securities for 2022-23 will be Rs 14,95,000 crore. Taking into account the switch operations conducted on January 28, 2022, the gross market borrowing through dated securities for 2022-23 is expected at Rs 14,31,352 crore, the ministry said in a statement.
The gross borrowing for 2021-22 was Rs 12,05,500 crore.
The borrowing is scheduled to be completed in 26 weekly tranches of Rs 32,000-33,000 crore, the ministry said.
The borrowing will be spread under 2, 5, 7, 10, 14, 30 and 40 year securities and Floating Rate Bonds (FRBs) of various tenors. Long term securities, including the 14, 30 and 40 year ones, will make up for a significant chunk of the borrowing.
FRBs of various tenors will be issued on a fortnightly basis.
The government will continue to carry out switching of securities to smoothen the redemptions, the statement said, adding that it may continue to exercise the greenshoe option to retain an additional subscription up to Rs 2,000 crore against each of the securities indicated in the auction notification.
Weekly borrowing under treasury bills in the first quarter of 2022-23 is expected to be Rs 33,000-34,000 crore, with net borrowing of Rs 2.40 lakh crore during the quarter.
There will also be an issuance of Rs 13,000 crore under 91 DTBs, Rs 12,000-13,000 crore under 182 DTBs and Rs 8,000 crore under 364 DTBs in each auction to be held during the quarter.
To take care of the temporary mismatches in government account, the statement said the Reserve Bank of India has fixed the Ways and Mean Advances (WMA) limit for H1 of FY'23 at Rs 1,50,000 crore.
The government and the RBI are working jointly to bring a framework for issuance of sovereign green bonds.
In her Union Budget speech, Finance Minister Nirmala Sitharaman had announced that the government proposes to issue sovereign green bonds to mobilise resources for green infrastructure.
The net borrowing during 2022-23 would be Rs 11.6 lakh crore, which is nearly Rs 2 lakh crore higher than the current year's budget estimate of Rs 9.7 lakh crore.
Gross borrowing includes repayment of past loans. The government raises money from the market to fund its fiscal deficit through dated securities and treasury bills.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.) | https://www.devdiscourse.com/article/business/1985405-govt-to-borrow-rs-845-lakh-crore-from-market-during-april-september-period | 2022-03-31T16:09:46 | en | 0.949542 |
Deuba, Modi to jointly inaugurate 35-km Jaynagar-Kurtha railway service between India and Nepal
Nepal Prime Minister Sher Bahadur Deuba and his Indian counterpart Narendra Modi will jointly inaugurate the 35-km Jaynagar-Kurtha railway service between India and Nepal on April 2, during Deubas maiden visit to India, sources said on Thursday. Both the Prime Ministers will jointly inaugurate the railway service from Hyderabad House, in New Delhi in a ceremony.
- Country:
- Nepal
Nepal Prime Minister Sher Bahadur Deuba and his Indian counterpart Narendra Modi will jointly inaugurate the 35-km Jaynagar-Kurtha railway service between India and Nepal on April 2, during Deuba’s maiden visit to India, sources said on Thursday. The train service will criss-cross from Jayanagar in Bihar to Kurtha in Janakpur, Nepal.
The Jaynagar-Kurtha section is part of the 68.7km Jaynagar-Bijalpura-Bardidas rail link built under the Government of India’s grant assistance of NPR 8.77 billion.
The new infrastructure was built for broad gauge railway operation by replacing the narrow gauge, which was stopped more than seven years ago. Nepal Railway Company has made all necessary preparations for the inaugural ceremony, according to officials. Both the Prime Ministers will jointly inaugurate the railway service from Hyderabad House, in New Delhi in a ceremony.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
ALSO READ
Turmoil in Bihar assembly even as speaker takes the Chair
Turmoil continues in Bihar Assembly even as Speaker takes the Chair
Highest number of undertrial prisoners in UP, Bihar, MP
'The Kashmir Files' made tax-free in Bihar
Nation's heartbeat will stop if Biharis decide not to work, RJD MP's retort to Trinamool MLA's 'Ek Bihari, sau Bimari' | https://www.devdiscourse.com/article/business/1985408-deuba-modi-to-jointly-inaugurate-35-km-jaynagar-kurtha-railway-service-between-india-and-nepal | 2022-03-31T16:09:54 | en | 0.953452 |
Protalix BioTherapeutics Reports Fiscal Year 2021 Financial and Business Results
Company to host conference call and webcast at 8:30 a.m. EDT
CARMIEL, Israel, March 31, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the fiscal year ended December 31, 2021 and provided a business update on recent corporate and clinical developments.
"2021 was a year of continued progress towards our key operational, clinical and regulatory goals," said Dror Bashan, Protalix's President and Chief Executive Officer. "We had a productive Type A meeting with the FDA in the fall during which the FDA, in principle, agreed that the data package proposed to the FDA for the anticipated BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. We also, together with Chiesi, submitted an MAA to the EMA, which was subsequently validated by the EMA. The submission followed an October 2021 meeting with the EMA's Rapporteur and Co-Rapporteur at which we and Chiesi discussed the scope of the anticipated submission, and the Rapporteur and Co-Rapporteur were generally supportive of a planned MAA submission."
"We are grateful to all of our key stakeholders for their dedication towards our mission of delivering new medicines to patients with high clinical unmet needs. 2022 has the potential to be a meaningful year for the company as we move towards our BLA resubmission in the United States, await feedback on our MAA submission in Europe and continue to advance our early stage pipeline. We look forward to updating you on our progress as the year moves on."
2021 Full-Year and Recent Business Highlights
Regulatory Advancements
- On February 24, 2022, the Company, together with its development and commercialization partner, Chiesi Farmaceutici S.p.A, or Chiesi, announced the submission and subsequent validation of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for PRX-102, the Company's product candidate, for the treatment of adults with Fabry disease. The MAA included final data from the Company's phase III BRIDGE and BRIGHT clinical trials; 12–month interim data from the Company's phase III BALANCE clinical trial; and final data from the Company's phase I/II clinical trial data from naïve/untreated patients, including the extension study related thereto, using 1 mg/kg every other week dosing.
- On October 11, 2021, the Company, together with Chiesi, completed a Type A (End of Review) meeting with the U.S. Food and Drug Administration (FDA) regarding the biologics license application (BLA) for PRX-102 for the treatment of adult patients with Fabry disease, following the complete response letter received on April 27, 2021 from the FDA. The Company gained clarity regarding the FDA's expectations and the FDA, in principle, agreed that the data package proposed to the FDA for the anticipated BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. A BLA resubmission is planned for the second half of 2022.
Clinical Advancements
- On March 18, 2022, the Company, together with Chiesi, announced positive final results from the phase III BRIGHT clinical trial, a multicenter, multinational open-label, switch-over study designed to evaluate the safety, efficacy and pharmacokinetics of treatment with 2 mg/kg of PRX-102 administered every four weeks for 52 weeks (a total of 14 infusions) in adult patients previously treated with a commercially available enzyme replacement therapy (ERT) (Fabrazyme® or Replagal®). Results of the BRIGHT study indicate that 2 mg/kg of PRX–102 administered by intravenous infusion every four weeks was well tolerated, and Fabry disease assessed by eGFR slope and plasma lyso-Gb3 was stable throughout PRX–102 treatment in adult Fabry patients.
- On October 15, 2021, the Company, together with Chiesi, announced the last patient from the phase III BALANCE clinical trial received the final dose in the study. The Company anticipates announcing top-line results from the study next week and final data in the second half of 2022.
- On June 2, 2021, the Company together Chiesi, announced topline results from an interim analysis of the phase III BALANCE clinical trial. The initial top-line results show that the lower boundary of the confidence interval for the mean difference between the two treatments (PRX–102 and Fabrazyme) was below the non-inferiority margin pre-specified for this interim analysis in the ITT analysis set and above such limit in the PP analysis set. At the time of this analysis, two patients had discontinued participation due to treatment emergent adverse events (TEAEs). Of these two patients, one discontinued participation due to a related adverse event. There were no deaths. Overall, safety data appears favorable and consistent with what was observed in previous clinical studies with PRX-102.
Corporate & Financial Developments
- On August 25, 2021, the Company strengthened its balance sheet through exchanges of a substantial majority of its then outstanding 7.50% Senior Secured Convertible Notes due 2021 for a combination of cash and new notes. The Company issued new 7.50% Senior Secured Convertible Notes due 2024 with a $28.75 million aggregate principal amount, and made principal and interest payments of approximately $27.00 million. The remaining 2021 Notes were repaid on the November 2021 maturity date.
- On July 2, 2021, the Company entered into a Sales Agreement with H.C. Wainwright & Co., LLC, as sales agent, or the Agent, pursuant to which the Company may sell from time to time up to $20.0 million worth of shares of its common stock in at-the-market transactions through the Agent. Upon execution of the Sales Agreement, the Company terminated the then existing ATM Equity OfferingSM Sales Agreement entered into on October 1, 2020 with BofA Securities.
- On May 13, 2021, the Company and Chiesi entered into a binding term sheet pursuant to which they amended the two exclusive license and supply agreements for PRX-102 in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0 million milestone payment to the Company in exchange for a $25.0 million reduction in a longer-term regulatory milestone payments in the Ex-US Exclusive License and Supply Agreement. All other regulatory and commercial milestone payments remained unchanged. The Company and Chiesi also agreed to negotiate certain manufacturing related matters. The Company received the payment in June 2021.
- On February 17, 2021, the Company successfully completed a public offering of its common stock raising gross proceeds of approximately $40.2 million at a price equal to $4.60 per share, before deducting the underwriting discount and estimated expenses of the offering, which was led by BofA Securities and Oppenheimer & Co.
Financial Results
For the year ended December 31, 2021, compared to the year ended December 31, 2020
- The Company recorded revenues from selling goods of $16.7 million for the year ended December 31, 2021, an increase of $0.5 million, or 3%, compared to revenues of $16.2 million for the same period of 2020.
- Revenue from licenses and R&D services for the year ended December 31, 2021 were $21.6 million, a decrease of $25.1 million, or 54%, compared to $46.7 million for the year ended December 31, 2020. Revenue from license agreements is recognized, mainly, in conjunction with the license and supply agreements with Chiesi. The decrease is primarily due to lower R&D costs related to PRX-102 incurred in the year ended December 31, 2021.
- Cost of goods sold for the year ended December 31, 2021 was $16.3 million, an increase of $5.4 million, or 50%, compared to cost of goods sold of $10.9 million for the same period in 2020. The increase was primarily the result of certain one-time manufacturing costs incurred while preparing for the then anticipated FDA approval of the PRX-102 BLA and higher manufacturing costs.
- Research and development expenses, net, for the year ended December 31, 2021 were $29.7 million, a decrease of $8.5 million, or 22%, compared to $38.2 million for the same period of 2020. The decrease is primarily due to the completion of the three phase III clinical trials of PRX-102.
- Selling, general and administrative expenses were $12.7 million for the year ended December 31, 2021, an increase of $1.6 million, or 14% from $11.1 million for the year ended December 31, 2020. The increase resulted primarily from an increase in corporate costs of $1.7 million related mainly to insurance.
- Financial expenses, net, were $7.1 million for the year ended December 31, 2021, a decrease of $2.1 million, or 23%, compared to financial expenses of $9.2 million for the year ended December 31, 2020. The decrease resulted primary from the exchange of our 2021 notes; a $0.7 million decrease in interest expenses; a $0.8 million decrease in amortization of debt discount; and a $1.3 million decrease in related expenses, offset by a $0.8 million loss on extinguishment related to the Exchanges.
- Cash, cash equivalents and short-term bank deposits were approximately $39.0 million at December 31, 2021.
- Net loss for the year ended December 31, 2021 was approximately $27.6 million, or $0.62 per share, basic and diluted, compared to a net loss of $6.5 million, or $0.22 per share, basic and diluted, for the year ended December 31, 2020.
Conference Call and Webcast Information
The Company will host a conference call today, March 31, 2022, at 8:30 a.m. Eastern Daylight Savings Time, to review the corporate, clinical and regulatory developments, which will also be available by webcast. To participate in the conference call, please dial the following numbers prior to the start of the call:
Conference Call Details:
Thursday, March 31, 2022, 8:30 a.m. Eastern Daylight Savings Time (EDT)
Domestic: 877-423-9813
International: 201-689-8573
Conference ID: 13727524
Webcast Details:
The conference will be webcast live from the Company's website and will be available via the following links:
Company Link: https://protalixbiotherapeutics.gcs-web.com/events0
Webcast Link: Registration – https://tinyurl.com/bdmsa52p
Conference ID: 13727524
Please access the websites at least 15 minutes ahead of the conference to register, download and install any necessary audio software.
The conference call will be available for replay for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Protalix was the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix's unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.
Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.
Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified stabilized version of the recombinant human α–Galactosidase–A protein for the treatment of Fabry disease; alidornase alfa or PRX–110, for the treatment of various human respiratory diseases or conditions; PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of refractory gout; PRX–119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.
Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms "expect," "anticipate," "believe," "estimate," "project," "may," "plan," "will," "would," "should" and "intend," and other words or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk and the final results of a clinical trial may be different than the preliminary findings for the clinical trial. Factors that might cause material differences include, among others: risks related to the timing and progress of the preparation of a Biologics License Application (BLA) resubmission addressing the complete response letter; risks related to the timing, progress and likelihood of final approval by the FDA and European Medicines Agency (EMA) of a resubmitted BLA and of a Marketing Authorization Application, respectively, for PRX–102 and, if approved, whether the use of PRX–102 will be commercially successful; likelihood that the FDA, EMA or other applicable health regulatory authorities will approve an alternative dosing regimen; failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; and inability to monitor patients adequately during or after treatment; delays in the approval or potential rejection of any applications we file with the FDA, EMA or other health regulatory authorities for our other product candidates, and other risks relating to the review process; risks associated with the novel coronavirus disease, or COVID–19, outbreak, which may adversely impact our business, preclinical studies and clinical trials; risks related to any transactions we may effect in the public or private equity markets to raise capital to finance future research and development activities, general and administrative expenses and working capital; the risk that the results of the clinical trials of our product candidates will not support the applicable claims of safety or efficacy, or that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics; risks related to our ability to maintain and manage our relationship with our collaborators, distributors or partners; risks related to the amount and sufficiency of our cash and cash equivalents; risks relating to our ability to make scheduled payments of the principal of, to pay interest on or to refinance our outstanding notes or any other indebtedness; our dependence on performance by third party providers of services and supplies, including without limitation, clinical trial services; delays in our preparation and filing of applications for regulatory approval; the inherent risks and uncertainties in developing drug platforms and products of the type we are developing; the impact of development of competing therapies and/or technologies by other companies and institutions; potential product liability risks, and risks of securing adequate levels of product liability and other necessary insurance coverage; and other factors described in our filings with the U.S. Securities and Exchange Commission. The statements in this press release are valid only as of the date hereof and we disclaim any obligation to update this information, except as may be required by law.
Investor Contact
Chuck Padala, Managing Director
LifeSci Advisors
646-627-8390
[email protected]
SOURCE Protalix BioTherapeutics, Inc. | https://www.prnewswire.com/news-releases/protalix-biotherapeutics-reports-fiscal-year-2021-financial-and-business-results-301514653.html | 2022-03-31T16:09:55 | en | 0.944821 |
ORANGE PARK, Fla. — Eric Strickland served our country for 13 years with 4 overseas deployments in the United States Army.
Currently, he's on disability from his job as a truck driver after dealing with a heart issue. He was served with an eviction notice after falling behind on rent.
"I always keep this with me, that's why I still have it," said Strickland while holding onto the American Flag that was given to him during his father's funeral.
Strickland served in the Army during the Persian Gulf War, his father was in the military during WWII, Korea and Vietnam.
He packed up his entire apartment with the threat of being evicted just one day away.
Strickland is also a single father who is on disability from his job as a truck driver after a series of heart attacks. The disability payments don't cover the cost of his rent, and trying to get help through 'Our Florida' was extremely frustrating.
"It takes three, sometimes four hours to get through, and you're on hold for two to three hours," said Strickland about his phone calls with Our Florida representatives."... Sometimes they don't help you out, they'll put you on hold and disconnect the call."
Strickland received an eviction notice, but before he gave up hope, he reached out to Jacksonville Area Legal Aid.
Within a matter of days, an attorney walked him through the steps of making sure his landlord would receive his Our Florida payments.
"It's a big relief," said Strickland, "as you can see, I moved everything out because I didn't want to come with a padlock on my door and my stuff in a dumpster."
He owes past due rent dating back to January, but his Our Florida payments will ensure that he's able to stay in his apartment through at least the end of May.
While Strickland unpacks his belongings, Jacksonville Area Legal Aid continues to help others in the community.
"The highest best use of civil legal aid is housing," said Jacksonville Area Legal Aid CEO Jim Kowalski. "That's really the core piece of our mission. You can't do all of the other things we need as citizens unless you have stable affordable housing. Where we've played that roll in securing housing is our best work."
Jacksonville Area Legal Aid created a website called FloridaEvictionHelp.org that helps Florida tenants facing eviction. The tenant fills out information on the website, and then the website creates an answer for the court after an eviction order has been filed by the landlord.
Strickland said that he wants to work again as a truck driver and added that doctors believe he should be able to make enough of a recovery from his heart issues to go back to work.
In the meantime, he's grateful for the help of Jacksonville Area Legal Aid for their assistance with his eviction.
"I encourage all the people who are going through what I'm going through to make sure to call the Jacksonville Area Legal Aid office," said Strickland. "It's been so much of a relief, right now I can probably go to sleep tonight because I haven't gotten any rest for the last 3 months."
For a full list of resources provided by Jacksonville Area Legal Aid, click here to visit their website.
Jacksonville Area Legal Aid has a network of 35 lawyers working in 3 different offices across North East Florida. The phone number for their downtown Jacksonville office is: (904) 356-8371. The phone number for their St. John's County office is: (904) 827-9921. And the phone number for their Clay County office is: (904) 284-8410. | https://www.firstcoastnews.com/article/news/local/disabled-army-vet-avoids-eviction/77-37b93ffe-d2f2-44a1-aa56-0f1354bca8b2 | 2022-03-31T16:09:56 | en | 0.988645 |
HOUSTON, March 31, 2022 /PRNewswire/ -- Quanta Services, Inc. (NYSE: PWR) announced today that its Board of Directors has declared a quarterly cash dividend to stockholders of $0.07 per share. The dividend is payable on April 18, 2022, to stockholders of record as of April 11, 2022.
Quanta Services is a leading specialized contracting services company, delivering comprehensive infrastructure solutions for the utility, renewable energy, communications, pipeline and energy industries. Quanta's comprehensive services include designing, installing, repairing and maintaining energy and communications infrastructure. With operations throughout the United States, Canada, Australia and select other international markets, Quanta has the manpower, resources and expertise to safely complete projects that are local, regional, national or international in scope. For more information, visit www.quantaservices.com.
This press release (and any oral statements regarding the subject matter of this press release) contains forward-looking statements intended to qualify for the "safe harbor" from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements relating to expectations regarding the declaration, amount or timing of any future dividends; expectations regarding Quanta's business or financial outlook; and Quanta's ability to deliver increased value or return capital to stockholders; as well as statements reflecting expectations, intentions, assumptions or beliefs about future events and other statements that do not relate strictly to historical or current facts. These forward-looking statements are not guarantees of future performance, involve or rely on a number of risks, uncertainties, and assumptions that are difficult to predict or are beyond our control, and reflect management's beliefs and assumptions based on information available at the time the statements are made. We caution you that actual outcomes and results may differ materially from what is expressed, implied or forecasted by our forward-looking statements and that any or all of our forward-looking statements may turn out to be inaccurate or incorrect. Forward-looking statements can be affected by inaccurate assumptions and by known or unknown risks and uncertainties, including, among others, market, industry, economic, financial or political conditions outside of the control of Quanta, quarterly variations in operating results, liquidity, financial condition, cash flows, capital requirements, reinvestment opportunities or other financial results; requirements relating to dividends under Delaware law and the credit agreement for Quanta's senior credit facility; and other risks and uncertainties detailed in Quanta's Annual Report on Form 10-K for the year ended Dec. 31, 2021 and any other documents that Quanta files with the Securities and Exchange Commission (SEC). For a discussion of these risks, uncertainties and assumptions, investors are urged to refer to Quanta's documents filed with the SEC that are available through the company's website at www.quantaservices.com or through the SEC's Electronic Data Gathering and Analysis Retrieval System (EDGAR) at www.sec.gov. Should one or more of these risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those expressed or implied in any forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which are current only as of this date. Quanta does not undertake and expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Quanta further expressly disclaims any written or oral statements made by any third party regarding the subject matter of this press release.
Investors - Kip Rupp, CFA, IRC
Quanta Services, Inc.
(713) 341-7260
SOURCE Quanta Services, Inc. | https://www.prnewswire.com/news-releases/quanta-services-announces-quarterly-cash-dividend-301514547.html | 2022-03-31T16:10:01 | en | 0.91832 |
Business briefs
- Country:
- India
Spirits maker Allied Blenders and Distillers Private Limited (ABD) on Thursday announced the appointment of Nasser Munjee and Balaji Swaminathan as independent directors on its board.
The new appointments bring a great amount of cognitive diversity to the board, the company said in a statement.
Munjee has been a part of creation and building of some of India’s foremost financial institutions such as the Housing Development Finance Corporation (HDFC) and Infrastructure Development Finance Company (IDFC).
While Swaminathan had a distinguished career in banking. He is the founder and CEO of a regulated fund management and wealth advisory business in Singapore.
''We are delighted with the addition of seasoned and eminent professionals to our board. As we continue to drive the growth agenda in our business, we look forward to the contribution of all our board members in our pursuit of excellence,'' ABD Executive Deputy Chairman Shekhar Ramamurthy, said.
*** Marico forays into healthy spreads through Saffola * FMCG major Marico on Thursday announced that it is entering into the healthy spreads segment with the launch of its all-new Saffola Mayonnaise and Saffola Peanut Butter.
Marico is strengthening its foothold in the healthy food and ready-to-eat segment, and has entered into several new categories after the pandemic.
Saffola Mayonnaise is a healthy eggless offering made with milk cream and Saffola Peanut Butter replaces refined sugar with its perfect blend of peanuts and jaggery.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.) | https://www.devdiscourse.com/article/business/1985411-business-briefs | 2022-03-31T16:10:01 | en | 0.962634 |
CRESCENT CITY, Fla. — Funeral arrangements for the Putnam County 22-month-old who died in a septic tank earlier this week have been announced.
The family of Jose Mayo Lara, Jr., shared that a funeral mass will take place Saturday at 9 a.m. at St. John the Baptist Catholic Church, located at 2725 Highway 17 South, Crescent City. A viewing and visitation will follow the mass from 10:30 a.m. to noon at Jesus is Lord Church, located at 2942 South US Highway 17 in Crescent City.
The burial will take place at St. John the Baptist Catholic Cemetery, 205 Oakwood Avenue, Crescent City.
Jose was reported missing Sunday afternoon, and his body was recovered nearly 24 hours later on Monday.
Jose's family says they are heartbroken over his loss. First Coast News spoke with his mother, Maria, who said the past couple of days have been an emotional rollercoaster.
Officials believe Jose wandered off while his mother was taking care of one of his siblings inside the house. To Sheriff "Gator" DeLoach, it appeared Jose stepped on rotten plywood that was covering the tank, and he fell in.
To Lara, her son was an affectionate child who loved to play and hug.
"Since the day he was born, he changed her life," a member of Lara's family translated to First Coast News.
While Lara holds on to the precious memories of her son, she said she is grateful for the support from the community. | https://www.firstcoastnews.com/article/news/local/funeral-arrangements-announced-putnam-county-toddler-died-septic-tank/77-3d82d58f-45ed-4353-9c35-e8e66b22b621 | 2022-03-31T16:10:03 | en | 0.990545 |
Quantix Terminal Manager Brittany Streadl Named a "Pro to Know" by Supply & Demand Chain Executive
This is the second year in a row Quantix has had an honoree on the list
HOUSTON, March 31, 2022 /PRNewswire/ -- Quantix, North America's leading supply chain services company to the chemical industry, announced today its Terminal Manager, Brittany Streadl, has been named a "Pro to Know" by leading industry publication, Supply & Demand Chain Executive. Over 360 nominations were submitted this year, the highest number of nominations ever for the award.
"Pros to Know" recognizes outstanding leaders whose accomplishments offer a roadmap for the success of others in the industry looking to leverage the supply chain for competitive advantage. It celebrates the work of professionals like Streadl who've helped clients and the supply chain community at large excel during yet another challenging year.
"While most trucking terminals in today's world of severe driver shortages are happy with minimal growth or holding driver count steady, the terminal Brittany manages grew from zero to 24 drivers within one year," said David Perry, President Liquid Chemical at Quantix. "Her ability to drive growth, provide superior customer service and advance the Quantix mission has been clear since her earliest days with the company."
Quantix has one of the largest transportation networks serving the chemical industry, featuring over 5,000 pieces of highly specialized equipment. Quantix also continues to scale to meet the needs of its customers with services spanning transportation, 3PL solutions, full scale warehousing among other services via a national network of over 50 facilities.
To learn more about Quantix, visit www.quantixscs.com. For the complete list of "Pros to Know" honorees, visit www.SDCExec.com/awards.
About Quantix
Quantix is the leading supply chain services company to the chemical industry. It provides the world's largest chemical providers with end-to-end support through a nationwide network and comprehensive suite of services including transportation, 3PL solutions, distribution centers, export/import, in-plant and resin enhancement services, and Eco-Recovery. Headquartered in The Woodlands, TX with over 50 locations across the U.S., Quantix is committed to providing the highest level of safety, quality, compliance and integrity across its entire operation. Learn more at www.quantixscs.com.
SOURCE Quantix | https://www.prnewswire.com/news-releases/quantix-terminal-manager-brittany-streadl-named-a-pro-to-know-by-supply--demand-chain-executive-301514193.html | 2022-03-31T16:10:07 | en | 0.950043 |
JACKSONVILLE, Fla. — In 2020, Coke killed Tab.
If you don’t remember Tab, it was a diet soda first made in 1963, but was really popular in the 1980s, famous for its pink can.
Some people enjoyed it, others not so much.
And then there’s Alan Jordan, who’s on a whole other scale. He's taken road trips across the Southeastern United States, from Piggly Wiggleys to Food Lions and everything in between, to collect all the Tab he can.
It’s like a 1980s love story for Alan.
And the tragic side of this story, in the not too distant future he'll be all out of the soda he loves so much.
“I started drinking Tab when I got out of college, probably 23-24," the Georgia man said over a Zoom call. "Those other sugar drinks tasted too sweet.”
Alan works full time at a senior living center in Georgia. His other job is traveling far and wide to collect as much Tab as he can, while he still can.
“I got hooked on Tab and in my younger days I'd drink 12 a day,” he said.
Now that Coke is no longer making it, Alan is stockpiling
“We went to a Piggly Wiggly and at the end of one of the aisles they had a stack of 70 12 packs, and I was like I’m moving to Alabama," he said laughing, but probably not exactly joking.
At one point, he had 80 cases of Tab saved up.
“Every time I went to the grocery store, I’d buy Tab, even though I had Tab.”
But now, there’s none to be found, and he still drinks at least one a day. He says he's now down to 42 twelve packs.
For those who've had Tab before, you may remember what it tastes like. But for those who haven't:
“It’s got a whole different flavor," he said. "It’s hard to describe, people say they either love it or hate it.
But time is fleeting, and so too is his, and world supply. Prices for the scarcity are through the roof.
“I saw [on Ebay] that $200 you could buy a 12 pack of Tab."
But apparently everything does not have a price, because Alan says his Tab are not for sale.
"To me, it’s one of those things that priceless, I wouldn’t sell it,” he said.
It's part nostalgia and part self-admitted addiction.
“I ran out of Tab and drank Coke Zero and got headaches."
But other than crippling headaches from withdrawal, he says he’ll be impacted most by the nostalgia of it all.
Because when it’s gone, all that’s left are the memories. Which could actually be impacted by those Tab withdrawal headaches.
“I’m never without Tab until now, when Coke did us in, so when my collection runs out, I’m not sure what I’ll do.” | https://www.firstcoastnews.com/article/news/local/georgia-mans-tab-addiction-soda/77-47075832-2ca2-4964-95d8-a3765e9735df | 2022-03-31T16:10:09 | en | 0.981328 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.